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Summary
Background In 2015, the second cycle of the CONCORD programme established global surveillance of cancer survival 
as a metric of the effectiveness of health systems and to inform global policy on cancer control. CONCORD-3 updates 
the worldwide surveillance of cancer survival to 2014.
Methods CONCORD-3 includes individual records for 37·5 million patients diagnosed with cancer during the 15-year 
period 2000–14. Data were provided by 322 population-based cancer registries in 71 countries and territories, 47 of 
which provided data with 100% population coverage. The study includes 18 cancers or groups of cancers: oesophagus, 
stomach, colon, rectum, liver, pancreas, lung, breast (women), cervix, ovary, prostate, and melanoma of the skin in 
adults, and brain tumours, leukaemias, and lymphomas in both adults and children. Standardised quality control 
procedures were applied; errors were rectified by the registry concerned. We estimated 5-year net survival. Estimates 
were age-standardised with the International Cancer Survival Standard weights.
Findings For most cancers, 5-year net survival remains among the highest in the world in the USA and Canada, in Australia 
and New Zealand, and in Finland, Iceland, Norway, and Sweden. For many cancers, Denmark is closing the survival gap 
with the other Nordic countries. Survival trends are generally increasing, even for some of the more lethal cancers: in 
some countries, survival has increased by up to 5% for cancers of the liver, pancreas, and lung. For women diagnosed 
during 2010–14, 5-year survival for breast cancer is now 89·5% in Australia and 90·2% in the USA, but international 
differences remain very wide, with levels as low as 66·1% in India. For gastrointestinal cancers, the highest levels of 5-year 
survival are seen in southeast Asia: in South Korea for cancers of the stomach (68·9%), colon (71·8%), and rectum 
(71·1%); in Japan for oesophageal cancer (36·0%); and in Taiwan for liver cancer (27·9%). By contrast, in the same world 
region, survival is generally lower than elsewhere for melanoma of the skin (59·9% in South Korea, 52·1% in Taiwan, and 
49·6% in China), and for both lymphoid malignancies (52·5%, 50·5%, and 38·3%) and myeloid malignancies (45·9%, 
33·4%, and 24·8%). For children diagnosed during 2010–14, 5-year survival for acute lymphoblastic leukaemia ranged 
from 49·8% in Ecuador to 95·2% in Finland. 5-year survival from brain tumours in children is higher than for adults but 
the global range is very wide (from 28·9% in Brazil to nearly 80% in Sweden and Denmark).
Interpretation The CONCORD programme enables timely comparisons of the overall effectiveness of health systems 
in providing care for 18 cancers that collectively represent 75% of all cancers diagnosed worldwide every year. It 
contributes to the evidence base for global policy on cancer control. Since 2017, the Organisation for Economic 
Co-operation and Development has used findings from the CONCORD programme as the official benchmark of 
cancer survival, among their indicators of the quality of health care in 48 countries worldwide. Governments must 
recognise population-based cancer registries as key policy tools that can be used to evaluate both the impact of 
cancer prevention strategies and the effectiveness of health systems for all patients diagnosed with cancer.
Funding American Cancer Society; Centers for Disease Control and Prevention; Swiss Re; Swiss Cancer Research 
foundation; Swiss Cancer League; Institut National du Cancer; La Ligue Contre le Cancer; Rossy Family Foundation; 
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Introduction
The incidence of cancer continues to rise, both in high-
income countries and, especially, in low-income and 
middle-income countries. Prevention is crucial, but 
implementation has been slow and incomplete, even in 
high-income countries. Prevention is a long-term 
strategy, and not all cancers can be prevented.1 To reduce 
cancer mortality, reduction of cancer incidence and 
improvement of cancer survival are both necessary.
Many patients will continue to be diagnosed with 
cancer every year for decades to come: an estimated 
14 million patients a year worldwide around 2012,2 with a 
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50% projected increase to 21·6 million patients a year 
by 2030.3 Those patients will all need prompt diagnosis 
and optimal treatment to improve their survival. 
Monitoring the effectiveness of national and regional 
health systems in treating and caring for these patients 
becomes ever more crucial.
In 2016, the WHO Executive Board recommended 
strengthening health systems to ensure early diagnosis 
and accessible, affordable, high-quality care for all 
patients with cancer.3 The World Health Assembly 
followed up with a resolution on cancer control in May, 
2017. It included recommendations that national cancer 
control strategies should aim to reduce late presentation 
and ensure appropriate treatment and care for potentially 
curable malignancies such as acute leukaemia in 
children “to increase survival, reduce mortality and 
improve quality of life”.4
President Tabaré Vázquez of Uruguay and WHO 
Director-General Tedros Ghebreyesus have called for all 
countries “to provide universal health coverage, thereby 
ensuring all people can access needed preventive and 
curative health-care services, without falling into 
poverty”.5 Their call relates to all non-communicable 
diseases, including cancer. Population-based cancer 
survival is one metric that can help evaluate whether all 
people have access to effective treatment services.
In 2015, the second cycle of the CONCORD programme 
(CONCORD-2) established global surveillance of cancer 
survival for the first time,6 with publication of trends in 
survival over the 15-year period 1995–2009 among 
patients diagnosed with cancer in 67 countries, home to 
two thirds (4·8 billion) of the world’s population. In 
40 countries, the data had 100% national popu-
lation coverage. CONCORD-2 incorporated centralised 
quality control and analysis of individual data for 
25 676 887 patients diagnosed with one of the ten 
common cancers that represented 63% of the global 
cancer burden in 2009. The 279 population-based 
Research in context
Evidence before this study
In 2015, the second cycle of the CONCORD programme 
(CONCORD-2) established global surveillance of cancer survival 
as one of the key metrics of the effectiveness of health systems 
and to inform global policy on cancer control. This was done by 
analysis of individual records for 25·7 million patients 
diagnosed with one of ten common cancers during 1995–2009 
and followed up to Dec 31, 2009. The data were provided by 
279 population-based cancer registries in 67 countries. 
CONCORD-2 revealed wide differences in cancer survival trends 
that were attributed to differences in access to early diagnosis 
and optimal treatment.
Added value of this study
CONCORD-3 covers almost 1 billion people worldwide. It 
includes 15 common cancers in adults and three common 
cancers in children. Data quality has improved. The results are 
timely, published within 3 years of the end of follow-up.
CONCORD-3 updates the worldwide surveillance of cancer 
survival to 2014. It includes data for over 37·5 million patients 
diagnosed with cancer during the 15-year period 2000–14. Data 
were provided by more than 320 population-based cancer 
registries in 71 countries and territories, including 27 countries 
of low or middle income; 47 countries provided data with 100% 
population coverage. The study now includes 18 cancers or 
groups of cancers: oesophagus, stomach, colon, rectum, liver, 
pancreas, lung, breast (women), cervix, ovary, prostate, and 
melanoma of the skin in adults, together with brain tumours, 
leukaemias, and lymphomas in both adults and children. These 
cancers represent 75% of all cancers diagnosed worldwide every 
year, in both low-income and high-income countries. The use 
of a similar study design and the same statistical methods as in 
CONCORD-2 enables the evaluation of survival trends for ten 
cancers over the 20-year period 1995–2014. 
For the first time, worldwide trends in survival are also available 
for cancers of the oesophagus, pancreas, and brain, and 
lymphomas and leukaemias.
Implications of all the available evidence
The CONCORD programme enables comparative evaluation of 
the effectiveness of health systems in providing cancer care. It 
also contributes to the evidence base for global policy on cancer 
control. CONCORD monitors progress towards the overarching 
goal of the 2013 World Cancer Declaration, to achieve “major 
reductions in premature deaths from cancer, and improvements 
in quality of life and cancer survival” by 2020. It provides 
evidence to support WHO policy following the Cancer Resolution 
passed by the World Health Assembly in 2017. The International 
Atomic Energy Agency’s Programme for Action on Cancer 
Therapy used CONCORD-2 results in 2015 to launch its 
worldwide campaign to highlight the global divide in cancer 
survival, and to raise awareness of persistent inequalities in 
access to life-saving cancer services. The results were used in a 
Lancet Series on women’s cancers in 2016. The US Centers for 
Disease Control and Prevention used the results in a 2017 
supplement to the journal Cancer to inform cancer control policy 
designed to reduce racial differences in cancer survival.
CONCORD-3 can be expected to affect cancer control policy 
worldwide, especially in countries with low survival. 
The Organisation for Economic Co-operation and Development 
published a subset of CONCORD-3 results in 2017 as the official 
benchmark of cancer survival, among their indicators of the 
quality of health care in 48 countries worldwide. The survival 
estimates will also form part of the Lancet Oncology Commission 
on childhood cancer in 2018. Future research will include 
examination of the impact on international differences in 
cancer survival of stage at diagnosis, compliance with 
treatment guidelines, and the quality of health care.
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registries covered a combined total population of 
896 million people.
The US National Cancer Institute, in an invited 
commentary7 for The Lancet, noted that the global analyses 
of cancer survival in CONCORD-2 provided insights 
from countries with successful cancer control initiatives 
that could be applied in other regions, and that the 
availability of better data “provides a clearer picture of the 
effect of cancer control programmes on the ultimate goal 
of improving survival and reducing the effect of cancer on 
the social and economic development of countries”.
The US Centers for Disease Control and Prevention 
described CONCORD-2 as the start of global surveillance 
of cancer survival,8 with survival estimates “that can be 
compared so scientists can begin to determine why 
survival differs among countries. This could lead to 
improvements in cancer control programs.” The results 
from CONCORD-2 influenced national cancer control 
strategy in the UK in July, 2015.9,10 In September, 2015, 
the International Atomic Energy Agency’s Programme 
for Action on Cancer Therapy used the results to launch 
a worldwide campaign11 to highlight the global divide in 
cancer survival, and to raise awareness of persistent 
inequalities in access to life-saving cancer services.12 
Further analyses of survival trends and disparities by race 
and stage at diagnosis in 37 US states have been included 
in a supplement to Cancer,13,14 designed to improve cancer 
control in the USA.
CONCORD-3 updates worldwide surveillance of cancer 
survival trends to include patients diagnosed up to 2014, 
with follow-up to Dec 31, 2014. In countries that were 
already involved, more registries are participating, and 
eight more countries have joined the programme. 
Follow-up for patients diagnosed during 2000–09 with 
one of the ten cancers included in CONCORD-2 has 
been updated. CONCORD-3 includes data for patients 
diagnosed during 2000–14 with one of 18 malignancies 
that represent 75% of the global cancer burden (table 1). 
In addition to information on stage at diagnosis, we have 
collected data on tumour grade and the first course of 
treatment. Findings are published within 3 years of the 
end of follow-up.
Methods
Cancer registries
We contacted 412 cancer registries in 85 countries: 20 in 
Africa (13 countries), 45 in Central and South America 
(15 countries), 68 in North America (two countries), 80 in 
Asia (20 countries), 189 in Europe (33 countries), and ten 
in Oceania (two countries).
When the data call for CONCORD-3 was issued in 
May, 2016, 12 of the 279 cancer registries that had 
participated in CONCORD-2 were no longer operational. 
The registry in Benghazi (Libya) had been disrupted by 
war, the registry in Macerata (Italy) had ceased operating, 
the Department of Health had ceased funding the UK 
National Registry of Childhood Tumours in 2013, and the 
nine English regional cancer registries had been replaced 
by a single cancer registry for England in 2013. Of the 
267 remaining registries, nine could no longer provide 
up-to-date follow-up of all registered patients, whereas 
13 did not reply to repeated approaches. Data from the 
Tirol (Austria) registry are no longer reported separately 
from the Austrian national estimates. In all, 244 (87%) of 
the 279 registries (63 of the 67 countries) that participated 
in CONCORD-2 submitted data (appendix p 266).
Of the 133 registries that had not previously participated 
in the CONCORD programme, 108 agreed to do so. Of 
these, 85 (78%) registries in 12 countries submitted data, 
whereas 11 were unable to complete follow-up of 
registered patients with cancer for their vital status, nine 
made no further contact, and three signed up too late 
(appendix p 266).
Of the 329 registries that submitted data, seven were 
excluded because their data were not compliant with 
the protocol and could not be rectified in time. These 
exclusions affected the only participating registry 
or registries from several countries: Tunisia (Central 
Region), Bosnia and Herzegovina (Republika Srpska), 
Saudi Arabia, and Serbia (Central Region and Vojvodina). 
We analysed data provided by 322 cancer registries 
(81% of the 400 operational registries invited) in 
71 countries and territories (appendix p 266), for patients 
diagnosed with cancer during the 15-year period 2000–14, 
with data on their vital status at least 5 years after 
diagnosis, or at Dec 31, 2014.
Eight countries from four world regions are 
participating in the global surveillance of cancer survival 
Overall 
(n=14 067 894)
More developed regions 
(n=6 053 621)
Less developed regions 
(n=8 014 273) 
Oesophagus 455 784 (3·2%) 86 144 (1·4%) 369 640 (4·6%)
Stomach 951 594 (6·8%) 274 509 (4·5%) 677 085 (8·4%)
Colorectum 1 360 602 (9·7%) 736 867 (12·2%) 623 735 (7·8%)
Liver 782 451 (5·6%) 134 302 (2·2%) 648 149 (8·1%)
Pancreas 337 872 (2·4%) 187 465 (3·1%) 150 407 (1·9%)
Lung 1 824 701 (13·0%) 758 214 (12·5%) 1 066 487 (13·3%)
Melanoma 232 130 (1·7%) 191 066 (3·2%) 41 064 (0·5%)
Breast (women) 1 671 149 (11·9%) 788 200 (13·0%) 882 949 (11·0%)
Cervix 527 624 (3·8%) 83 078 (1·4%) 444 546 (5·5%)
Ovary 238 719 (1·7%) 99 752 (1·6%) 138 967 (1·7%)
Prostate 1 094 916 (7·8%) 741 966 (12·3%) 352 950 (4·4%)
Brain and central 
nervous system
256 213 (1·8%) 88 967 (1·5%) 167 246 (2·1%)
Lymphomas 451 691 (3·2%) 219 255 (3·6%) 232 436 (2·9%)
Leukaemias 351 965 (2·5%) 141 274 (2·3%) 210 691 (2·6%)
All index cancers* 10 537 411 (74·9%) 4 531 059 (74·8%) 6 006 352 (74·9%)
Data are from Globocan, 2012.15 Index cancer refers to a cancer or group of malignancies included in CONCORD-3. 
More developed regions refers to North America, Europe, Australia, New Zealand, and Japan; all other countries and 
regions are classified as less developed.15 These are UN designations intended for statistical convenience and do not 
reflect a judgment about the stage reached by a particular country or area in the development process.16 *Excluding 
non-melanoma skin cancer. 
Table 1: Estimated number of patients diagnosed with an index cancer worldwide each year around 2012
See Online for appendix
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for the first time: Morocco (Africa); Costa Rica (national), 
Mexico (children, national), and Peru (Central and 
South America); Iran, Kuwait (national), and Singapore 
(national; Asia), and Greece (children, national; Europe).
Ethical approvals
We maintain approvals from the Confidentiality Advisory 
Group of the UK’s statutory Health Research 
Authority (HRA; reference ECC 3-04(i)/2011; last update 
March 3, 2017), the National Health Service Research 
Ethics Service (11/LO/0331; Feb 21, 2017), and the London 
School of Hygiene & Tropical Medicine (12171; 
Sept 6, 2017). The HRA also approves the Cancer Survival 
Group’s System-Level Security Policy, governing data 
security. One investigator (MPC) maintains triennial 
certification with the Collaborative Institutional Training 
Initiative in Human Subjects Research for Biomedical 
Investigators (CITI Program; ID3327653; certification 
updated May 2, 2016). We maintain statutory or 
ethical approvals and data sharing agreements, 
usually with annual renewal, in 85 other jurisdictions 
participating in the CONCORD programme. Registries 
in all other jurisdictions obtain local approval. The data 
belong to the participating registries and are only used 
for purposes agreed in the CONCORD protocol.
Participants transmit data via a specially configured file 
transmission utility with 256-bit Advanced Encryption 
Security. The utility automatically generates a random, 
strong, one-time password for each data file at the time 
of transmission, and emails it to a different address. 
Neither the password nor the address are seen by 
the sender. This avoids the need for confirmation of 
passwords by email or telephone. Tumour records are 
effectively anonymised: they do not contain the patient’s 
name, address, postcode, or any national identity or 
social security number. All variables are numeric or 
alphanumeric codes. Each registry is sent a set of unique 
codes that must be used in naming each cancer data file, 
including distinct filenames for any retransmission. The 
codes have no meaning outside of the study. Data files 
thus contain no information that could be used to 
identify a person or a cancer registry, and neither the 
name nor the content of the file would indicate that the 
file contains cancer data. This enhances security and 
facilitates efficient handling of thousands of data files.
Protocol
The CONCORD-3 protocol defining the data structure, 
file transmission procedures, and statistical analyses was 
expanded and updated from the CONCORD-2 protocol, 
with the inclusion of variables on five additional cancers 
or groups of malignancies, tumour grade, and the 
modality and date of the first course of treatment by 
surgery, radiotherapy, or systemic therapy.
In a study of this scale, adherence to protocol is crucial. 
The protocol and analytic approaches were discussed with 
CONCORD Working Group members from 27 countries 
at a 1-day meeting in Marrakesh, Morocco, on Oct 17, 2016. 
The protocol was also discussed at workshops in China, 
Romania, Russia, Singapore, and the USA (for North 
America), and in conference calls with Costa Rica, Hong 
Kong, Malaysia, Mauritius, Mexico, and Mongolia.
English is still a barrier to communication in many 
countries, so the CONCORD-3 protocol was translated 
into eight other languages: Arabic, Chinese (Mandarin), 
French, Italian, Japanese, Portuguese, Russian, and 
Spanish. Translations were done by native speakers in the 
CONCORD Central Analytic Team in London or the 
wider CONCORD Working Group, and checked against 
the English original by other native speakers. The protocol 
was made available to participants in all nine languages 
on the CONCORD website. The Central Analytic Team 
communicates with participants in six languages.
We examined survival for 18 cancers or groups of 
malignancies (referred to as index cancers): oesophagus, 
stomach, colon, rectum, liver, pancreas, lung, melanoma 
of the skin, breast (women), cervix, ovary, and prostate in 
adults (15–99 years); brain tumours, myeloid, and 
lymphoid malignancies in adults; and brain tumours, 
acute lymphoblastic leukaemia, and lymphomas in 
children (0–14 years). Collectively, these cancers accounted 
for about 75% of the estimated number of patients 
diagnosed with cancer worldwide each year around 2012 
(table 1). The overall proportion is very similar in 
North America, Europe, Australia, New Zealand, and 
Japan (referred to as developed countries15) and in other 
world regions (referred to as developing countries15), but 
it varies widely between cancers: prostate cancer is 
proportionately three times more common in developed 
countries, and cervical cancer is four times more common 
in developing countries (table 1).
Solid tumours were defined by anatomical site 
(topography), and the leukaemias, lymphomas, and 
mela noma of the skin by morphology (table 2). Topog-
raphy and morphology were coded to the International 
Classification of Diseases for Oncology (third edition, 
ICD-O-3),17 including its first revision.18 We restricted 
estimation of survival for melanomas to those arising in 
the skin, including the skin of the labia majora, vulva, 
penis, and scrotum (table 2). Melanomas arising in 
internal organs were included with all other malignancies 
in those organs. For ovarian cancer, we included the 
fallopian tube, uterine ligaments, and adnexa, as well as 
the peritoneum and retroperitoneum, where high-grade 
serous ovarian carcinomas are often detected.21 Registries 
were not asked to select cancers by sex, although some 
did so. Where datasets did include records for breast 
cancer in men, the proportion was consistently 
around 0·7%; these records were excluded. We also 
excluded small numbers of retroperitoneal malignancies 
in men, as well as Kaposi’s sarcoma, and tumours in 
solid organs with haemopoietic morphology.
Registries provided data for all haemopoietic 
malignancies (ICD-O-3 morphology codes in the 
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Topography or morphology codes* Description Contributing countries and registries
2000–04 2005–09 2010–14 Any period (2000–14)
Countries Registries Countries Registries Countries Registries Countries Registries
Oesophagus C15.0–C15.5, C15.8–C15.9 Oesophagus 55 249 59 287 58 273 60 290
Stomach C16.0–C16.6, C16.8–C16.9 Stomach 57 252 62 293 60 277 62 294
Colon C18.0–C18.9, C19.9 Colon and rectosigmoid 
junction
57 251 64 294 64 280 65 296
Rectum C20.9, C21.0–C21.2, C21.8 Rectum, anus, and anal 
canal
56 250 63 292 63 278 64 294
Liver C22.0–C22.1 Liver and intrahepatic 
bile ducts
56 250 60 289 60 275 61 291
Pancreas C25.0–C25.4, C25.7–C25.9 Pancreas 55 249 58 288 58 274 59 290
Lung C34.0–C34.3, C34.8–C34.9 Lung and bronchus 57 250 61 289 61 275 61 290
Melanoma of 
the skin
8720–8790 provided topography was 
C44.0–C44.9, C51.0, C51.9, C60.9, or C63.2
Melanoma of the skin, 
including skin of labia 
majora, vulva, penis, and 
scrotum
55 239 58 278 59 266 59 281
Breast 
(women)
C50.0–C50.6, C50.8–C50.9 Breast 59 255 64 295 65 282 66 298
Cervix C53.0–C53.1, C53.8–C53.9 Cervix uteri 57 253 63 293 62 277 64 295
Ovary C48.0–C48.2, C56.9, C57.0–C57.4, C57.7–C57.9 Ovary, fallopian tube and 
uterine ligaments, other 
and unspecified female 
genital organs, 
peritoneum, and 
retroperitoneum
56 249 61 288 59 272 61 289
Prostate C61.9 Prostate gland 58 249 62 289 62 275 62 290
Brain (adults) C71.0–C71.9 Brain (adults) 55 247 58 283 58 269 59 286
Myeloid 
(adults)†
9740, 9741, 9742, 9800, 9801, 9805, 9806, 
9807, 9808, 9809, 9840, 9860, 9861, 9863, 
9865, 9866, 9867, 9869, 9870, 9871, 9872, 
9873, 9874, 9875, 9876, 9891, 9895, 9896, 
9897, 9898, 9910, 9911, 9920, 9930, 9931, 
9945, 9946, 9950, 9960, 9961, 9962, 9963, 
9964, 9975, 9980, 9982, 9983, 9984, 9985, 
9986, 9987, 9989, 9991, 9992
All myeloid malignancies 56 249 59 280 60 268 61 286
Lymphoid 
(adults)†
9590, 9591, 9596, 9597, 9650–9655, 9659, 
9661–9665, 9667, 9670, 9671, 9673, 9675, 
9678, 9679, 9680, 9684, 9687–9691, 9695, 
9698, 9699, 9700–9702, 9705, 9708, 9709, 
9712, 9714, 9716–9719, 9725–9729, 9731–9735, 
9737, 9738, 9760–9762, 9764, 9811–9818, 9820, 
9823, 9826, 9827,9831–9837, 9940, 9948
All lymphoid 
malignancies
57 250 60 284 61 271 62 289
Brain 
(children)
C71.0–C71.9 Brain (children) 54 219 58 257 60 245 60 260
Acute 
lymphoblastic 
leukaemia 
(children)‡
9835–9837; plus 9811–9818 provided 
topography was C42.0, C42.1, C42.3, C42.4, 
or C80.9
Precursor-cell acute 
lymphoblastic leukaemia
56 214 60 247 61 233 61 254
Lymphoma 
(children)‡
9590, 9591, 9596, 9597, 9650–9655, 9659, 
9661–9665, 9667, 9670, 9671, 9673, 9675, 
9678–9680, 9684, 9687–9691, 9695, 
9698–9702, 9705, 9708, 9709, 9712, 9714, 
9716–9719, 9725–9729, 9731–9735, 9737, 9738, 
9740–9742, 9750–9762, 9764–9769, 9970, 
9971; plus 9811–9818 provided topography was 
not C42.0, C42.1, C42.3, C42.4, or C80.9
All lymphomas 55 214 60 253 62 235 62 257
Some registries contributed data for selected cancers or calendar periods, so the number of participating countries also varies by cancer and calendar period. The number of countries and registries that contributed data 
at some point during 2000–14 is thus greater than or equal to the number in any 5-year period. *International Classification of Diseases for Oncology (ICD-O-3),17 including its first revision.18 †Lymphoid malignancies 
were defined by HAEMACARE19 groups 1–19 and myeloid malignancies by HAEMACARE groups 20–25, incorporating morphology codes from the first revision of ICD-O-3. ‡The International Classification of Childhood 
Cancer (third edition)20 incorporating morphology codes from the first revision of ICD-O-318 was used to define childhood acute lymphoblastic leukaemia (group Ia1) and lymphoma in children (group II).
Table 2: Definition of malignancies and number of contributing countries and registries by calendar period of diagnosis
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For the database of global 
administrative areas see 
http://www.gadm.org/
range 9590–9992) in adults and children, to minimise 
differences in the spectrum of leukaemias and lym-
phomas submitted for analysis. In consultation with 
specialists in the HAEMACARE19 and InterLymph22,23 
groups, we agreed to analyse survival for adults in two 
broad groups: lymphoid malignancies (HAEMACARE 
groups 1–19) and myeloid malignancies (groups 20–25; 
table 2; appendix pp 2–5).
For children, we agreed to present survival estimates 
separately for acute lymphoblastic leukaemia and 
lymphomas, based on ICD-O-3 codes, grouped according 
to the third edition of the International Classification 
of Childhood Cancer.20 The first revision of ICD-O-3, 
published in 2013,18 introduced eight new entities for 
acute lymphoblastic leukaemia or lymphoma (morph-
ology codes 9811–9818). These new entities were not used 
at all by registries in 42 of the 58 countries that submitted 
data for children diagnosed with acute lymphoblastic 
leukaemia during 2010–14, and very rarely in eight 
countries (ie, the combined number of children coded to 
a new entity was fewer than 100), but the proportions 
ranged from 11% to 89% in large datasets from 
Australia, Belgium, Canada, the Netherlands, Puerto 
Rico, Singapore, Taiwan, and the USA. The overall 
proportion for all 58 countries combined during 2010–14 
was 29% (10 679 of 36 867 children). We therefore 
included the new entities in all analyses. We included 
them among the acute lymphoblastic leukaemias if the 
anatomical site was coded as blood, bone marrow, 
reticulo-endothelial, or haemopoietic system not 
otherwise specified (C42.0–42.1, C42.3–42.4), or unknown 
primary site (C80.9). Otherwise, such malignancies were 
included with the lymphomas (appendix pp 2–5).
Survival analyses include only primary, invasive 
malignancies (ICD-O-3 behaviour code 3), except for the 
brain, where benign tumours (behaviour code 0) are also 
included. To facilitate quality control and comparison of 
the intensity of early diagnostic and screening activity, 
registries were asked to provide data for all registered 
malignancies at each index site, including those that 
were benign, of uncertain or borderline malignancy 
(behaviour code 1), in situ (behaviour code 2), metastatic 
(behaviour code 6), or uncertain whether primary or 
metastatic (behaviour code 9).
Registries were asked to provide full dates (day, month, 
and year) of birth, diagnosis, and death or last known 
vital status, both for quality control and to enable 
comparable estimation of survival.24 Where the day or 
month of birth, or the day of the date of diagnosis, or the 
day or month of the date of last known vital status was 
missing, we used an algorithm (details on request) to 
standardise the imputation of missing components of 
dates for all populations.
Participating registries completed a questionnaire on 
their methods of operation, including data definitions, 
data collection procedures, coding of anatomical site, 
morphology and behaviour, the tracing of patients 
registered with cancer to ascertain their vital status, and 
how tumour records are linked with data on vital status.
Patients diagnosed with two or more primary cancers 
at different index sites during 2000–14 were included 
in the analyses for each cancer—eg, colon cancer in 
2005 followed by a breast cancer in 2010. Survival was 
measured from the date of diagnosis until death, loss to 
follow-up, or censoring. We retained the most complete 
record for patients with synchronous primary cancers in 
the same organ. If a patient was registered with two or 
more primary malignancies in the same index site 
during 2000–14 (metachronous primaries), only the first 
was included in analyses.
North American registries define multiple primary 
cancers under the rules of the Surveillance Epidemiology 
and End Results programme.25 Those rules accept more 
cancers as new primary cancers than do the rules of the 
International Association of Cancer Registries (IACR),26 
which are used by most cancer registries in other 
continents. The North American Association of Central 
Cancer Registries (NAACCR) kindly updated the program 
developed for CONCORD-2 to enable all North American 
registries to recode their entire incidence databases to the 
IACR multiple primary rules before their datasets for 
2000–14 were extracted for CONCORD-3.
Countries and territories were defined by their United 
Nations (UN) name, continent, and code as of 2015.16 The 
names of jurisdictions used in the text, tables, graphics, 
maps, and appendix are based on those used for statistical 
purposes by the Statistics Division of the UN Secretariat; 
similarly, we use the terms “national coverage” to contrast 
with “regional coverage” for statistical purposes. These 
designations and the presentation of data here do not 
imply any assumption regarding the political affiliation of 
countries or territories, or the expression of any opinion 
whatsoever on the part of the CONCORD programme 
concerning the legal status of any country, territory, city, or 
area, or of its authorities, or concerning the delimitation of 
its frontiers or boundaries. Some names have been 
shortened for convenience (eg, Korea for South Korea): 
this does not carry any political significance.
Cyprus is a Member State of the European Union, but 
it is part of Asia. Costa Rica, Cuba, Guadeloupe, 
Martinique, Mexico, and Puerto Rico (Caribbean and 
Central America) were grouped with South America as 
Central and South America. World maps and 29 regional 
maps were prepared in ArcGIS Release 10.3,27 using 
digital boundaries (shapefiles) from the database of 
global administrative areas (GADM 2.8).
The population coverage of the data from participating 
registries is given as the proportion of the country or 
jurisdiction’s population, taken from the UN Population 
Division database for 2014,28 or from the authorities for 
Australia, Guadeloupe, Hong Kong, Poland, Portugal, 
and Taiwan, or the registries concerned. Belarus, Greece, 
and Mexico provided data only for childhood cancers, so 
the populations used were for children (0–14 years), 
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and Mali, Mongolia, and Morocco only provided cancer 
data for women, so we used the female populations.
Quality control
As for the previous cycle of the CONCORD programme,6 
we carried out data quality checks in three phases: 
protocol adherence, exclusions, and editorial checks. 
After each phase, a detailed report was sent to each 
cancer registry for discussion and correction of data 
where required.
First, we sent registries a report showing the percentage 
compliance with the protocol for each of 51 variables in 
each cancer file. Compliance of less than 100% required 
correction or resubmission of data. Next, we checked for 
logical inconsistencies between the variables in each 
tumour record. Exclusion criteria were defined a priori, 
on the basis of experience from CONCORD-2, and 
extended to cover features of some of the five additional 
cancers such as Ann Arbor stage for the lymphomas and 
14 additional variables on tumour grade and treatment. 
The variables in each record were checked for logical 
coherence against 20 sets of criteria, including eligibility 
(eg, age and tumour behaviour), definite errors (eg, sex-
site errors, invalid dates, impossible date sequence, and 
missing vital status), and possible errors, including a 
wide range of inconsistencies between age, tumour 
site, and morphology.6,29 Registries were sent exclusion 
reports for each index cancer and each calendar period, 
summarising the number of tumour records with each 
type of definite or possible error, the number registered 
from a death certificate only (DCO) or detected at autopsy, 
and the number and proportion of eligible patients 
whose data could be included in survival analyses. 
Registries were invited to request details of tumour 
records in which errors had been detected. Many 
registries used this information to update their databases. 
Where errors in classification, coding, or pathological 
assignment were identified, registries were asked to 
correct and resubmit their data.
Finally, we examined the proportion of tumour records 
with morphological verification of the diagnosis, whether 
from histology of a biopsy or surgical specimen, cytology 
of a smear or bone marrow aspirate, or from imaging 
or biomarkers, including tumours with a specific 
morphology code. We also examined the proportion of 
cases with non-specific morphology; the distributions of 
the day and month of the dates of birth, diagnosis, and 
last known vital status; and the proportion of patients 
who died within 30 days, were lost to follow-up, or were 
censored within 5 years of diagnosis.
Follow-up for vital status
Cancer registries use various methods to determine the 
vital status (alive, dead, emigrated, or lost to follow-up) 
of patients registered with cancer.6 Among 243 registries 
that provided specific information on follow-up 
procedures, 242 (99%) determine the vital status of 
registered patients with cancer using passive follow-up 
techniques in which tumour registration records are 
regularly linked to a regional or national index of all 
death registrations, regardless of the cause of death. 
Linkages are usually based on a national identity or 
social security number that is stored in both records. 
Such linkages are increasingly done electronically, but 
manual scrutiny of printed lists is still required in 
places. Tumour records that match to a death record are 
updated with the date of death. Some registries routinely 
receive paper or electronic death certificates for their 
territory but this is insufficient on its own because death 
certificates that do not mention cancer are rarely 
included. Transcription errors can arise with identity 
numbers, so variables such as the name, sex, and date 
of birth are often used to improve the probability of an 
accurate match between a cancer record and a death 
registration.
Many registries use electoral registers, hospital records, 
or official databases, such as social insurance, health 
insurance, and driving licences, to determine the date on 
which a patient was last known or believed to have been 
alive. Patients recorded as having migrated beyond the 
registry’s jurisdiction, or to another country, might be 
recorded as lost to follow-up because the patient’s 
eventual death is unlikely to be recorded: they are 
censored from survival analysis on that date.
Active follow-up techniques are also used by 124 (51%) 
of the 243 registries, which routinely contact the treating 
physician, general practitioner, or hospital administration 
to determine the vital status for each registered patient, 
often on a quarterly or annual basis. Some registries also 
determine the vital status by contact with the patient’s 
family, by telephone or home visit, or with the village 
administration.
Registries were asked to submit data with follow-up for 
at least 5 years or, for patients diagnosed during 2010–14, 
until Dec 31, 2014. Registration and follow-up for patients 
diagnosed in 2000–09 was updated and new datasets 
were submitted.
Patients registered solely from a death certificate or 
diagnosed at autopsy were excluded from analyses 
because their survival time is unknown.
Statistical analysis
Most registries submitted data for patients diagnosed 
between 2000 and 2014, with follow-up to 2014, although 
some registries only began operation after 2000 or 
provided data for less than 15 years. The study design 
we used to examine survival trends among patients 
diagnosed in three consecutive 5-year calendar periods 
was “cohort, cohort, period”. We used the cohort 
approach to estimate survival for patients diagnosed 
during 2000–04 and 2005–09 and the period approach 
for patients diagnosed during 2010–14. This design was 
also used for CONCORD-2,6 so it enables us to examine 
global trends in survival over a 20-year period by 
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including the estimates for patients diagnosed during 
1995–99.
The cohort approach is considered the gold standard30,31 
because it provides a survival estimate for a group of 
patients who were diagnosed during the same year or 
period, are likely to have been treated in similar fashion, 
and who have all been followed up for at least the 
duration of survival required, such as 5 years. This 
approach to the estimation of survival is easy to interpret, 
but other approaches are required when some patients 
have been followed up for less than 5 years.
We used the cohort approach for patients diagnosed in 
2000–04 and 2005–09 because in most datasets all 
patients had been followed up for at least 5 years. We 
used the period approach32 for patients diagnosed during 
2010–14 because 5 years of follow-up data were not 
available for all patients. This combination of cohort and 
period approaches facilitates monitoring of cancer 
survival trends over an extended time span, from the 
earliest to the most recent years of cancer registration 
for which follow-up data are available (appendix p 267).33
To ensure comparability of survival trends from 1995,6 
we estimated net survival up to 5 years after diagnosis for 
both adults and children. Net survival is the cumulative 
probability of surviving up to a given time since diagnosis 
(eg, 5 years) after correcting for other causes of death 
(background mortality). We used the Pohar Perme 
estimator,34 which takes unbiased account of the higher 
competing risks of death in elderly people, implemented 
with the algorithm stns35 in Stata (version 14).
To control for the wide differences in background 
mortality between participating jurisdictions and over 
time, we produced 6210 life tables of all-cause mortality 
rates for each calendar year during 2000–14 in the general 
population of each country or registry territory, by single 
year of age, by sex, and by race or ethnicity in Australia 
(Northern Territory: Indigenous or non-Indigenous), 
Israel (Arab or Jewish), New Zealand (Māori or non-
Māori), and Singapore (Chinese, Malay, or Indian). For 
127 registries, we obtained complete life tables that did 
not require interpolation or smoothing for each calendar 
year in 2000–14.
For 193 registries, the method of life table construction 
depended on whether we received raw data (numbers of 
deaths and populations) or mortality rates, and on 
whether the raw data or the mortality rates were by 
single year of age (ie, complete) or by 5-year age group 
(ie, abridged).
For 108 registries, we obtained death and population 
counts from the registry or the relevant national 
statistical authority. We derived life tables for 2001 and 
2013 if possible, each centred on 3 calendar years of 
data (eg, 2000–02 or 2012–14) to increase the robustness 
of the rates. We constructed raw mortality rates from 
the death and population counts using a Poisson 
regression model with flexible functions,36 then 
smoothed and extended the rates to obtain complete 
life tables by sex and single year of age up to age 
99 years. Life tables for each calendar year in 2002–12 
were created by linear interpolation between the 2001 
and 2010 life tables.37 Rather than extrapolate, we used 
the life table centred on 2001 for 2000, and the life table 
centred on 2013 for 2014.
For 56 registries that provided abridged mortality rates, 
or complete mortality rates that were not smoothed, we 
used the Ewbank relational model38 with three or four 
parameters to interpolate (if abridged) and smooth the 
mortality rates for the registry territory against a high-
quality smooth life table for a country with a similar 
pattern of mortality by age.39
Each set of life tables was checked with a standardised 
statistical summary on the earliest and latest year of 
available data, showing the data source and the method of 
construction and smoothing. For each sex and, where 
relevant, each race or ethnicity, the reports show the life 
expectancy at birth, the probability of death in the age 
bands 15–59, 60–84, and 85–99 years, and semi-log plots 
of the age–mortality rates from 0 to 99 years, showing 
both the raw datapoints and the final smoothed life-table 
curve, and the model residuals by age group (appendix 
pp 268–271).
Collection of authoritative raw data on the numbers of 
deaths and populations by age, sex, and calendar year or 
period in participating jurisdictions proved more difficult 
than in 2013–14. For 29 registries, no reliable data on all-
cause mortality could be obtained for the registry 
territory. We took national life tables published by the 
UN Population Division28 and interpolated and extended 
them to age 99 years with the Elandt-Johnson method.40
For the 42 participating states in the USA, we used life 
tables by state, race, and socioeconomic status, provided 
by the US National Cancer Institute (Mariotto A; personal 
communication on Jan 26, 2016).
For each country, registry, and calendar period, we 
present age-standardised net survival estimates for each 
cancer at 5 years after diagnosis. For adults, we used the 
International Cancer Survival Standard (ICSS) weights,41 
in which age at diagnosis is categorised into five groups: 
15–44, 45–54, 55–64, 65–74, and 75–99 years and, for 
prostate cancer, 15–54, 55–64, 65–74, 75–84, and 
85–99 years. Of the three sets of ICSS weights, we used 
group 2 (cancers for which incidence does not increase 
steeply with age) for melanoma of the skin, cervix uteri, 
and brain (adults), and group 1 (cancers for which 
incidence does increase steeply with age) for oesophagus, 
stomach, colon, rectum, liver, pancreas, lung, breast, 
ovary, and prostate, and both groups of haemopoietic 
malignancies. For children, we estimated survival for 
the age groups 0–4, 5–9, and 10–14 years; we obtained 
age-standardised estimates by assigning equal weights 
to the three age-specific estimates.41,42
Cumulative survival probabilities in the range 0–1 are 
presented for convenience as percentages in the 
range 0–100%. 95% CIs for both unstandardised and 
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age-standardised survival estimates were derived assuming 
a normal distribution, truncated to the range 0–100. 
Standard errors to construct the CIs were derived with the 
Greenwood method.43 If no death or censoring occurred 
within 5 years, or if all patients died within 5 years (survival 
probability 1 or 0), we obtained a binomial approximation 
for the lower or upper bound, respectively, of the CI.30
We did not estimate survival if fewer than ten patients 
were available for analysis. If 10–49 patients were available 
for analysis in a given calendar period, we only estimated 
survival for all ages combined. If 50 or more patients 
were available, we attempted survival estimation for each 
age group. If a single age-specific estimate could not be 
obtained, we merged the data for adjacent age groups and 
assigned the combined estimate to both age groups 
before standardisation for age. If two or more age-specific 
estimates could not be obtained, we present only the 
unstandardised estimate for all ages combined. We did 
not merge data between consecutive calendar periods.
We considered survival estimates as less reliable if 
15% or more of patients were lost to follow-up or 
censored alive within 5 years of diagnosis. For patients 
diagnosed in 2010 or later, this criterion was applied for 
patients censored alive before Dec 31, 2014, the study 
closure date. Estimates are also considered less reliable 
if 15% or more of patients were registered only from a 
death certificate or at autopsy and excluded from 
analysis, because their survival is unknown. Finally, 
estimates are also considered less reliable if 15% or 
more of patients were excluded from analysis because 
one or more dates was incomplete: unknown year of 
birth, unknown month or year of diagnosis, or 
unknown year of last known vital status.
The pooled estimates for countries with more than one 
registry do not include data from registries for which the 
estimates were less reliable. Less reliable estimates are 
shown with a flag in figures and tables when they are the 
only available information from a given country or territory.
Role of the funding source
The funding sources played no part in the design, data 
collection, quality control, analysis, interpretation of the 
findings, writing of the manuscript, or the decision to 
submit for publication. The corresponding author had 
full access to all data and responsibility for submission 
for publication.
Figure 1: Participating countries and regions: world (adults)
Registries in smaller countries are shown in boxes, at different scales. See appendix (pp 178–208) for regional maps and for world map for childhood cancers.
National coverage
Regional coverage
Regional territory (no data)
No coverage
Guadeloupe
Martinique Gibraltar
Cuba
Puerto Rico Malta Qatar MauritiusCyprus Jordan
Israel
TaiwanHong Kong
0 25001250 5000 10 000 km
Articles
1032 www.thelancet.com   Vol 391   March 17, 2018
Results
The CONCORD database 2000–14
We analysed data for 322 cancer registries in 71 countries 
in Africa (eight registries, six countries), Central and 
South America (33 registries, 13 countries), North 
America (57 registries, two countries), Asia (66 registries, 
17 countries), Europe (149 registries, 31 countries), and 
Oceania (nine registries, two countries; figure 1).
For 47 countries, data were provided with 100% coverage 
of the national population: 41 countries for both adults and 
children, and six for children only (Argentina, Belarus, 
France, Greece, Mexico, and Switzerland; table 3). In the 
other countries, population coverage varied from less than 
1% in India to 86% in the USA (tables 4, 5). 80 cancer 
registries joined the CONCORD programme for the first 
time. The 322 participating registries covered a combined 
pop ulation of almost 1 billion people around 2014 
(989 082 244; tables 4, 5). Detailed maps of participating 
jurisdictions are shown in the appendix (pp 178–208).
Coverage is now national in Australia, and contributions 
from additional registries increased the population 
coverage in another 14 of the 25 countries that participated 
in CONCORD-2 with subnational coverage. These are 
Africa: Algeria (from 1·6% to 6·0%); Central and South 
America: Brazil (from 5·7% to 7·7%), Chile (from 5·5% 
to 13·8%), Colombia (from 6·9% to 9·0%), and Ecuador 
(from 33·8% to 40·2%); North America: the USA (from 
83·2% to 85·8%); Asia: Japan (from 29·2% to 40·6%), 
Thailand (from 5·9% to 20·3%), and Turkey (from 5.4% 
to 23·4%); Europe: France (from 18·4% to 21·7%), Italy 
(from 38·6% to 58·3%), Romania (from 3·1% to 5·0%), 
Russia (from 0·9% to 5·6%), and Switzerland (from 
47·4% to 54·7%); and Oceania: Australia (from 90·8% to 
100·0%). International coverage has been reduced by the 
loss of data from Indonesia (Jakarta) and from four 
countries in Africa: Gambia, Lesotho, Libya, and Tunisia.
Three of the Polish registries that participated in 
CONCORD-2 now use a different or anglicised name, 
changing the alphabetical order in the supplementary 
tables: Holy Cross (formerly Kielce), Lower Silesia 
(Wrocław), and Subcarpathia (Podkarpackie). All 
16 voivodeships of Poland are now included.
Four registries submitted data with wider territorial 
coverage than before. The Burgundy (Digestive) registry 
in France submitted data for both the Saône-et-Loire and 
the Côte-d’Or departments; in Italy, the Biella registry 
now covers the Vercelli province as well as Biella, and the 
Milan registry now covers the Milan province and Lodi as 
well as the city of Milan; and the Cluj registry in Romania 
expanded coverage from Cluj county to include Bistrița-
Năsăud county.
We received more than 4700 datasets. We examined 
individual cancer registrations for 42 222 177 patients 
diagnosed with an index cancer during the period 2000–14 
(table 3). Of these, 2 690 466 (6·4%) were for an in-situ 
cancer, mostly of the cervix (54·6% of 1 708 385 women), 
melanoma of the skin (27·0% of 2 262 368 patients), breast 
(10·6% of 7 379 194 women), rectum (4·8% of 
1 881 039 patients), colon (4·4% of 4 619 844 adults), or 
prostate (0·6% of 6 069 870 men; appendix pp 6–101). The 
proportions of in-situ cancer are not directly comparable 
between countries because some registries still do not 
record in-situ malignancies, whereas others did not 
submit data for cancers for which in-situ malignancy 
is common. The variation between continents is still 
of interest: for cervical cancer, it ranged from 2·2% in 
African registries to 23·6% in Central and South American 
registries, 37·4% in Asian registries, 66·7% in European 
registries, and 81·9% in Oceania; US registries did not 
submit data for in-situ cervical cancers and only three 
Canadian provinces did so. The proportion of in-situ breast 
cancers varied from 0·2% in African registries to 4-6% in 
Central and South America, Asia, Europe, and Oceania, 
and 17·3% in North America (appendix pp 52–56).
Patients with in-situ cancer were not included in 
survival analyses. We excluded a further 227 038 (0·5%) 
patients because the year of birth, the month or year of 
diagnosis, or the year of last known vital status was 
unknown; and 527 408 (1·2%) patients because the 
tumour was not a primary, invasive malignancy 
(behaviour code 3); or the morphology was that of 
Kaposi’s sarcoma or lymphoma in a solid organ; or for 
other reasons (table 3). The proportion of records 
excluded for these reasons is shown for each cancer and 
each cancer registry in the appendix (pp 6–101).
Of the 38 777 265 patients otherwise eligible for inclusion 
in survival analyses, we excluded 1 132 833 (2·9%) records 
because the cancer was registered only from a death 
certificate or discovered at autopsy (table 3) and a further 
131 407 (0·3%) for other reasons. These reasons included 
definite errors (unknown vital status, unknown sex, sex-
site error, and invalid dates or sequence of dates) and 
possible errors, such as apparent inconsistencies between 
age, cancer site, and morphology (details on request). For 
example, we excluded hepato blastomas in children older 
than 6 years and multiple myeloma in people aged less 
than 20 years, unless the record was confirmed as correct 
by the registry concerned.
Among the 37 513 025 patients available for survival 
analyses for all cancers combined (96·7% of those 
eligible for inclusion), pathological evidence of 
malignancy (histology, cytology, or haematology) was 
available for 35 502 123 (94·6%). This proportion ranged 
from 88·6% in Asia, 91·6% in Africa, and 92·4% in 
Central and South America up to 94–98% in Europe, 
Oceania, and North America (table 3). Continental 
variation was much wider for some cancers (appendix 
pp 6–101).
In what follows, we present results in a similar structure 
for each group of cancers. Differences between survival 
estimates are given as the arithmetic difference: 
for example, 12% is 2% (not 20%) higher than 10%. We use 
flags in the figures (figures 2, 3) and tables (tables 6, 7) to 
indiate where survival estimates are based on national 
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Calendar 
period
Patients 
submitted
Ineligible patients† Eligible 
patients
Excluded§ Patients 
included
Data quality indicators¶
Incomplete 
dates
In situ Other DCO Other Micro scop-
ically verified
Non-specific 
morphology
Lost to 
follow-up
Censored
Africa 46 627 9·6% 0·4% 1·1% 41 447 0·9% 2·1% 40 197 91·6% 14·1% 7·6% 37·7%
Algerian registries 2000–14 18 157 7·6% 0·1% 1·8% 16 434 1·8% 3·3% 15 602 98·4% 10·2% 0·0% 31·5%
Mali (Bamako) 2010–12 104 41·3% 0·0% 0·0% 61 0·0% 1·6% 60 100·0% 20·0% 0·0% 0·0%
Mauritius* 2005–12 4125 0·0% 0·0% 0·4% 4109 0·0% 3·7% 3959 96·7% 19·8% 0·0% 2·3%
Morocco 
(Casablanca)
2008–12 4840 1·4% 0·0% 0·1% 4769 0·0% 1·8% 4683 100·0% 2·4% 33·0% 35·6%
Nigeria (Ibadan) 2003–14 11 726 25·4% 1·4% 1·2% 8443 0·9% 1·1% 8274 98·7% 2·0% 0·0% 65·3%
South Africa 
(Eastern Cape)
2000–14 7675 0·0% 0·0% 0·6% 7631 0·0% 0·2% 7619 62·3% 39·5% 19·7% 40·2%
America (Central and 
South)
906 076 5·4% 3·1% 0·7% 822 687 13·7% 1·1% 700 946 92·4% 8·0% 5·2% 3·7%
Argentinian 
registries‡
2000–14 75 167 1·7% 1·5% 0·5% 72 366 10·8% 0·6% 64 151 96·5% 5·7% 0·0% 2·3%
Brazilian registries 2000–14 191 344 18·5% 3·9% 0·5% 147 622 8·0% 0·9% 134 597 90·0% 10·6% 22·9% 0·3%
Chilean registries 2000–12 28 987 0·0% 0·8% 0·7% 28 555 7·6% 0·1% 26 363 86·2% 12·0% 0·0% 13·6%
Colombian 
registries
2000–14 63 402 3·1% 1·5% 1·2% 59 740 5·0% 0·9% 56 245 89·9% 11·3% 0·0% 21·0%
Costa Rica* 2002–14 72 900 0·0% 4·1% 1·4% 68 900 8·4% 0·8% 62 536 90·1% 13·0% 0·0% 0·0%
Cuba* 2000–12 193 196 0·0% 0·0% 0·2% 192 755 32·3% 2·5% 125 696 91·8% 5·1% 2·6% 0·0%
Ecuadorian 
registries
2000–14 71 798 7·7% 8·2% 0·8% 59 892 9·8% 1·6% 53 043 92·0% 9·9% 0·3% 2·7%
Guadeloupe* 2008–13 8896 0·0% 12·0% 0·3% 7802 0·0% 0·2% 7787 99·1% 2·1% 0·0% 57·7%
Martinique* 2000–12 16 066 0·0% 0·0% 0·1% 16 053 0·0% 1·7% 15 779 97·3% 0·7% 7·3% 0·1%
Mexico 
(childhood)‡
2008–14 9749 5·8% 0·0% 9·7% 8236 0·0% 0·5% 8194 99·8% 3·9% 9·3% 7·6%
Peru (Lima) 2010–12 19 078 0·1% 0·0% 0·7% 18 929 8·9% 0·1% 17 226 93·9% 2·9% 0·0% 10·2%
Puerto Rico* 2000–11 118 877 3·7% 3·9% 0·7% 109 001 6·4% 0·3% 101 613 98·4% 3·4% 0·0% 0·0%
Uruguay* 2008–12 36 616 0·0% 9·6% 0·7% 32 836 15·5% 0·1% 27 716 85·0% 15·9% 0·0% 0·0%
America (North) 15 925 870 0·7% 6·8% 0·7% 14 622 183 1·8% 0·3% 14 320 034 97·7% 3·0% 1·4% 0·0%
Canadian registries 2000–14 1 519 461 0·1% 4·9% 0·7% 1 431 975 1·2% 0·4% 1 409 413 94·8% 5·5% 0·0% 0·0%
US registries 2000–14 14 406 409 0·7% 7·0% 0·7% 13 190 208 1·8% 0·3% 12 910 621 98·0% 2·8% 1·5% 0·0%
Asia 6 595 363 0·6% 3·4% 0·4% 6 298 518 4·7% 0·4% 5 976 959 88·6% 11·5% 0·4% 1·0%
Chinese registries 2003–13 610 729 0·8% 0·2% 0·2% 603 861 1·4% 0·1% 594 533 66·2% 41·8% 3·2% 0·1%
Cyprus* 2004–14 25 086 1·4% 2·6% 0·8% 23 880 9·0% 0·5% 21 610 98·9% 1·8% 0·0% 34·8%
Hong Kong* 2005–14 78 127 3·8% 0·0% 0·0% 75 146 0·4% 0·2% 74 721 96·6% 0·0% 5·5% 0·0%
Indian registries 2000–14 5048 3·2% 0·0% 0·0% 4882 1·7% 0·6% 4774 82·1% 25·1% 1·8% 0·1%
Iran (Golestan) 2006–08 1187 0·0% 0·0% 0·5% 1181 8·9% 3·1% 1 039 82·1% 17·9% 8·9% 0·0%
Israel* 2000–13 282 191 0·0% 7·3% 2·2% 255 359 4·8% 0·4% 241 881 96·8% 4·2% 0·0% 0·0%
Japanese registries 2000–14 2 237 861 1·0% 4·8% 0·5% 2 096 697 12·4% 0·1% 1 834 894 91·4% 11·3% 0·0% 1·7%
Jordan* 2000–14 43 442 0·2% 1·2% 1·5% 42 179 0·2% 1·6% 41 433 99·1% 3·0% 5·9% 0·0%
Korea* 2000–14 1 770 463 0·5% 0·0% 0·0% 1 762 176 0·0% 0·1% 1 760 804 93·1% 7·8% 0·0% 0·0%
Kuwait* 2000–13 8931 0·0% 1·4% 1·1% 8710 2·3% 0·3% 8484 99·8% 0·4% 1·2% 0·0%
Malaysia (Penang) 2000–13 19 612 0·3% 0·0% 0·1% 19 527 1·6% 2·1% 18 805 94·2% 9·5% 0·0% 13·0%
Mongolia* 2003–14 1025 0·0% 1·1% 0·0% 1014 0·3% 1·2% 999 77·0% 4·1% 7·6% 0·0%
Qatar* 2000–14 7940 0·0% 1·0% 1·0% 7778 1·0% 0·7% 7642 95·4% 6·3% 0·0% 51·0%
Singapore* 2000–14 122 461 0·0% 7·0% 1·9% 111 495 1·1% 0·3% 109 992 91·7% 1·9% 0·0% 0·0%
Taiwan* 2000–14 941 313 0·1% 8·6% 0·1% 859 169 0·0% 0·1% 858 683 86·6% 0·5% 0·0% 0·0%
Thai registries 2000–14 183 776 0·0% 0·3% 0·5% 182 455 3·8% 8·7% 159 528 68·6% 34·0% 0·0% 3·0%
Turkish registries 2000–13 256 171 1·5% 2·7% 0·9% 243 009 1·9% 0·5% 237 137 94·7% 7·9% 0·2% 3·8%
(Table 3 continues on next page)
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population coverage, are unstandardised, or are considered 
less reliable. Where relevant, we mention in the text only 
reliable, age-standardised survival estimates. Where 
possible, we also present graphics of national trends in 
cancer survival over the 20-year period 1995–2014. 
Estimates for patients diagnosed during 1995–99 are for 
countries that provided data for one of the ten cancers 
included in CONCORD-2.6
Calendar 
period
Patients 
submitted
Ineligible patients† Eligible 
patients
Excluded§ Patients 
included
Data quality indicators¶
Incomplete 
dates
In situ Other DCO Other Micro scop-
ically verified
Non-specific 
morphology
Lost to 
follow-up
Censored
(Continued from previous page)
Europe 17 057 088 0·1% 7·0% 2·1% 15 481 564 2·8% 0·3% 14 991 316 94·0% 3·9% 0·9% 2·1%
Austria* 2000–14 486 379 0·0% 7·4% 1·2% 444 735 6·1% 1·1% 412 683 98·0% 4·9% 0·0% 0·0%
Belarus 
(childhood)‡
2000–14 1740 0·0% 0·0% 0·0% 1740 0·6% 2·5% 1687 97·9% 2·5% 1·5% 0·0%
Belgium* 2004–14 616 737 0·0% 11·4% 0·2% 545 373 0·0% 0·2% 544 110 98·4% 2·0% 1·1% 0·0%
Bulgaria* 2000–14 299 563 0·0% 0·0% 0·1% 299 333 8·5% 0·0% 273 868 89·2% 1·4% 0·1% 0·0%
Croatia* 2000–14 246 883 0·0% 3·5% 0·2% 237 793 6·2% 0·1% 222 776 82·9% 0·5% 0·0% 0·0%
Czech Republic* 2000–14 640 594 0·0% 7·5% 1·6% 582 748 1·3% 0·4% 572 368 90·3% 1·5% 0·0% 0·0%
Denmark* 2000–14 366 310 0·0% 0·0% 0·2% 365 525 0·0% 0·1% 365 105 96·3% 6·8% 0·2% 0·0%
Estonia* 2000–12 64 038 0·0% 1·8% 0·7% 62 396 3·9% 0·2% 59 848 89·2% 2·0% 0·3% 0·0%
Finland* 2000–14 328 513 0·6% 5·4% 0·9% 306 077 3·8% 0·1% 294 268 95·8% 3·2% 0·1% 0·0%
French registries‡ 2000–12 466 020 0·2% 0·0% 0·3% 463 588 0·0% 0·6% 460 927 96·1% 0·6% 1·8% 0·1%
German registries 2000–14 1 925 070 0·4% 4·5% 1·0% 1 811 465 10·3% 0·2% 1 621 312 97·5% 0·7% 0·3% 17·7%
Gibraltar* 2000–10 732 13·0% 11·7% 1·1% 543 0·2% 1·7% 533 99·6% 0·8% 0·0% 41·7%
Greece (childhood)‡ 2000–14 1743 0·6% 0·0% 0·0% 1733 0·0% 0·4% 1726 99·9% 0·1% 0·8% 0·2%
Iceland* 2000–14 15 245 0·0% 1·4% 0·8% 14 918 0·8% 0·1% 14 782 96·5% 3·9% 0·0% 0·0%
Ireland* 2000–13 240 962 0·0% 16·3% 0·9% 199 552 1·5% 0·2% 196 331 92·2% 1·7% 0·0% 0·0%
Italian registries 2000–14 1 452 003 0·0% 1·8% 0·8% 1 414 476 0·7% 0·3% 1 400 117 87·5% 14·1% 0·7% 0·8%
Latvia* 2000–14 97 852 0·0% 0·1% 26·8% 71 511 0·0% 0·6% 71 082 99·8% 1·1% 0·0% 0·0%
Lithuania* 2000–12 154 857 0·0% 4·1% 1·1% 146 896 4·9% 0·2% 139 475 87·6% 1·5% 0·0% 0·3%
Malta* 2000–13 17 625 0·0% 6·9% 1·8% 16 091 3·1% 0·4% 15 518 92·4% 8·9% 0·0% 0·0%
Netherlands* 2000–14 1 047 456 0·0% 3·8% 1·2% 994 826 0·2% 0·6% 987 029 96·2% 4·0% 0·5% 0·0%
Norway* 2000–14 488 733 0·0% 10·3% 32·5% 279 696 0·5% 0·1% 277 991 99·8% 0·4% 0·2% 0·0%
Poland* 2000–14 1 389 978 0·0% 0·1% 0·3% 1 383 780 2·5% 0·3% 1 344 837 91·4% 1·3% 0·0% 0·0%
Portugal* 2000–14 408 523 0·7% 2·7% 1·5% 388 199 0·1% 0·2% 386 853 96·7% 2·7% 1·7% 0·0%
Romania (Cluj) 2006–12 17 740 0·0% 3·1% 1·7% 16 894 16·6% 0·2% 14 060 90·1% 10·7% 0·0% 0·0%
Russian registries 2000–14 252 171 0·0% 0·5% 0·4% 249 928 0·8% 1·0% 245 591 85·4% 4·1% 2·0% 1·3%
Slovakia* 2000–10 180 029 0·0% 4·1% 1·3% 170 269 8·2% 0·1% 156 122 94·0% 6·7% 0·0% 0·0%
Slovenia* 2000–13 124 213 0·0% 13·0% 2·4% 105 052 2·0% 0·0% 102 970 93·5% 0·3% 0·1% 0·0%
Spanish registries 2000–14 417 865 0·3% 6·8% 0·9% 384 586 1·9% 0·2% 376 759 91·7% 2·2% 0·5% 0·5%
Sweden* 2000–14 676 693 0·0% 15·4% 3·0% 551 717 1·1% 0·2% 544 531 98·6% 2·2% 0·2% 0·0%
Swiss registries‡ 2000–14 241 610 0·0% 7·9% 2·5% 216 439 1·2% 0·5% 212 695 95·9% 2·4% 4·6% 3·9%
UK* 2000–14 4 389 211 0·1% 13·0% 1·4% 3 753 685 1·8% 0·3% 3 673 362 94·9% 4·5% 1·9% 0·0%
Oceania 1 691 153 0·3% 9·7% 0·7% 1 510 866 1·6% 0·2% 1 483 573 96·5% 3·6% 0·0% 0·0%
Australia* 2000–14 1 443 620 0·3% 11·3% 0·8% 1 263 961 1·4% 0·2% 1 244 350 97·0% 3·0% 0·0% 0·0%
New Zealand* 2000–14 247 533 0·0% 0·0% 0·3% 246 905 2·9% 0·2% 239 223 94·3% 6·3% 0·0% 0·0%
Total 42 222 177 0·5% 6·4% 1·2% 38 777 265 2·9% 0·3% 37 513 025 94·6% 4·9% 1·0% 1·1%
DCO=death certificate only. *Data with 100% coverage of the national population. †Incomplete dates: records in which the year of birth is unknown; or the month or year of diagnosis is unknown; or the year 
of last known vital status is unknown. In-situ malignancy (ICD-O-3 behaviour code 2): some registries do not register in-situ cancers; other registries did not submit them. Other: records with incomplete 
data or for tumours that are benign (behaviour code 0, except brain tumours), of uncertain behaviour (behavior code 1), metastatic from another organ (behavior code 6), or unknown if primary or 
metastatic (behavior code 9); or for patients with age outside the range 0–14 years (children) or 15–99 years (adults); or other conditions. ‡Data with 100% coverage of the national population for childhood 
malignancies only. §DCO: tumours registered only from a death certificate or detected at autopsy. Sweden does not register DCOs; autopsy-detected cases were not submitted for CONCORD-2 but have been 
submitted for CONCORD-3. Other: vital status or sex unknown; invalid date or sequence of dates; inconsistency of sex–site, site-morphology, age–site, age-morphology, or age–site-morphology. 
¶Non-specific morphology (solid tumours only): ICD-O-317,18 morphology code in the range 8000–8005. Censored: patients whose last known vital status is “alive” and who were censored within 5 years of 
diagnosis or, if diagnosed in 2010 or later, before Dec 31, 2014. 
Table 3: Data quality indicators: patients diagnosed during 2000–14 by continent and country
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Oesophagus
Results are available for 734 428 adults from 
290 registries in 60 countries (table 2, table 4). In 
2010–14, 5-year age-standardised net survival was in 
the range 10–30% in most countries, with a much 
wider range in Asia (appendix p 248). Most survival 
estimates were considered reliable (table 6; appendix 
pp 138–151).
Population 
covered
Percentage 
of national 
population 
covered
Number of patients Total 
number of 
patients†
Oesophagus Stomach Colon Rectum Liver Pancreas Lung Melanoma 
of the skin
Africa 10 533 762 3·5% 3057 1731 2172 1487 869 379 2734 368 40 197
Algerian registries 2 447 075 6·3% 104 1129 1331 827 244 272 1852  248 15 602
Mali (Bamako) 764 245 9·0% ·· ·· ·· ·· ·· ·· ··  ·· 60
Mauritius* 1 268 567 100·0% 59 494 494 289 27 45 584  4 3959
Morocco (Casablanca) 2 178 083 12·7% ·· ·· ·· ·· ·· ·· ·· ·· 4683
Nigeria (Ibadan) 2 797 220 1·6% ·· ·· 230 266 333 ·· ··  69 8274
South Africa (Eastern 
Cape)
1 078 572 2·0% 2894 108 117 105 265 62 298  47 7619
America (Central and 
South)
99 818 363 23·7% 13 528 60 643 82 843 26 424 9019 15 731 53 959 8202 700 946
Argentinian registries‡ 3 973 922 9·2% 1152 2686 6076 1959 968 1657 5195 1084 64 151
Brazilian registries 15 882 624 7·7% 6678 15 567 21 984 10 354 858 5520 4884 1424 134 597
Chilean registries 2 459 133 13·8% 918 4423 1949 824 525 793 2166 554 26 363
Colombian registries 4 277 369 9·0% 642 7988 3874 1990 1129 1303 3965 1373 56 245
Costa Rica* 4 757 606 100·0% 528 8577 5438 1926 1239 1188 2688 1432 62 536
Cuba* 11 379 111 100·0% ·· 6664 15 047 ·· ·· ·· 19 344 ·· 125 696
Ecuadorian registries 6 398 546 40·2% 486 7210 3203 1622 1502 1069 2641 1080 53 043
Guadeloupe* 450 273 100·0% 119 521 724 210 82 167 308 52 7787
Martinique* 396 425 100·0% 213 973 1305 423 206 473 693 164 15 779
Mexico (childhood)‡ 35 188 624 100·0% ·· ·· ·· ·· ·· ·· ·· ·· 8194
Peru (Lima) 7 548 697 24·4% ·· ·· 2803 992 ·· ·· ·· ·· 17 226
Puerto Rico* 3 686 517 100·0% 1743 3900 14 594 3882 2202 1984 6570 1039 101 613
Uruguay* 3 419 516 100·0% 1049 2134 5846 2242 308 1577 5505 ·· 27 716
America (North) 301 237 785 84·8% 195 255 283 566 1 471 548 461 707 246 966 462 187 2 564 507 678 206 14 320 034
Canadian registries 27 213 277 76·5% 18 788 33 889 166 760 60 958 20 858 41 908 236 434 65 235 1 409 413
US registries 274 024 508 85·8% 176 467 249 677 1 304 788 400 749 226 108 420 279 2 328 073 612 971 12 910 621
Asia 227 771 765 7·2% 206 254 971 935 703 081 361 987 617 479 205 345 950 362 31 314 5 976 959
Chinese registries 31 755 347 2·3% 72 714 92 578 35 001 31 498 74 295 19 110 133 932 1 449 594 533
Cyprus* 1 153 658 100·0% 81 802 2665 788 247 534 2489 589 21 610
Hong Kong* 7 241 700 100·0% ·· ·· 28 797 12 856 ·· ·· ·· ·· 74 721
Indian registries 1 005 294 0·1% 269 303 199 191 230 134 850 29 4774
Iran (Golestan) 1 893 646 2·4% 412 353 216 58 ·· ·· ·· ·· 1039
Israel* 7 939 483 100·0% 1691 9737 33 938 9401 2310 8083 25 347 12 265 241 881
Japanese registries 51 445 407 40·6% 63 631 381 457 247 682 102 776 122 792 79 636 276 444 4018 1 834 894
Jordan* 7 416 083 100·0% 352 1955 5116 1775 606 952 4282 214 41 433
Korea* 50 074 400 100·0% 30 627 396 213 187 078 121 053 214 821 59 357 257 345 5771 1 760 804
Kuwait* 3 753 121 100·0% 90 207 908 330 261 240 559 18 8484
Malaysia (Penang) 1 543 500 5·2% 290 1061 2285 1126 927 539 2863 ·· 18 805
Mongolia* 1 468 823 100·0% ·· ·· ·· ·· ·· ·· ·· ·· 999
Qatar* 2 172 065 100·0% 98 361 784 283 438 186 587 55 7642
Singapore* 3 870 700 100·0% 1 434 6822 17 225 6241 7101 3481 17 921 367 109 992
Taiwan* 23 123 866 100·0% 27 680 54 983 108 844 57 163 158 157 22 283 141 108 2988 858 683
Thai registries 13 738 188 20·3% 3344 5321 13 801 6679 30 814 3284 28 865 695 159 528
Turkish registries 18 176 484 23·4% 3541 19 782 18 542 9769 4480 7526 57 770 2856 237 137
(Table 4 continues on next page)
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Survival was highest in Japan (36·0%) and Korea 
(31·3%), and less than 30% in all other countries (table 6; 
appendix p 210). Survival was in the range 20–30% in 
ten countries: Puerto Rico; the USA; China and Israel; 
five European countries (Ireland [northern Europe]; and 
Belgium, Germany, the Netherlands, and Switzerland 
[western Europe]); and Australia.
Survival trends from 2000 to 2014 increased by 4–5% 
in three European countries (Denmark and the UK 
[northern Europe]; and Germany [western Europe]), and 
Population 
covered
Percentage 
of national 
population 
covered
Number of patients Total 
number of 
patients†
Oesophagus Stomach Colon Rectum Liver Pancreas Lung Melanoma 
of the skin
(Continued from previous page)
Europe 321 365 615 50·0% 294 606 668 096 1 764 170 801 387 283 720 506 723 2 317 434 647 507 14 991 316
Austria* 8 516 916 100·0% 5324 19 308 46 127 23 360 10 570 18 371 56 130 19 150 412 683
Belarus (childhood)‡ 1 498 163 100·0% ·· ·· ·· ·· ·· ·· ·· ·· 1687
Belgium* 11 226 322 100·0% 10 191 15 222 63 540 27 614 7026 15 015 83 551 21 905 544 110
Bulgaria* 7 201 308 100·0% ·· 21 404 37 854 22 511 5704 ·· 50 210 5875 273 868
Croatia* 4 255 853 100·0% 3007 14 589 27 382 15 309 5456 8596 41 744 7848 222 776
Czech Republic* 10 542 666 100·0% 7764 24 157 83 481 34 838 12 056 27 622 93 241 27 800 572 368
Denmark* 5 646 899 100·0% 6556 8022 40 495 22 384 4708 13 279 62 402 24 630 365 105
Estonia* 1 316 203 100·0% 786 5212 6523 3062 903 2698 9201 1983 59 848
Finland* 5 479 660 100·0% 3686 9871 25 374 12 847 5096 12 851 31 950 14 949 294 268
French registries‡ 13 891 552 21·7% 9958 13 770 53 149 20 018 14 818 15 328 51 989 13 677 460 927
German registries 29 655 933 36·8% 27 208 75 378 191 396 99 791 28 301 57 498 212 897 78 713 1 621 312
Gibraltar* 31 997 100·0% 12 29 81 21 5 13 63 31 533
Greece (childhood)‡ 1 610 335 100·0% ·· ·· ·· ·· ·· ·· ·· ·· 1726
Iceland* 327 318 100·0% 271 473 1433 580 165 481 2 314 713 14 782
Ireland* 4 675 164 100·0% 4899 6801 21 724 9085 2178 5931 26 838 9470 196 331
Italian registries 34 479 972 57·7% 12 219 80 686 188 983 53 226 63 084 56 698 203 548 46 607 1 400 117
Latvia* 1 989 354 100·0% 1294 6878 7658 4748 464 1072 9691 2503 71 082
Lithuania* 2 916 798 100·0% 2130 11 840 11 148 7694 1776 5421 18 499 3317 139 475
Malta* 417 723 100·0% 184 656 1908 781 152 709 2043 541 15 518
Netherlands* 16 868 020 100·0% 25 342 29 585 126 237 51 839 6397 28 717 159 895 59 088 987 029
Norway* 5 147 970 100·0% 3021 7548 36 646 16 306 1916 6671 33 558 19 994 277 991
Poland* 38 483 957 100·0% 18 959 79 466 140 075 83 669 20 764 47 635 306 136 35 834 1 344 837
Portugal* 10 566 132 100·0% 6122 33 865 57 219 25 989 5107 8303 40 422 9358 386 853
Romania (Cluj) 983 525 5·0% 216 1201 1552 657 547 563 2126 436 14 060
Russian registries 8 081 400 5·6% 6000 31 711 28 946 16 305 3757 10 048 42 434 4914 245 591
Slovakia* 5 422 861 100·0% 2794 9604 23 694 11 066 2741 6624 22 971 6389 156 122
Slovenia* 2 066 068 100·0% 1202 6443 12 376 6682 1964 4073 16 051 5603 102 970
Spanish registries 9 396 745 20·3% 5637 17 844 54 250 18 245 11 848 12 438 54 237 11 028 376 759
Sweden* 9 703 247 100·0% 6233 13 463 55 664 29 777 7242 14 240 51 122 36 921 544 531
Swiss registries‡ 4 368 854 53·2% 3583 6135 21 137 8633 5070 7694 27 116 14 893 212 695
UK* 64 596 700 100·0% 120 008 116 935 398 118 174 350 53 905 118 134 605 055 163 337 3 673 362
Oceania 27 952 971 100·0% 21 728 33 411 174 823 67 496 20 311 39 014 162 266 187 512 1 483 573
Australia* 23 457 489 100·0% 17 877 27 952 144 382 56 260 17 281 33 319 136 318 156 302 1 244 350
New Zealand* 4 495 482 100·0% 3851 5459 30 441 11 236 3030 5695 25 948 31 210 239 223
Total 988 680 261 20·2% 734 428 2 019 382 4 198 637 1 720 488 1 178 364 1 229 379 6 051 262 1 553 109 37 513 025
Populations given are for 2014 or nearest available year. Populations for 2014 are from the UN Population Division28 or national authorities in Australia, Guadeloupe, Hong Kong, Poland, Portugal, and Taiwan 
(2010). Subnational populations were provided by the registry concerned. Belarus, Greece, and Mexico only provided data for childhood cancers: national populations shown are for children (0–14 years). Mali, 
Mongolia, and Morocco only provided cancer data for women: national populations shown are for women. Population shown for France excludes Guadeloupe and Martinique. *Data with 100% coverage of the 
national population. †Total given is for all 18 cancers (see also table 5). ‡Data with 100% coverage of the national population for childhood malignancies only.
Table 4: Population covered by participating registries (number of people and percentage of national population) and number of adults diagnosed with cancer of the oesophagus, 
stomach, colon, rectum, liver, pancreas, or lung, or melanoma of the skin during 2000–14 by continent and country
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the USA (appendix p 229). Survival increased by 6–10% 
in Puerto Rico; China, Israel, Japan, and Singapore; 
six European countries (Ireland and Norway [northern 
Europe]; Portugal [southern Europe]; Belgium, the 
Netherlands, and Switzerland [western Europe]); and 
Australia. The increase in Korea was 12·7%.
Stomach
Results are available for 2 019 382 adults from 294 registries 
in 62 countries (table 2, table 4). Age-standardised 5-year 
net survival was generally in the range 20–40%, with very 
wide variation in Asia (appendix p 249). Most estimates 
were considered reliable (table 6; appendix pp 138–151).
In 2010–14, survival was very high in Korea (68·9%) and 
Japan (60·3%; table 6; appendix p 211). Survival was in the 
range 30–40% in 16 countries: Canada and the USA; Puerto 
Rico and Martinique; five Asian countries (Malaysia 
[Penang] and Singapore [south Asia]; China and Taiwan 
[east Asia]; and Israel [west Asia]); six European countries 
(Italy and Portugal [southern Europe]; and Austria, 
Belgium, Germany, and Switzerland [western Europe]); 
and Australia (table 6; appendix p 211).
Survival was in the range 20–29% in 24 countries 
(Mauritius, Kuwait, Turkey, 20 European countries, and 
New Zealand), and less than 20% in Chile, Ecuador, 
India (Karunagappally), Thailand, and Bulgaria.
Population 
covered
Percentage 
of national 
population 
covered
Number of patients Total 
number of 
patients†
Breast 
(women)
Cervix Ovary Prostate Brain 
(adults)
Myeloid 
(adults)
Lymphoid 
(adults)
Brain 
(children)
Acute 
lympho-
blastic 
leukaemia 
(children)
Lymph-
oma 
(children)
Africa 10 533 762 3·5% 15 117 5017 1010 2726 592 425 2042 179 64 228 40 197
Algerian 
registries
2 447 075 6·3% 5196 885 423 764 392 290 1376 109 45 115 15 602
Mali 
(Bamako)
764 245 9·0% 60 ·· ·· ·· ·· ·· ·· ·· ·· ·· 60
Mauritius* 1 268 567 100·0% 483 436 244 628 36 42 86 3 ·· 5 3959
Morocco 
(Casablanca)
2 178 083 12·7% 4683 ·· ·· ·· ·· ·· ·· ·· ·· ·· 4683
Nigeria 
(Ibadan)
2 797 220 1·6% 3962 1578 225 833 148 76 412 45 12 85 8274
South Africa 
(Eastern 
Cape)
1 078 572 2·0% 733 2118 118 501 16 17 168 22 7 23 7619
America 
(Central and 
South)
99 818 363 23·7% 159 976 49 067 16 023 115 102 8547 10 842 47 740 4936 13 299 5065 700 946
Argentinian 
registries‡
3 973 922 9·2% 15 282 2467 1688 7115 1217 1588 4281 2662 5119 1955 64 151
Brazilian 
registries
15 882 624 7·7% 49 811 3083 1201 7556 1011 852 3270 168 233 143 134 597
Chilean 
registries
2 459 133 13·8% 3717 1564 698 4816 475 652 1968 83 171 67 26 363
Colombian 
registries
4 277 369 9·0% 9609 5124 1759 8722 1601 1476 5004 243 306 137 56 245
Costa Rica* 4 757 606 100·0% 12 019 7466 1408 11 345 1067 857 4646 153 456 103 62 536
Cuba* 11 379 111 100·0% 33 313 16 396 4560 21 358 ·· ·· 8451 ·· ·· 563 125 696
Ecuadorian 
registries
6 398 546 40·2% 8283 5453 1732 7939 1481 1489 6330 324 859 340 53 043
Guadeloupe* 450 273 100·0% 1266 160 110 3389 55 115 480 14 9 6 7787
Martinique* 396 425 100·0% 2279 399 191 6480 182 482 1257 20 29 10 15 779
Mexico 
(childhood)‡
35 188 624 100·0% ·· ·· ·· ·· ·· ·· ·· 1047 5647 1500 8194
Peru (Lima) 7 548 697 24·4% 5590 2917 ·· ·· ·· 891 3 653 ·· 268 112 17 226
Puerto Rico* 3 686 517 100·0% 18 807 2458 1728 29 855 1458 2440 8400 222 202 129 101 613
Uruguay* 3 419 516 100·0% ·· 1580 948 6 527 ·· ·· ·· ·· ·· ·· 27 716
(Table 5 continues on next page)
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Population 
covered
Percentage 
of national 
population 
covered
Number of patients Total 
number of 
patients†
Breast 
(women)
Cervix Ovary Prostate Brain 
(adults)
Myeloid 
(adults)
Lymphoid 
(adults)
Brain 
(children)
Acute 
lympho-
blastic 
leukaemia 
(children)
Lymph-
oma 
(children)
(Continued from previous page)
America 
(North)
301 237 785 84·8% 2 587 798 163 517 312 954 2 703 952 251 888 508 562 1 356 829 27 157 29 995 13 440 14 320 034
Canadian 
registries
27 213 277 76·5% 237 321 16 054 31 395 256 736 28 186 49 474 139 370 2196 2712 1139 1 409 413
US registries 274 024 508 85·8% 2 350 477 147 463 281 559 2 447 216 223 702 459 088 1 217 459 24 961 27 283 12 301 12 910 621
Asia 227 771 765 7·2% 726 968 161 620 109 998 397 673 73 306 140 066 293 307 8513 11 371 6380 5 976 959
Chinese 
registries
31 755 347 2·3% 53 791 13 131 10 517 12 380 11 341 12 171 19 388 526 498 213 594 533
Cyprus* 1 153 658 100·0% 5069 321 553 4088 394 555 2326 14 56 39 21 610
Hong Kong* 7 241 700 100·0% 28 956 4112 ·· ·· ·· ·· ·· ·· ·· ·· 74 721
Indian 
registries
1 005 294 0·1% 812 753 172 183 162 153 272 18 32 12 4774
Iran 
(Golestan)
1 893 646 2·4% ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· 1039
Israel* 7 939 483 100·0% 51 125 2942 5663 32 503 5235 8375 30 911 843 754 758 241 881
Japanese 
registries
51 445 407 40·6% 184 372 30 606 31 244 168 505 15 007 37 845 85 640 1293 1438 508 1 834 894
Jordan* 7 416 083 100·0% 11 584 579 ·· 2457 1483 1917 6511 489 681 480 41 433
Korea* 50 074 400 100·0% 179 520 58 663 28 076 83 892 17 701 42 322 70 594 2333 3389 2049 1 760 804
Kuwait* 3 753 121 100·0% 2568 163 221 509 230 346 1405 49 251 129 8484
Malaysia 
(Penang)
1 543 500 5·2% 4606 1046 805 915 289 504 1244 84 156 65 18 805
Mongolia* 1 468 823 100·0% 999 ·· ·· ·· ·· ·· ·· ·· ·· ·· 999
Qatar* 2 172 065 100·0% 1861 196 214 586 287 489 1042 33 71 71 7642
Singapore* 3 870 700 100·0% 22 473 2943 3514 7991 1202 3339 7187 196 388 167 109 992
Taiwan* 23 123 866 100·0% 116 929 29 214 16 872 52 681 8410 17 813 39 704 1211 1811 832 858 683
Thai 
registries
13 738 188 20·3% 25 001 12 737 5469 5869 2779 5177 8486 385 605 217 159 528
Turkish 
registries
18 176 484 23·4% 37 302 4214 6678 25114 8786 9060 18 597 1039 1241 840 237 137
Europe 321 365 615 50·0% 2 700 348 267 986 399 675 2 355 249 297 032 436 684 1 182 009 24 316 29 544 14 830 14 991 316
Austria* 8 516 916 100·0% 74 818 6455 11 567 75 082 7615 7223 31 583 ·· ·· ·· 412 683
Belarus 
(childhood)‡
1 498 163 100·0% ·· ·· ·· ·· ·· ·· ·· 580 740 367 1687
Belgium* 11 226 322 100·0% 111 685 6929 10 447 97 316 9057 19 790 42 772 781 720 549 544 110
Bulgaria* 7 201 308 100·0% 53 605 16 329 12 206 26 190 ·· 6226 14 919 ·· 537 298 273 868
Croatia* 4 255 853 100·0% 35 323 5279 7138 22 066 7515 5026 15 421 403 443 231 222 776
Czech 
Republic*
10 542 666 100·0% 89 989 14 950 18 875 78 581 11 007 9734 36 974 489 531 279 572 368
Denmark* 5 646 899 100·0% 65 840 5755 9024 55 052 8951 8951 27 756 493 574 233 365 105
Estonia* 1 316 203 100·0% 8149 2232 2122 9734 1295 1512 4193 103 93 47 59 848
Finland* 5 479 660 100·0% 62 282 2318 8101 66 706 5953 5573 25 395 503 572 241 294 268
French 
registries‡
13 891 552 21·7% 82 538 5125 8 658 91 806 7532 18 897 41 784 4477 4 830 2573 460 927
German 
registries
29 655 933 36·8% 300 626 24 302 38 064 284 771 27 683 45 934 126 594 691 1019 446 1 621 312
Gibraltar* 31 997 100·0% 169 10 14 62 11 4 8 ·· ·· ·· 533
(Table 5 continues on next page)
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Survival trends between 1995–99 and 2010–14 were 
rather flat in most countries (appendix p 230), but after 
2000, survival increased by up to 5% in six European 
countries (Denmark, Lithuania, and the UK [northern 
Europe]; Poland [eastern Europe]; and Austria and 
the Netherlands [western Europe]). Over the same 
20 years, 5-year survival increased by 6–10% in Canada, 
Israel, Japan, Estonia, and Ireland, by 11% in the 
USA and Germany, and by 20% or more in China and 
Korea.
Colon
Results are available for 4 198 637 adults from 
296 registries in 65 countries (tables 2, 4). Survival for 
colon cancer varied widely, especially in Central and 
South America, Asia, and Europe (figure 4; appendix 
p 250). Most estimates were considered reliable (table 6; 
appendix pp 139–151).
For patients diagnosed during 2010–14, survival was 
higher than 70% in three countries: Israel, Korea, and 
Australia. Survival was in the range 60–69% in 25 countries: 
Population 
covered
Percentage 
of national 
population 
covered
Number of patients Total 
number of 
patients†
Breast 
(women)
Cervix Ovary Prostate Brain 
(adults)
Myeloid 
(adults)
Lymphoid 
(adults)
Brain 
(children)
Acute 
lympho-
blastic 
leukaemia 
(children)
Lymph-
oma 
(children)
(Continued from previous page)
Greece 
(childhood)‡
1 610 335 100·0% ·· ·· ·· ·· ·· ·· ·· 237 1 092 397 1726
Iceland* 327 318 100·0% 2743 225 276 3083 348 433 1167 35 31 11 14 782
Ireland* 4 675 164 100·0% 34 632 3573 4952 37 536 4605 6250 16 806 396 461 194 196 331
Italian 
registries
34 479 972 57·7% 250 204 13 394 31 025 196 256 28 325 49 653 121 301 1613 2022 1273 1 400 117
Latvia* 1 989 354 100·0% 13 020 3148 3842 10 674 1415 1749 2679 100 147 ·· 71 082
Lithuania* 2 916 798 100·0% 17 699 6318 5452 30 156 2942 4850 9741 136 250 106 139 475
Malta* 417 723 100·0% 3523 136 547 2069 315 492 1383 24 35 20 15 518
Netherlands* 16 868 020 100·0% 198 074 10 317 19 252 142 578 17 261 30 256 78 420 1428 1588 755 987 029
Norway* 5 147 970 100·0% 43 349 4458 7207 57 657 5647 8374 24 389 484 511 255 277 991
Poland* 38 483 957 100·0% 220 036 48 857 53 462 131 099 37 794 21 008 94 159 2071 2505 1308 1 344 837
Portugal* 10 566 132 100·0% 69 599 9013 6532 64 886 7348 9414 32 024 549 627 476 386 853
Romania 
(Cluj)
983 525 5·0% 2205 1004 460 1301 291 482 969 19 21 10 14 060
Russian 
registries
8 081 400 5·6% 41 903 10 897 10 628 20 346 4449 3190 9209 327 320 207 245 591
Slovakia* 5 422 861 100·0% 23 698 6170 5207 14 376 3695 4466 11 821 323 304 179 156 122
Slovenia* 2 066 068 100·0% 15 822 2281 2750 14 932 1943 3026 7498 114 122 88 102 970
Spanish 
registries
9 396 745 20·3% 56 759 5023 7710 63 237 8685 13 483 31 782 1521 1917 1115 376 759
Sweden* 9 703 247 100·0% 102 483 6816 12 132 139 051 9327 14 280 43 784 761 926 309 544 531
Swiss 
registries‡
4 368 854 53·2% 39 262 1858 4964 40 528 4102 7175 18 923 565 733 324 212 695
UK* 64 596 700 100·0% 680 313 44 814 97 061 578 118 71 921 129 233 308 555 5093 5873 2539 3 673 362
Oceania 27 952 971 100·0% 232 346 13 537 25 841 290 176 25 294 54 647 129 127 1713 3078 1253 1 483 573
Australia* 23 457 489 100·0% 193 134 11 065 21 124 247 000 21 569 46 955 108 727 1484 2565 1036 1 244 350
New 
Zealand*
4 495 482 100·0% 39 212 2472 4717 43 176 3725 7692 20 400 229 513 217 239 223
Total 988 680 261 20·2% 6 422 553 660 744 865 501 5 864 878 656 659 1151 226 3 011 054 66 814 87 351 41 196 37 513 025
Populations given are for 2014 or nearest available year. Populations for 2014 are from the UN Population Division28 or national authorities in Australia, Guadeloupe, Hong Kong, Poland, Portugal, and Taiwan 
(2010). Subnational populations were provided by the registry concerned. Belarus, Greece, and Mexico only provided data for childhood cancers: national populations shown are for children (0–14 years). Mali, 
Mongolia, and Morocco only provided cancer data for women: national populations shown are for women. Population shown for France excludes Guadeloupe and Martinique. *Data with 100% coverage of the 
national population. †Total is for all 18 cancers (see table 4). ‡Data with 100% coverage of the national population for childhood malignancies only.
Table 5: Population covered by participating registries (number of people and percentage of national population) and number of patients diagnosed with cancer of the breast 
(women), cervix, ovary, prostate, or brain, or myeloid or lymphoid malignancies (adults), and brain, acute lymphoblastic leukaemia, or lymphoma (children) during 2000–14 by 
continent and country
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Costa Rica and Puerto Rico; Canada and the USA; Japan, 
Singapore, and Taiwan; 17 European countries (Denmark, 
Finland, Iceland, Ireland, Norway, Sweden, and the UK 
[northern Europe]; Italy, Portugal, Slovenia, and Spain 
[southern Europe]; and Austria, Belgium, France, 
Germany, the Netherlands, and Switzerland [western 
Europe]); and New Zealand (table 6; appendix p 212).
Survival ranged from 50% to 60% in 18 countries: 
Mauritius; three Central and South American countries 
(Martinique, Peru [Lima], and Uruguay); five Asian 
countries (Malaysia [Penang; south Asia]; China and Hong 
Kong [east Asia]; and Kuwait and Turkey [west Asia]); and 
nine European countries (Estonia, Lithuania, and Latvia 
[northern Europe]; Croatia and Malta [southern Europe]; 
and Bulgaria, the Czech Republic, Poland, and Slovakia 
[eastern Europe]). 5-year net survival was less than 50% in 
Ecuador, Thailand, Russia, and India (table 6).
Survival trends between 1995–99 and 2000–14 were 
generally flat or increasing (appendix p 231). 5-year survival 
increased over this period by 5–10% in 14 countries: 
Canada; Japan and Taiwan; ten European countries 
(Estonia, Finland, Ireland, Lithuania, and Sweden [northern 
Europe]; Italy and Malta [southern Europe]; Austria, France, 
and the Netherlands [western Europe]); and Australia. Over 
the same period, survival increased by more than 10% in 
China, Israel, and Korea, and in 13 European countries 
(Denmark, Iceland, Latvia, Norway, and the UK [northern 
Europe]; Portugal, Slovenia, and Spain [southern Europe]; 
and Bulgaria, the Czech Republic, and Poland [eastern 
Europe]; and Germany and Switzerland [western Europe]).
Rectum
Results are available for 1 720 488 adults from 
294 registries in 64 countries (table 2, table 4). Similarly 
Figure 2: Global distribution by continent and country of age-standardised 5-year net survival for adults (15–99 years) diagnosed during 2010–14 with colon cancer or breast cancer (women) 
and children (0–14 years) diagnosed with acute lymphoblastic leukaemia
Survival estimates for each country are ranked from highest to lowest within each continent. Where data were available for more than one registry in a given country, the survival estimates are derived 
by pooling the data for that country, but excluding data from registries for which the estimates are considered less reliable. See appendix (pp 209–227) for all 18 cancers included in CONCORD-3 and 
for each calendar period 2000–04, 2005–09, and 2010–14. *Data with 100% coverage of the national population. †National estimate not age-standardised. §National estimate flagged as less reliable 
because the only available estimates are from a registry or registries in this category. 
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to colon cancer, 5-year net survival for rectal cancer varied 
widely. The range of survival estimates in Asia for 
2010–14 was even wider than that for colon cancer 
(appendix p 251). Almost all the survival estimates were 
considered reliable (table 6; appendix pp 139–151).
Survival was higher than 70% in Korea and Australia 
(table 6). For patients diagnosed during 2010–14, survival 
was in the range 60–69% in 24 countries: Canada and 
the USA; four Asian countries (Singapore [south Asia]; 
Japan and Taiwan [east Asia]; and Israel [west Asia]); 
17 European countries (Denmark, Finland, Iceland, 
Ireland, Norway, Sweden, and the UK [northern Europe]; 
Italy, Portugal, Slovenia, and Spain [southern Europe]; 
and Austria, Belgium, France, Germany, the Netherlands, 
and Switzerland [western Europe]); and New Zealand 
(table 6; appendix p 213).
Survival was in the range 50–59% in 18 countries: 
six countries in Central and South America (Argentina, 
Costa Rica, Martinique, Peru [Lima], Puerto Rico, 
and Uruguay); five Asian countries (Malaysia [Penang; 
south Asia]; China and Hong Kong [east Asia]; and Kuwait 
and Turkey [west Asia]); and six European countries 
(Estonia, Latvia, and Lithuania [northern Europe]; Malta 
[southern Europe]; and the Czech Republic and Romania 
Figure 3: 20-year trends in age-standardised 5-year net survival for women (15–99 years) with breast cancer, by calendar period of diagnosis, continent (or continental region), and country
Estimates for women diagnosed during 1995–99 are taken from the analyses for CONCORD-2.6 Where data were available for more than one registry in a given country, the survival estimates 
are derived by pooling the data for that country, excluding data from registries for which the survival estimates are considered less reliable. See appendix (pp 227–246) for other cancers. 
Standard International Organization for Standardization abbreviations for country names: Algeria=DZA; Argentina=ARG; Australia=AUS; Austria=AUT; Belgium=BEL; Brazil=BRA; 
Bulgaria=BGR; Canada=CAN; Chile=CHL; China=CHN; Colombia=COL; Costa Rica=CRI; Croatia=HRV; Cuba=CUB; Cyprus=CYP; Czech Republic=CZE; Denmark=DNK; Ecuador=ECU; Estonia=EST; 
Finland=FIN; France=FRA; Germany=DEU; Gibraltar=GIB; Guadeloupe=GLP; Hong Kong=HKG; Iceland=ISL; India=IND; Ireland=IRL; Israel=ISR; Italy=ITA; Japan=JPN; Jordan=JOR; Kuwait=KWT; 
Latvia=LVA; Lithuania=LTU; Malaysia=MYS; Malta=MLT; Martinique=MTQ; Mauritius=MUS; Mongolia=MNG; Morocco=MAR; Netherlands=NLD; New Zealand=NZL; Nigeria=NGA; 
Norway=NOR; Peru=PER; Poland=POL; Portugal=PRT; Puerto Rico=PRI; Qatar=QAT; Romania=ROU; Russia=RUS; Singapore=SGP; Slovakia=SVK; Slovenia=SVN; South Africa=ZAF; South 
Korea=KOR; Spain=ESP; Sweden=SWE; Switzerland=CHE; Taiwan=TWN; Thailand=THA; Turkey=TUR; UK=GBR; USA=USA. §Continent or continental region with one or more national 
estimates flagged as less reliable.
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[Cluj; eastern Europe]). 5-year survival was less than 50% 
in Slovakia, Poland, Croatia, Bulgaria, Ecuador, Thailand, 
Russia, and India (table 6).
Survival trends between 1995–99 and 2000–14 were 
generally increasing, especially since 2000, in Asia, 
Europe, and Oceania (appendix p 232). Survival increased 
Gastrointestinal cancers Lung Melanoma of 
the skin
Oesophagus Stomach Colon Rectum Liver Pancreas
Africa
Algeria (three registries)
2000–04 ·· 20·7§ 
(14·3–27·1)
88·1§ 
(80·1–96·0)
63·4§ 
(48·3–78·5)
6·2†§ 
(0·0–13·7)
8·3†§ 
(0·0–20·3)
18·0§ 
(14·0–22·0)
6·9†§ 
(0·0–18·5)
2005–09 55·4†§ 
(36·4–74·5)
42·4§ 
(36·4–48·4)
76·7§ 
(69·6–83·9)
64·5§ 
(56·4–72·7)
13·9§ 
(8·6–19·2)
30·2§ 
(21·3–39·2)
30·2§ 
(25·7–34·8)
63·4§ 
(59·4–67·3)
2010–14 37·3§ 
(23·4–51·1)
41·6§ 
(35·5–47·7)
74·2§ 
(65·7–82·7)
67·3§ 
(58·0–76·5)
13·5§ 
(6·9–20·1)
29·8§ 
(18·7–40·9)
33·7§ 
(28·5–38·9)
54·9§ 
(47·3–62·6)
Mali (Bamako)
2000–04 ·· ·· ·· ·· ·· ·· ·· ··
2005–09 ·· ·· ·· ·· ·· ·· ·· ··
2010–14 ·· ·· ·· ·· ·· ·· ·· ··
Mauritius*
2000–04 ·· ·· ·· ·· ·· ·· ·· ··
2005–09 ·· 44·3 
(36·8–51·7)
65·9 
(56·7–75·1)
83·6§ 
(75·0–92·1)
·· ·· 31·7 
(25·9–37·6)
··
2010–14 28·1† 
(14·6–41·5)
25·7 
(18·0–33·3)
57·9 
(48·5–67·2)
72·9§ 
(62·7–83·0)
17·0† 
(2·6–31·3)
24·5† 
(11·4–37·6)
20·4 
(13·2–27·7)
··
Morocco (Casablanca)
2000–04 ·· ·· ·· ·· ·· ·· ·· ··
2005–09 ·· ·· ·· ·· ·· ·· ·· ··
2010–14 ·· ·· ·· ·· ·· ·· ·· ··
Nigeria (Ibadan)
2000–04 ·· ·· ·· ·· ·· ·· ·· ··
2005–09 ·· ·· 41·2†§ 
(16·9–65·6)
25·9†§ 
(0·0–53·7)
·· ·· 100·0†§ 
(100·0–100·0)
2010–14 ·· ·· 17·4†§ 
(0·1–34·8)
16·9†§ 
(0·0–37·8)
·· ·· ·· 97·7†§ 
(74·6–100·0)
South Africa (Eastern Cape)
2000–04 12·1†§ 
(0·0–27·0)
·· ·· ·· 27·1†§ 
(0·0–57·1)
·· ·· ··
2005–09 19·2§ 
(12·0–26·4)
25·0†§ 
(6·1–44·0)
31·9†§ 
(10·7–53·1)
19·9†§ 
(0·0–46·4)
·· ·· 16·7†§ 
(0·8–32·5)
··
2010–14 18·0§ 
(12·6–23·4)
25·6†§ 
(7·2–43·9)
12·3§ 
(4·3–20·2)
9·1†§ 
(0·0–21·5)
0·0†§ 
(0·0–0·0)
21·8†§ 
(0·0–49·5)
15·0§ 
(6·1–24·0)
16·7†§ 
(0·0–41·0)
America (Central and South)
Argentina (five registries)‡
2000–04 18·7§ 
(12· 7–24·8)
21·7§ 
(17· 1–26·2)
54·2§ 
(49· 7–58·7)
48·9 
(41·5– 56·3)
14·1§ 
(6· 0–22·1)
9·6§ 
(5· 5–13·6)
19·5§ 
(15·5–23·5)
68·4 
(60·6–76·3)
2005–09 15·0§ 
(11· 4–18·6)
19·3§ 
(16· 9–21·7)
51·2§ 
(49· 0–53·5)
47·5 
(43·3– 51·7)
11·4§ 
(8· 2–14·5)
8·3§ 
(6· 0–10·7)
12·4§ 
(10·9–14·0)
68·1 
(63·4–72·9)
2010–14 16·4§ 
(11· 9–21·0)
21·5§ 
(18· 5–24·4)
54·4§ 
(51· 8–57·1)
49·9 
(45·3– 54·4)
12·6§ 
(8· 7–16·6)
11·4§ 
(8· 1–14·6)
13·1§ 
(11·2–15·1)
71·0 
(65·6–76·4)
Brazil (six registries)
2000–04 10·7§ 
(9· 0–12·4)
19·1§ 
(17· 9–20·3)
44·5§ 
(42· 9–46·0)
37·7§ 
(35· 7–39·6)
15·4§ 
(10· 4–20·5)
3·9§ 
(3· 0–4·9)
10·7 
(8·3–13·1)
76·7 
(71·5–81·8)
2005–09 12·5§ 
(10· 6–14·5)
24·7§ 
(23· 2–26·2)
50·6§ 
(49· 3–52·0)
45·7§ 
(43· 7–47·8)
9·6§ 
(6· 5–12·8)
9·1§ 
(7· 3–10·9)
7·8 
(5·8–9·8)
75·9 
(71·7–80·1)
2010–14 9·7§ 
(7· 9–11·4)
20·6§ 
(18· 9–22·2)
48·3§ 
(46· 7–49·9)
42·4§ 
(40· 1–44·6)
11·2§ 
(7· 6–14·7)
9·5§ 
(7· 4–11·5)
8·5 
(5·3–11·6)
70·0 
(65·4–74·7)
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Chile (four registries)
2000–04 7·0 
(3·1– 10·9)
14·5 
(11·7– 17·4)
35·5 
(28·6– 42·3)
35·9 
(26·3– 45·5)
3·6†§ 
(0·0–7·4)
2·2 
(0·2– 4·2)
7·1§ 
(4·4–9·8)
57·4 
(46·6–68·1)
2005–09 10·8 
(7·5– 14·1)
16·3 
(14·7– 18·0)
47·1 
(43·1– 51·0)
39·5 
(33·9– 45·0)
2·7§ 
(1· 0–4·4)
3·6 
(1·9– 5·4)
6·3§ 
(4·7–7·8)
64·4 
(54·4–74·4)
2010–14 8·7 
(0·3– 17·0)
16·7 
(14·2– 19·3)
43·9§ 
(39· 3–48·5)
32·7§ 
(26· 6–38·8)
3·7§ 
(0· 7–6·8)
4·4† 
(1·0–7·8)
4·6§ 
(3·0–6·2)
59·7§ 
(49·4–69·9)
Colombia (four registries)
2000–04 10·7§ 
(5· 6–15·8)
18·4 
(16·0– 20·9)
45·0 
(40·6– 49·4)
38·3 
(32·9– 43·7)
4·8§ 
(1· 8–7·9)
6·4§ 
(3· 5–9·4)
9·4 
(7·2–11·5)
63·1§ 
(57·0–69·1)
2005–09 9·5 
(4·6– 14·4)
17·7 
(16·2– 19·3)
41·3 
(37·9– 44·7)
37·2 
(32·7– 41·7)
5·4 
(3·1– 7·7)
3·4 
(1·6– 5·2)
10·5 
(8·5–12·5)
71·3§ 
(66·2–76·5)
2010–14 10·5§ 
(3· 9–17·1)
17·1§ 
(15· 4–18·8)
34·5§ 
(31· 2–37·9)
38·0§ 
(33· 2–42·8)
5·2§ 
(2· 7–7·8)
5·3§ 
(2· 8–7·8)
8·7§ 
(6·7–10·6)
65·1§ 
(59·2–71·1)
Costa Rica*
2000–04 35·7§ 
(26· 3–45·1)
48·4 
(45·5– 51·2)
63·8 
(59·5– 68·1)
48·4 
(41·3– 55·6)
39·0§ 
(32· 4–45·6)
38·1§ 
(31· 3–44·8)
36·2§ 
(31·0–41·5)
82·6 
(77·2–88·1)
2005–09 19·2§ 
(11· 3–27·1)
38·4 
(36·3– 40·5)
55·1 
(52·2– 58·0)
50·2 
(45·2– 55·2)
23·6§ 
(18· 5–28·7)
23·8§ 
(19· 1–28·6)
22·0§ 
(19·0–25·1)
76·2 
(71·5–80·8)
2010–14 20·9§ 
(14· 3–27·6)
40·6 
(38·5– 42·7)
60·1 
(57·4– 62·8)
53·9 
(49·2– 58·5)
24·1§ 
(19· 7–28·5)
24·5§ 
(19· 5–29·5)
20·1§ 
(17·1–23·1)
77·2 
(72·7–81·7)
Cuba*
2000–04 ·· 17·2§ 
(15· 7–18·7)
39·8§ 
(38· 3–41·2)
·· ·· ·· 4·5§ 
(3·8–5·1)
··
2005–09 ·· 25·6§ 
(23· 6–27·5)
48·5§ 
(46· 9–50·1)
·· ·· ·· 23·2§ 
(22·1–24·2)
··
2010–14 ·· 35·7§ 
(32· 8–38·6)
63·9§ 
(61· 6–66·2)
·· ·· ·· 30·1§ 
(28·4–31·8)
··
Ecuador (five registries)
2000–04 20·9† 
(9·9–31·9)
17·8 
(12·3– 23·3)
47·7 
(41·0– 54·4)
38·7 
(30·4– 47·1)
8·1§ 
(4· 6–11·5)
8·4§ 
(4· 7–12·2)
10·1§ 
(7·2–13·0)
59·0 
(50·9–67·1)
2005–09 7·7 
(3·5– 11·9)
17·4 
(12·0– 22·7)
46·7 
(42·9– 50·5)
43·5 
(38·8– 48·2)
6·3§ 
(4· 1–8·6)
9·0§ 
(6· 2–11·8)
10·5§ 
(8·5–12·4)
60·5 
(54·5–66·5)
2010–14 12·7 
(6·7– 18·7)
19·1 
(13·1– 25·1)
47·8 
(43·9– 51·6)
44·5 
(39·2– 49·8)
5·9§ 
(3· 9–7·8)
8·4§ 
(5· 7–11·2)
12·2§ 
(10·0–14·4)
57·9 
(51·6–64·1)
Guadeloupe*
2000–04 ·· ·· ·· ·· ·· ·· ·· ··
2005–09 0·0† 
(0·0–0·1)
11·7§ 
(5· 7–17·7)
30·9§ 
(23· 1–38·7)
21·3§ 
(8· 8–33·8)
9·5†§ 
(0·0–20·3)
11·2†§ 
(1·7–20·8)
6·8 
(2·3–11·2)
86·2†§ 
(53·0–100·0)
2010–14 ·· 11·7§ 
(6· 8–16·6)
26·8§ 
(19· 5–34·0)
35·6§ 
(22· 4–48·8)
3·7†§ 
(0·0–9·2)
·· 4·0§ 
(0·2–7·7)
14·1†§ 
(0·0–36·7)
Martinique*
2000–04 4·2† 
(0·4–8·1)
29·7 
(24·2– 35·2)
57·0 
(50·4– 63·6)
44·1 
(35·1– 53·1)
12·0 
(5·6– 18·4)
13·4 
(7·8– 19·1)
12·5 
(7·6–17·4)
81·8†§ 
(68·5–95·1)
2005–09 4·9 
(1·1– 8·7)
33·0 
(27·5– 38·5)
54·9 
(49·5– 60·3)
54·0 
(46·0– 62·1)
12·4 
(5·6– 19·1)
6·9 
(3·2– 10·5)
14·7 
(10·4–18·9)
86·4†§ 
(74·7–98·2)
2010–14 4·0† 
(1·8–6·3)
32·1 
(24·5– 39·6)
53·6 
(46·9– 60·3)
52·0 
(42·2– 61·7)
15·6 
(7·2– 23·9)
11·9 
(6·5– 17·3)
11·8 
(6·4–17·2)
77·8§ 
(61·3–94·3)
Peru (Lima)
2000–04 ·· ·· ·· ·· ·· ·· ·· ··
2005–09 ·· ·· ·· ·· ·· ·· ·· ··
2010–14 ·· ·· 59·0 
(55·8– 62·1)
54·8 
(50·0– 59·5)
·· ·· ·· ··
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Puerto Rico*
2000–04 10·9 
(8·5– 13·4)
26·6 
(24·1– 29·1)
60·9 
(59·3– 62·5)
53·9 
(50·9– 57·0)
11·8§ 
(9· 0–14·6)
8·8§ 
(6· 3–11·2)
14·7§ 
(13·1–16·3)
73·3 
(68·2–78·4)
2005–09 13·0 
(10·1– 15·9)
29·9 
(27·3– 32·5)
62·1 
(60·6– 63·5)
59·4 
(56·6– 62·3)
8·7§ 
(6· 9–10·5)
9·0§ 
(6· 9–11·1)
16·0 
(14·5–17·5)
75·4 
(70·6–80·1)
2010–14 20·4 
(14·8– 25·9)
34·6 
(30·3– 39·0)
63·4 
(61·1– 65·7)
59·0 
(54·6– 63·4)
14·2§ 
(10· 4–18·0)
10·2§ 
(7· 1–13·3)
17·6 
(14·9–20·3)
75·1 
(68·2–81·9)
Uruguay*
2000–04 ·· ·· ·· ·· ·· ·· ·· ··
2005–09 12·0§ 
(8· 4–15·6)
20·5 
(17·5– 23·5)
57·7 
(55·0– 60·4)
50·5 
(46·3– 54·6)
12·0§ 
(4· 4–19·7)
4·3§ 
(2· 3–6·3)
9·9§ 
(8·3–11·5)
··
2010–14 8·0§ 
(5· 3–10·7)
18·5§ 
(15· 4–21·5)
53·5 
(49·2– 57·7)
50·1 
(44·8– 55·4)
14·3§ 
(8· 0–20·6)
4·4§ 
(3· 0–5·8)
9·0§ 
(7·4–10·6)
··
America (North)
Canada (nine registries)
2000–04 14·5 
(13·4– 15·6)
25·1 
(24·2– 26·0)
61·6 
(61·1– 62·1)
61·9 
(61·1– 62·8)
17·4 
(16·2– 18·5)
7·9 
(7·3– 8·5)
16·3 
(15·9–16·6)
87·9 
(87·3–88·6)
2005–09 14·7 
(13·7– 15·7)
26·6 
(25·7– 27·5)
65·7 
(65·2– 66·2)
65·5 
(64·7– 66·3)
19·2 
(18·2– 20·2)
9·4 
(8·8– 10·0)
18·5 
(18·1–18·8)
88·5 
(88·0–89·1)
2010–14 16·1 
(15·1– 17·1)
29·6 
(28·6– 30·5)
67·0 
(66·5– 67·5)
66·8 
(66·0– 67·5)
18·7 
(17·8– 19·7)
10·8 
(10·2– 11·4)
20·6 
(20·2–20·9)
89·1 
(88·6–89·6)
USA (48 registries)
2000–04 16·5 
(16·1– 16·8)
26·2 
(25·8– 26·5)
64·7 
(64·5– 64·9)
63·9 
(63·5– 64·2)
12·5 
(12·2– 12·8)
7·2 
(7·0– 7·4)
17·0 
(16·9–17·1)
88·9 
(88·7–89·1)
2005–09 18·7 
(18·4– 19·1)
30·1 
(29·7– 30·4)
65·5 
(65·3– 65·7)
64·5 
(64·1– 64·8)
15·6 
(15·3– 15·9)
8·9 
(8·7– 9·1)
19·4 
(19·3–19·5)
90·4 
(90·2–90·6)
2010–14 20·0 
(19·6– 20·4)
33·1 
(32·7– 33·4)
64·9 
(64·7– 65·1)
64·1 
(63·7– 64·4)
17·4 
(17·1– 17·7)
11·5 
(11·3– 11·7)
21·2 
(21·1–21·3)
90·8 
(90·6–91·0)
Asia
China (21 registries)
2000–04 22·9 
(22·0– 23·9)
30·2 
(29·3– 31·1)
51·4 
(49·6– 53·3)
49·5 
(47·5– 51·4)
11·7 
(10·9– 12·5)
14·4 
(12·8– 16·0)
18·7 
(18·0–19·4)
35·6 
(25·8–45·4)
2005–09 27·1 
(26·5– 27·7)
33·2 
(32·7– 33·7)
55·6 
(54·6– 56·5)
52·5 
(51·5– 53·6)
11·6 
(11·1– 12·0)
10·2 
(9·4– 11·0)
17·7 
(17·4–18·1)
45·5 
(40·8–50·2)
2010–14 29·7 
(29·0– 30·4)
35·9 
(35·3– 36·5)
57·6 
(56·6– 58·6)
56·9 
(55·8– 58·0)
14·1 
(13·6– 14·7)
9·9 
(9·1– 10·7)
19·8 
(19·4–20·2)
49·6 
(44·5–54·6)
Cyprus*
2000–04 ·· 36·6† 
(22·2–51·1)
70·7§ 
(61· 8–79·6)
61·9†§ 
(43·0–80·8)
8·4†§ 
(0·0–21·0)
12·8†§ 
(1·7–23·9)
18·3 
(12·2–24·3)
89·0†§ 
(73·6–100·0)
2005–09 47·2†§ 
(30·5–63·8)
28·1§ 
(22· 9–33·3)
67·6§ 
(63· 9–71·4)
78·3§ 
(71· 3–85·4)
13·3†§ 
(6·3–20·2)
8·0§ 
(4· 5–11·6)
18·2 
(15·6–20·8)
82·1§ 
(75·8–88·4)
2010–14 39·0†§ 
(21·8–56·3)
35·6§ 
(30· 0–41·2)
72·1§ 
(68· 5–75·8)
75·9§ 
(69· 6–82·2)
10·6§ 
(5· 8–15·5)
11·6§ 
(7· 7–15·5)
18·7 
(16·2–21·2)
79·0§ 
(73·1–85·0)
Hong Kong*
2000–04 ·· ·· ·· ·· ·· ·· ·· ··
2005–09 ·· ·· 56·1 
(55·1– 57·1)
57·3 
(55·8– 58·7)
·· ·· ·· ··
2010–14 ·· ·· 56·4 
(55·4– 57·3)
58·0 
(56·6– 59·4)
·· ·· ·· ··
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India (two registries)
2000–04 2·9† 
(0·0–6·4)
6·4 
(2·5– 10·3)
46·9† 
(31·9–61·8)
36·9† 
(16·1–57·8)
2·4† 
(0·0–6·0)
4·2† 
(0·0–10·5)
6·9 
(2·3–11·5)
··
2005–09 3·4 
(0·7– 6·0)
9·8 
(3·4– 16·3)
33·8† 
(21·1–46·4)
33·6 
(20·8– 46·3)
3·7 
(0·0– 7·7)
5·3† 
(0·0–11·4)
3·5 
(1·4–5·7)
··
2010–14 4·1 
(0·0– 8·5)
8·9 
(4·0– 13·9)
38·9 
(24·6– 53·3)
30·0 
(20·5– 39·5)
6·3† 
(0·6–11·9)
5·6† 
(0·0–11·6)
3·7 
(1·6–5·7)
61·5† 
(27·3–95·8)
Iran (Golestan)
2000–04 ·· ·· ·· ·· ·· ·· ·· ··
2005–09 7·4 
(4·8– 10·0)
5·7 
(3·3– 8·0)
29·1 
(20·2– 38·0)
26·2† 
(14·1–38·3)
·· ·· ·· ··
2010–14 ·· ·· ·· ·· ·· ·· ·· ··
Israel*
2000–04 17·9 
(14·3– 21·5)
29·3 
(27·6– 31·1)
66·5 
(65·4– 67·6)
62·7 
(60·6– 64·7)
15·1§ 
(12· 2–17·9)
7·6§ 
(6· 4–8·8)
20·8 
(19·8–21·8)
85·6 
(84·2–87·0)
2005–09 22·4 
(18·6– 26·2)
29·8 
(28·1– 31·5)
71·4 
(70·3– 72·4)
67·3 
(65·3– 69·3)
15·6§ 
(13· 1–18·2)
9·2§ 
(8· 0–10·5)
23·8 
(22·8–24·8)
88·4 
(87·2–89·7)
2010–14 25·8 
(21·4– 30·2)
32·3 
(30·4– 34·3)
71·7 
(70·6– 72·9)
67·8 
(65·6– 70·0)
18·9§ 
(15· 6–22·2)
12·4§ 
(10· 8–14·0)
26·6 
(25·4–27·7)
87·4 
(86·1–88·8)
Japan (16 registries)
2000–04 27·7 
(26·4– 29·0)
50·5 
(50·0– 50·9)
63·4 
(62·7– 64·0)
58·6 
(57·6– 59·5)
25·7§ 
(25· 1–26·3)
6·9§ 
(6· 4–7·4)
29·3 
(28·1–30·5)
68·9 
(65·1–72·8)
2005–09 33·3 
(32·3– 34·2)
57·6 
(57·3– 57·9)
66·8 
(66·3– 67·3)
64·0 
(63·3– 64·6)
28·6§ 
(28· 1–29·1)
7·6§ 
(7· 2–7·9)
29·3 
(28·9–29·7)
68·3 
(65·6–71·0)
2010–14 36·0 
(34·8– 37·3)
60·3 
(59·9– 60·7)
67·8 
(67·3– 68·4)
64·8 
(64·0– 65·7)
30·1§ 
(29· 5–30·6)
8·3§ 
(7· 8–8·7)
32·9 
(32·3–33·4)
69·0 
(66·0–72·0)
Jordan*
2000–04 52·6§ 
(41· 3–63·9)
76·1§ 
(69· 7–82·5)
86·0§ 
(81· 6–90·5)
79·9§ 
(71· 1–88·8)
71·5§ 
(58·1–84·9)
66·9§ 
(52· 0–81·8)
42·9§ 
(38·3–47·4)
68·5†§ 
(56·4–80·6)
2005–09 53·9§ 
(43· 0–64·8)
64·8§ 
(58· 4–71·3)
80·8§ 
(77· 0–84·7)
76·2§ 
(67· 1–85·3)
64·3§ 
(54· 5–74·1)
32·5§ 
(25· 6–39·4)
44·1§ 
(39·4–48·7)
63·1†§ 
(49·3–76·9)
2010–14 41·1§ 
(30· 4–51·9)
55·7§ 
(48· 7–62·6)
76·1§ 
(72· 1–80·1)
73·2§ 
(65· 0–81·4)
40·0§ 
(28·6–51·3)
24·0§ 
(18· 7–29·3)
28·3§ 
(24·9–31·6)
55·9§ 
(41·5–70·4)
Korea*
2000–04 18·6 
(17·6– 19·6)
48·6 
(48·2– 48·9)
60·5 
(59·9– 61·2)
60·8 
(60·0– 61·6)
15·3 
(15·0– 15·7)
7·6 
(7·2– 8·1)
15·3 
(15·0–15·6)
51·4 
(48·3–54·4)
2005–09 26·9 
(25·8– 28·0)
61·1 
(60·8– 61·5)
68·1 
(67·6– 68·6)
68·1 
(67·5– 68·7)
22·4 
(22·1– 22·8)
8·4 
(8·0– 8·9)
19·9 
(19·6–20·2)
55·3 
(52·8–57·7)
2010–14 31·3 
(30·3– 32·4)
68·9 
(68·6– 69·2)
71·8 
(71·4– 72·2)
71·1 
(70·6– 71·7)
27·2 
(26·8– 27·6)
10·5 
(10·0– 10·9)
25·1 
(24·8–25·4)
59·9 
(57·5–62·2)
Kuwait*
2000–04 17·6†§ 
(2·9–32·4)
15·0 
(7·1– 22·9)
64·8 
(53·1– 76·5)
59·3 
(48·1– 70·4)
11·4†§ 
(3·5–19·2)
11·2†§ 
(3·1–19·3)
13·3 
(8·9–17·7)
··
2005–09 9·5† 
(0·0–20·6)
13·4 
(7·1– 19·7)
50·2 
(42·7– 57·7)
53·3 
(42·4– 64·2)
12·4† 
(5·8–19·1)
7·0 
(3·0– 11·0)
16·3 
(11·1–21·5)
··
2010–14 25·4† 
(10·5–40·4)
22·4 
(12·6– 32·3)
58·5 
(49·4– 67·7)
58·2 
(48·5– 67·9)
18·6 
(9·8– 27·3)
23·6 
(12·0– 35·2)
13·4 
(8·8–18·0)
··
Malaysia (Penang)
2000–04 ·· ·· ·· ·· ·· ·· ·· ··
2005–09 13·2 
(6·5– 19·9)
23·2 
(17·5– 29·0)
54·9 
(49·2– 60·6)
37·3 
(30·1– 44·5)
6·4 
(3·7– 9·1)
8·9 
(4·5– 13·3)
6·8 
(4·9–8·7)
··
2010–14 13·7† 
(3·8–23·6)
30·0 
(22·9– 37·0)
55·9 
(46·1– 65·8)
58·0 
(46·6– 69·4)
9·6† 
(3·9–15·2)
19·0 
(12·0– 26·0)
10·1 
(7·1–13·2)
··
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Mongolia*
2000–04 ·· ·· ·· ·· ·· ·· ·· ··
2005–09 ·· ·· ·· ·· ·· ·· ·· ··
2010–14 ·· ·· ·· ·· ·· ·· ·· ··
Qatar*
2000–04 36·1†§ 
(10·3–61·9)
15·0§ 
(2· 0–28·0)
62·1§ 
(50· 1–74·1)
67·8†§ 
(48·7–86·9)
7·1§ 
(2· 6–11·5)
9·9†§ 
(0·0–21·2)
7·4†§ 
(0·8–14·1)
77·5†§ 
(48·0–100·0)
2005–09 33·4†§ 
(9·4–57·5)
22·0§ 
(12· 2–31·7)
64·3§ 
(47· 6–80·9)
60·5§ 
(46· 7–74·3)
10·3†§ 
(3·2–17·3)
4·2†§ 
(0·0–10·4)
14·3§ 
(7·4–21·2)
30·1†§ 
(0·0–65·3)
2010–14 42·2†§ 
(9·4–75·0)
17·5§ 
(9· 7–25·3)
63·5§ 
(51· 7–75·2)
43·6§ 
(31· 2–56·1)
27·2§ 
(12· 9–41·5)
16·6§ 
(7· 2–26·1)
17·2§ 
(10·3–24·2)
99·7†§ 
(84·7–100·0)
Singapore*
2000–04 9·0 
(6·2– 11·8)
25·4 
(23·3– 27·4)
56·1 
(54·4– 57·8)
51·4 
(48·5– 54·2)
13·2 
(11·6– 14·9)
5·3 
(3·6– 7·0)
10·3 
(9·4–11·2)
62·8 
(51·0–74·6)
2005–09 10·5 
(7·4– 13·5)
27·1 
(25·0– 29·2)
60·3 
(58·7– 61·8)
59·0 
(56·3– 61·8)
20·4 
(18·6– 22·2)
6·7 
(5·1– 8·3)
13·0 
(12·0–13·9)
59·0 
(50·5–67·5)
2010–14 14·8 
(11·1– 18·4)
30·3 
(28·2– 32·4)
61·7 
(60·2– 63·2)
60·5 
(58·0– 63·0)
24·7 
(22·8– 26·6)
9·4 
(7·6– 11·2)
15·5 
(14·5–16·5)
60·0 
(51·7–68·2)
Taiwan*
2000–04 13·0 
(12·0– 13·9)
35·6 
(34·8– 36·4)
56·8 
(56·0– 57·5)
57·7 
(56·8– 58·7)
19·5 
(19·1– 19·9)
7·0 
(6·3– 7·7)
11·6 
(11·2–12·0)
48·6 
(44·6–52·6)
2005–09 13·2 
(12·3– 14·1)
36·7 
(35·9– 37·5)
60·4 
(59·8– 61·0)
61·5 
(60·6– 62·3)
24·4 
(24·0– 24·8)
6·5 
(5·9– 7·1)
16·0 
(15·6–16·4)
53·3 
(49·7–56·9)
2010–14 15·5 
(14·6– 16·4)
38·6 
(37·8– 39·4)
62·6 
(62·0– 63·1)
62·5 
(61·7– 63·3)
27·9 
(27·5– 28·4)
7·7 
(7·0– 8·3)
20·6 
(20·2–21·0)
52·1 
(48·5–55·6)
Thailand (six registries)
2000–04 8·8§ 
(6· 6–11·1)
22·3§ 
(18· 7–25·8)
39·8§ 
(37· 2–42·5)
43·0§ 
(38· 5–47·4)
7·7§ 
(6· 9–8·6)
6·9§ 
(5· 1–8·7)
10·2§ 
(9·3–11·1)
44·7§ 
(34·4–55·0)
2005–09 7·8 
(5·9– 9·7)
16·1 
(13·9– 18·3)
42·8 
(41·1– 44·6)
38·6 
(36·0– 41·1)
7·9 
(7·3– 8·6)
9·6 
(7·7– 11·5)
10·3 
(9·6–11·1)
37·9§ 
(30·6–45·2)
2010–14 7·1 
(5·1– 9·1)
12·5 
(10·7– 14·3)
47·0 
(45·2– 48·8)
44·4 
(41·8– 47·1)
6·9 
(6·3– 7·5)
6·8 
(5·3– 8·2)
8·6 
(7·9–9·2)
29·9§ 
(23·7–36·1)
Turkey (nine registries)
2000–04 14·8§ 
(9· 2–20·4)
21·9§ 
(18· 5–25·4)
52·9§ 
(49· 1–56·7)
48·5 
(43·9– 53·0)
20·1§ 
(15· 0–25·2)
10·9§ 
(7· 8–14·1)
11·9§ 
(10·6–13·3)
60·9§ 
(53·2–68·6)
2005–09 14·7 
(12·9– 16·5)
21·4 
(20·3– 22·4)
52·7 
(51·3– 54·2)
49·3 
(47·3– 51·3)
14·9 
(12·9– 17·0)
9·5 
(8·4– 10·7)
12·7 
(12·2–13·2)
57·7 
(54·6–60·9)
2010–14 19·0 
(16·9– 21·1)
24·6 
(23·6– 25·6)
55·2 
(53·8– 56·6)
52·6 
(50·6– 54·5)
15·9 
(14·0– 17·8)
10·4 
(9·3– 11·5)
14·9 
(14·3–15·4)
60·7 
(57·6–63·7)
Europe
Austria*
2000–04 16·2 
(14·2– 18·3)
30·0 
(28·7– 31·3)
60·7 
(59·7– 61·7)
60·2 
(58·9– 61·5)
11·2 
(10·0– 12·4)
6·7§ 
(5· 9–7·5)
15·4 
(14·8–16·0)
83·4 
(82·2–84·7)
2005–09 16·8 
(15·0– 18·7)
34·2 
(32·9– 35·6)
63·5 
(62·5– 64·4)
63·5 
(62·2– 64·8)
14·2§ 
(12· 9–15·6)
8·5 
(7·7– 9·4)
18·0 
(17·4–18·6)
84·6 
(83·5–85·8)
2010–14 18·6 
(16·6– 20·6)
35·4 
(34·0– 36·9)
63·7 
(62·7– 64·7)
64·2 
(62·9– 65·6)
14·8§ 
(13· 4–16·2)
10·5§ 
(9· 5–11·4)
19·7 
(19·1–20·4)
87·8 
(86·7–88·8)
Belgium*
2000–04 16·6 
(13·8– 19·4)
29·3 
(26·4– 32·2)
64·3 
(62·7– 66·0)
62·9 
(60·4– 65·4)
21·3 
(16·8– 25·8)
8·9 
(6·9– 10·8)
15·4 
(14·4–16·4)
86·3 
(83·9–88·7)
2005–09 23·2 
(21·7– 24·7)
35·8 
(34·4– 37·1)
65·0 
(64·3– 65·7)
65·3 
(64·3– 66·4)
20·6 
(19·0– 22·3)
10·5 
(9·6– 11·4)
17·0 
(16·5–17·4)
88·9 
(87·9–89·8)
2010–14 23·6 
(22·1– 25·0)
37·5 
(36·2– 38·9)
67·9 
(67·2– 68·6)
66·6 
(65·6– 67·6)
20·7 
(19·2– 22·2)
12·4 
(11·4– 13·3)
18·2 
(17·7–18·6)
91·0 
(90·1–91·8)
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Bulgaria*
2000–04 ·· 11·2§ 
(10· 3–12·0)
43·9 
(42·7– 45·2)
37·0 
(35·6– 38·4)
4·0§ 
(2· 9–5·1)
·· 5·8 
(5·3–6·3)
50·8 
(47·9–53·8)
2005–09 ·· 13·9 
(13·0– 14·9)
48·5 
(47·4– 49·6)
42·1 
(40·7– 43·5)
4·6§ 
(3· 5–5·6)
·· 7·0 
(6·5–7·6)
56·0 
(53·3–58·6)
2010–14 ·· 16·0 
(14·9– 17·0)
52·4 
(51·3– 53·6)
45·9 
(44·4– 47·4)
6·5§ 
(5· 1–7·9)
·· 7·7 
(7·1–8·2)
61·2 
(58·8–63·7)
Croatia*
2000–04 6·8 
(4·9– 8·7)
19·7 
(18·4– 20·9)
47·3 
(45·9– 48·7)
44·4 
(42·7– 46·1)
9·2§ 
(7· 6–10·7)
9·1 
(7·9– 10·4)
11·2 
(10·5–11·9)
66·4 
(64·0–68·8)
2005–09 9·1 
(6·9– 11·2)
18·9 
(17·6– 20·2)
49·5 
(48·2– 50·8)
47·1 
(45·5– 48·7)
9·2§ 
(7· 7–10·8)
8·2 
(7·0– 9·4)
10·6 
(10·0–11·3)
74·7 
(72·7–76·7)
2010–14 8·7 
(6·6– 10·8)
20·0 
(18·6– 21·3)
51·1 
(49·9– 52·4)
48·2 
(46·5– 49·8)
9·3§ 
(7· 7–10·9)
8·4§ 
(7· 1–9·7)
10·0 
(9·3–10·6)
77·2 
(75·3–79·1)
Czech Republic*
2000–04 7·3 
(6·0– 8·6)
18·7 
(17·7– 19·7)
48·0 
(47·3– 48·8)
43·8 
(42·6– 44·9)
3·0 
(2·3– 3·6)
3·6 
(3·0– 4·1)
8·6 
(8·2–9·0)
80·7 
(79·5–81·8)
2005–09 9·0 
(7·5– 10·5)
19·3 
(18·3– 20·3)
52·0 
(51·3– 52·7)
47·9 
(46·8– 49·0)
5·3 
(4·5– 6·2)
4·7 
(4·1– 5·3)
9·8 
(9·4–10·3)
84·6 
(83·7–85·6)
2010–14 9·8 
(8·3– 11·4)
20·6 
(19·6– 21·6)
56·1 
(55·4– 56·9)
52·3 
(51·2– 53·4)
6·7 
(5·6– 7·7)
6·1 
(5·4– 6·7)
10·6 
(10·2–11·1)
85·7 
(84·8–86·6)
Denmark*
2000–04 8·4 
(6·9– 9·8)
14·7 
(13·2– 16·3)
51·5 
(50·4– 52·6)
53·2 
(51·7– 54·7)
4·4 
(3·1– 5·8)
3·8 
(3·0– 4·5)
9·5 
(9·0–10·1)
87·3 
(86·0–88·5)
2005–09 10·4 
(8·9– 11·9)
15·4 
(13·9– 16·9)
56·5 
(55·5– 57·6)
59·8 
(58·4– 61·1)
5·6 
(4·2– 7·0)
5·6 
(4·7– 6·4)
12·3 
(11·7–12·8)
89·1 
(88·1–90·0)
2010–14 13·7 
(12·0– 15·4)
19·9 
(18·1– 21·6)
61·6 
(60·6– 62·7)
64·8 
(63·4– 66·1)
7·5 
(5·9– 9·1)
8·0 
(7·0– 9·1)
16·6 
(16·0–17·3)
91·1 
(90·2–91·9)
Estonia*
2000–04 5·7 
(2·8– 8·6)
22·3 
(20·2– 24·4)
48·9 
(46·2– 51·5)
46·4 
(42·9– 49·9)
5·5§ 
(2· 8–8·3)
4·8 
(3·2– 6·5)
10·8 
(9·5–12·2)
71·4 
(67·0–75·8)
2005–09 6·0 
(3·5– 8·5)
24·2 
(22·1– 26·4)
53·8 
(51·3– 56·3)
50·5 
(46·9– 54·1)
6·5 
(3·9– 9·2)
5·4 
(3·8– 7·0)
14·3 
(12·6–15·9)
75·2 
(71·7–78·8)
2010–14 5·4 
(2·3– 8·5)
29·2 
(26·1– 32·3)
58·4 
(55·2– 61·6)
54·8 
(50·1– 59·5)
4·2 
(1·8– 6·6)
10·2 
(7·0– 13·4)
16·9 
(14·9–19·0)
81·8 
(77·6–86·0)
Finland*
2000–04 11·8 
(9·5– 14·1)
26·0 
(24·3– 27·6)
61·3 
(59·9– 62·8)
59·9 
(58·0– 61·9)
7·1 
(5·5– 8·8)
4·1 
(3·2– 4·9)
11·9 
(11·0–12·7)
84·8 
(83·3–86·4)
2005–09 12·8 
(10·6– 15·0)
25·1 
(23·4– 26·8)
63·2 
(61·9– 64·5)
63·8 
(62·0– 65·6)
9·1§ 
(7· 3–10·8)
7·3 
(6·2– 8·5)
12·1 
(11·3–13·0)
87·4 
(86·2–88·6)
2010–14 12·4 
(10·5– 14·4)
25·7 
(23·9– 27·5)
64·9 
(63·7– 66·2)
64·4 
(62·6– 66·1)
10·4§ 
(8· 5–12·2)
7·4§ 
(6· 3–8·4)
13·0 
(12·1–13·9)
88·7 
(87·6–89·8)
France (23 registries)‡
2000–04 13·0 
(11·8– 14·2)
26·3 
(24·9– 27·7)
60·7 
(59·8– 61·5)
58·3 
(56·9– 59·6)
14·0 
(12·9– 15·1)
7·8 
(6·9– 8·7)
14·1 
(13·5–14·6)
89·7 
(88·5–90·9)
2005–09 14·9 
(13·6– 16·1)
27·1 
(25·8– 28·4)
63·6 
(62·8– 64·3)
60·7 
(59·5– 61·9)
16·5 
(15·4– 17·6)
9·0 
(8·2– 9·8)
16·2 
(15·7–16·7)
90·9 
(89·9–91·9)
2010–14 13·9 
(11·4– 16·4)
26·7 
(23·9– 29·6)
63·7 
(62·2– 65·3)
60·9 
(58·4– 63·4)
18·3 
(16·0– 20·5)
8·6 
(7·0– 10·2)
17·3 
(16·1–18·5)
90·8 
(88·7–92·9)
(Table 6 continues on next page)
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Germany (ten registries)
2000–04 16·6 
(15·3– 17·8)
31·8 
(30·0– 33·5)
62·0 
(61·2– 62·8)
60·9 
(60·2– 61·6)
12·5§ 
(11· 6–13·4)
8·0§ 
(7· 5–8·6)
14·9 
(14·3–15·4)
91·0 
(90·4–91·6)
2005–09 19·7 
(18·8– 20·6)
31·4 
(30·8– 32·0)
64·9 
(64·4– 65·3)
62·2 
(61·6– 62·8)
12·9 
(11·3– 14·5)
9·3 
(8·4– 10·2)
16·9 
(16·5–17·4)
92·0 
(91·5–92·6)
2010–14 20·8 
(19·8– 21·8)
33·5 
(32·8– 34·2)
64·8 
(64·3– 65·3)
62·3 
(61·6– 62·9)
13·0 
(10·5– 15·5)
10·7 
(9·6– 11·8)
18·3 
(17·9–18·8)
93·1 
(92·6–93·6)
Gibraltar*
2000–04 ·· 8·0† 
(0·0–19·9)
38·8† 
(17·7–59·9)
·· ·· ·· 21·7†§ 
(0·0–44·9)
65·4† 
(37·6–93·3)
2005–09 ·· 39·2†§ 
(12·8–65·5)
52·3†§ 
(24·3–80·4)
39·3†§ 
(7·6–70·9)
·· 0·6†§ 
(0·0–1·9)
19·6†§ 
(8·0–31·1)
100·0†§ 
(88·5–100·0)
2010–14 ·· ·· ·· ·· ·· ·· ·· ··
Iceland*
2000–04 13·1† 
(3·8–22·4)
32·9 
(24·9– 40·9)
61·4 
(55·4– 67·4)
71·0 
(63·0– 79·0)
3·9† 
(0·0–10·0)
4·8 
(1·4– 8·1)
14·1 
(11·2–16·9)
84·5 
(77·7–91·3)
2005–09 19·1† 
(10·4–27·8)
30·3 
(21·9– 38·6)
64·0 
(58·8– 69·1)
66·3 
(58·2– 74·5)
16·0† 
(6·0–26·1)
0·0 
(0·0– 0·1)
16·0 
(12·9–19·1)
85·4 
(79·5–91·3)
2010–14 17·7 
(10·5– 24·8)
28·1 
(20·2– 36·1)
68·2 
(63·2– 73·1)
63·0 
(55·5– 70·5)
14·3 
(6·9– 21·7)
0·0† 
(0·0–0·0)
20·2 
(16·9–23·4)
87·5 
(82·1–92·9)
Ireland*
2000–04 12·9 
(11·0– 14·7)
18·6 
(16·7– 20·4)
53·3 
(51·8– 54·7)
51·1 
(48·9– 53·2)
11·6 
(8·7– 14·6)
5·7 
(4·4– 7·0)
10·1 
(9·3–10·9)
85·5 
(83·6–87·4)
2005–09 17·2 
(15·2– 19·1)
22·2 
(20·4– 24·1)
58·4 
(57·1– 59·7)
57·1 
(55·0– 59·1)
11·8 
(9·4– 14·2)
6·9 
(5·6– 8·2)
13·5 
(12·7–14·3)
86·6 
(85·1–88·1)
2010–14 20·3 
(18·0– 22·7)
27·6 
(25·4– 29·8)
60·5 
(59·1– 62·0)
61·7 
(59·4– 64·0)
14·2 
(11·2– 17·2)
9·6 
(7·9– 11·4)
17·5 
(16·5–18·5)
89·2 
(87·7–90·7)
Italy (45 registries)
2000–04 11·5 
(10·5– 12·6)
31·6 
(30·9– 32·2)
59·0 
(58·6– 59·5)
55·8 
(54·9– 56·6)
15·9 
(15·2– 16·5)
6·8 
(6·3– 7·3)
14·0 
(13·7–14·3)
84·1 
(83·3–84·8)
2005–09 12·9 
(11·9– 14·0)
31·1 
(30·5– 31·7)
64·3 
(63·9– 64·7)
61·1 
(60·4– 61·8)
20·0 
(19·4– 20·6)
7·9 
(7·5– 8·3)
15·5 
(15·2–15·8)
86·0 
(85·5–86·6)
2010–14 13·8 
(12·3– 15·3)
30·5 
(29·7– 31·3)
64·2 
(63·6– 64·7)
61·3 
(60·3– 62·2)
20·3 
(19·6– 21·1)
9·2 
(8·5– 9·8)
15·9 
(15·5–16·3)
85·7 
(85·0–86·5)
Latvia*
2000–04 6·9 
(3·4– 10·3)
24·2 
(22·2– 26·3)
50·5 
(47·8– 53·3)
39·4 
(36·3– 42·5)
12·0† 
(3·8–20·3)
8·8 
(5·4– 12·1)
17·3 
(15·3–19·3)
66·3 
(62·0–70·6)
2005–09 10·8 
(7·3– 14·2)
26·7 
(24·6– 28·9)
54·0 
(51·4– 56·5)
46·6 
(43·4– 49·7)
7·8 
(3·8– 11·7)
11·2 
(7·5– 14·8)
19·5 
(17·7–21·2)
65·1 
(61·1–69·1)
2010–14 6·1 
(3·6– 8·6)
28·0 
(25·7– 30·3)
56·5 
(54·0– 58·9)
53·3 
(50·2– 56·5)
12·9 
(7·7– 18·0)
13·7 
(9·3– 18·1)
20·4 
(18·7–22·1)
72·1 
(68·3–75·8)
Lithuania*
2000–04 4·7 
(2·9– 6·4)
22·0 
(20·7– 23·3)
44·5 
(42·6– 46·3)
40·6 
(38·4– 42·8)
7·9 
(5·6– 10·2)
6·5 
(5·3– 7·7)
8·8 
(8·0–9·6)
67·2 
(63·9–70·6)
2005–09 6·2 
(4·2– 8·1)
24·9 
(23·4– 26·4)
51·1 
(49·2– 53·0)
48·8 
(46·6– 51·1)
8·3§ 
(5· 9–10·7)
5·4§ 
(4· 3–6·5)
8·8 
(8·0–9·7)
70·6 
(67·6–73·7)
2010–14 5·6 
(3·3– 7·8)
27·0 
(24·9– 29·0)
56·9 
(54·4– 59·4)
52·7 
(49·7– 55·7)
8·0§ 
(5· 3–10·7)
7·0§ 
(5· 2–8·8)
9·9 
(8·7–11·0)
75·3 
(71·8–78·9)
Malta*
2000–04 7·8† 
(0·0–15·6)
19·9 
(14·6– 25·2)
57·0 
(51·9– 62·2)
55·1 
(47·7– 62·5)
4·2† 
(0·0–10·5)
5·9 
(3·0– 8·7)
9·2 
(6·5–12·0)
87·3 
(80·0–94·7)
2005–09 6·1† 
(0·5–11·8)
24·8 
(19·3– 30·3)
52·9 
(48·5– 57·4)
53·8 
(47·2– 60·5)
0·0†§ 
(0·0–0·0)
2·2§ 
(0· 5–4·0)
11·4 
(8·7–14·1)
81·6 
(75·2–88·1)
2010–14 11·2† 
(1·6–20·8)
23·8 
(17·5– 30·0)
57·5 
(52·6– 62·3)
56·1 
(49·2– 62·9)
0·0†§ 
(0·0–0·0)
5·5§ 
(2· 7–8·3)
14·9 
(11·5–18·2)
81·9 
(75·6–88·3)
(Table 6 continues on next page)
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Gastrointestinal cancers Lung Melanoma of 
the skin
Oesophagus Stomach Colon Rectum Liver Pancreas
(Continued from previous page)
Netherlands*
2000–04 12·1 
(11·2– 13·0)
19·7 
(18·8– 20·6)
58·1 
(57·4– 58·7)
58·0 
(57·0– 59·1)
10·1 
(8·6– 11·7)
3·7 
(3·2– 4·2)
12·4 
(12·1–12·7)
88·4 
(87·6–89·2)
2005–09 16·8 
(15·8– 17·7)
22·9 
(22·0– 23·9)
60·9 
(60·3– 61·5)
63·1 
(62·2– 64·0)
13·4 
(11·8– 14·9)
5·5 
(5·0– 6·1)
15·7 
(15·3–16·0)
89·8 
(89·1–90·4)
2010–14 21·0 
(20·0– 22·0)
25·0 
(24·0– 26·0)
63·1 
(62·5– 63·7)
65·3 
(64·5– 66·2)
15·8 
(14·2– 17·4)
7·4 
(6·8– 8·1)
17·3 
(16·9–17·6)
91·0 
(90·4–91·6)
Norway*
2000–04 9·0 
(6·7– 11·3)
22·4 
(20·5– 24·2)
60·0 
(58·8– 61·2)
62·4 
(60·8– 64·1)
7·9 
(5·4– 10·3)
5·0 
(3·9– 6·0)
12·3 
(11·5–13·1)
86·4 
(85·1–87·6)
2005–09 13·3 
(10·8– 15·8)
25·3 
(23·3– 27·4)
64·3 
(63·2– 65·4)
66·8 
(65·1– 68·4)
14·2 
(11·2– 17·2)
6·1 
(5·0– 7·2)
15·9 
(15·1–16·8)
87·3 
(86·2–88·3)
2010–14 16·5 
(14·0– 19·0)
26·5 
(24·4– 28·6)
66·7 
(65·6– 67·8)
69·2 
(67·6– 70·8)
18·7 
(15·5– 22·0)
9·5 
(8·0– 11·0)
19·0 
(18·1–19·8)
89·3 
(88·3–90·3)
Poland (16 registries)*
2000–04 7·2 
(6·3– 8·1)
15·9 
(15·2– 16·5)
45·3 
(44·6– 45·9)
42·5 
(41·8– 43·3)
9·5 
(8·5– 10·5)
8·2 
(7·6– 8·8)
12·1 
(11·8–12·4)
63·2 
(62·0–64·4)
2005–09 8·9 
(7·9– 9·8)
19·9 
(19·3– 20·4)
51·1 
(50·5– 51·6)
47·6 
(46·9– 48·3)
10·7 
(9·8– 11·7)
9·7 
(9·2– 10·3)
14·1 
(13·8–14·4)
67·1 
(66·2–68·1)
2010–14 9·1 
(8·1– 10·1)
20·9 
(20·3– 21·4)
52·9 
(52·3– 53·4)
48·4 
(47·7– 49·1)
10·8 
(9·9– 11·8)
8·0 
(7·5– 8·5)
14·4 
(14·1–14·7)
69·8 
(68·9–70·7)
Portugal (four registries)*
2000–04 10·2 
(8·6– 11·7)
29·8 
(28·9– 30·8)
56·5 
(55·6– 57·4)
54·4 
(53·1– 55·7)
13·6 
(11·8– 15·5)
8·0 
(6·7– 9·2)
10·6 
(10·0–11·2)
78·8 
(76·8–80·7)
2005–09 12·5 
(11·0– 14·1)
32·4 
(31·5– 33·3)
61·1 
(60·4– 61·9)
59·8 
(58·7– 60·9)
15·3 
(13·6– 17·0)
10·3 
(9·1– 11·4)
14·1 
(13·5–14·7)
81·7 
(80·2–83·2)
2010–14 16·1 
(12·0– 20·2)
32·2 
(30·2– 34·2)
60·9 
(59·2– 62·6)
59·6 
(57·1– 62·1)
18·7 
(14·5– 22·9)
10·7 
(8·2– 13·1)
15·7 
(14·3–17·1)
83·7 
(80·4–87·0)
Romania (Cluj)
2000–04 ·· ·· ·· ·· ·· ·· ·· ··
2005–09 10·2§ 
(4· 4–16·0)
19·3§ 
(16· 0–22·7)
53·5§ 
(48· 9–58·0)
44·8 
(38·9– 50·8)
4·1§ 
(1· 8–6·4)
4·5§ 
(2· 2–6·7)
7·9§ 
(6·1–9·6)
68·4 
(61·5–75·3)
2010–14 0·0†§ 
(0·0–0·1)
26·0§ 
(21· 5–30·5)
52·2§ 
(46· 0–58·4)
58·4 
(49·8– 67·0)
13·2§ 
(9· 2–17·3)
6·0†§ 
(2·6–9·3)
11·1§ 
(8·7–13·6)
71·3 
(63·0–79·6)
Russia (five registries)
2000–04 10·9 
(8·8– 13·0)
22·9 
(21·7– 24·1)
40·4 
(38·9– 41·9)
38·5 
(36·4– 40·6)
7·4 
(5·2– 9·5)
7·5 
(6·0– 9·1)
16·8 
(15·7–17·8)
64·7 
(61·4–68·0)
2005–09 8·6 
(7·0– 10·2)
20·2 
(19·3– 21·1)
42·4 
(41·2– 43·6)
38·9 
(37·3– 40·5)
5·1 
(3·6– 6·6)
5·4 
(4·5– 6·4)
13·9 
(13·2–14·6)
63·3 
(60·3–66·3)
2010–14 8·6 
(7·1– 10·1)
21·0 
(20·0– 21·9)
44·9 
(43·8– 46·1)
41·9 
(40·2– 43·5)
6·3 
(4·8– 7·9)
4·4 
(3·7– 5·2)
13·7 
(13·0–14·4)
66·5 
(63·6–69·3)
Slovakia*
2000–04 5·8§ 
(3· 8–7·9)
20·6§ 
(19· 1–22·0)
50·4 
(49·1– 51·7)
43·6 
(41·7– 45·5)
5·6§ 
(4· 1–7·2)
4·8§ 
(3· 8–5·8)
9·5§ 
(8·7–10·3)
75·0 
(72·7–77·3)
2005–09 6·4 
(4·7– 8·0)
20·9 
(19·5– 22·4)
51·2 
(50·1– 52·4)
47·5 
(45·8– 49·2)
6·1§ 
(4· 8–7·5)
5·8 
(4·8– 6·7)
10·5 
(9·7–11·2)
79·7 
(77·7–81·7)
2010–14 6·4 
(3·3– 9·4)
21·1 
(17·8– 24·3)
51·8 
(49·1– 54·4)
48·6 
(44·9– 52·4)
7·6§ 
(4· 5–10·7)
6·4 
(4·4– 8·4)
11·2 
(9·5–12·8)
78·2 
(73·9–82·5)
Slovenia*
2000–04 8·2 
(5·7– 10·8)
25·9 
(23·8– 27·9)
53·6 
(51·6– 55·6)
48·6 
(46·1– 51·1)
3·8 
(2·2– 5·4)
4·7 
(3·4– 6·1)
9·9 
(9·1–10·8)
79·3 
(76·7–81·9)
2005–09 9·3 
(6·2– 12·3)
25·8 
(23·7– 27·8)
56·2 
(54·4– 58·0)
57·0 
(54·6– 59·4)
7·0 
(5·2– 8·8)
5·7 
(4·3– 7·1)
12·7 
(11·7–13·7)
85·0 
(83·0–87·0)
2010–14 8·6 
(5·2– 11·9)
28·8 
(26·4– 31·2)
61·9 
(60·0– 63·8)
60·3 
(57·7– 62·9)
7·4 
(5·3– 9·5)
6·6 
(4·9– 8·4)
14·8 
(13·6–16·1)
85·1 
(83·0–87·1)
(Table 6 continues on next page)
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by 5–10% in Japan, Taiwan, and Turkey; Austria, Finland, 
France, Italy, Malta, and Sweden; and New Zealand.
Over the same period, 5-year survival increased 
by 10% or more in Canada; Israel and Korea; 16 European 
countries (Denmark, Estonia, Iceland, Ireland, Latvia, 
Lithuania, Norway, and the UK [northern Europe]; Portugal 
and Spain [southern Europe], Bulgaria, the Czech 
Republic, and Poland [eastern Europe]; and Germany, the 
Gastrointestinal cancers Lung Melanoma of 
the skin
Oesophagus Stomach Colon Rectum Liver Pancreas
(Continued from previous page)
Spain (ten registries)
2000–04 8·9 
(7·5– 10·3)
25·7 
(24·5– 26·9)
56·5 
(55·6– 57·4)
55·2 
(53·7– 56·6)
14·4 
(13·2– 15·7)
5·6 
(4·8– 6·4)
10·8 
(10·4–11·3)
85·3 
(83·8–86·8)
2005–09 11·6 
(10·2– 13·1)
26·7 
(25·5– 27·9)
61·1 
(60·3– 61·9)
58·6 
(57·3– 59·9)
16·3 
(15·1– 17·4)
6·9 
(6·1– 7·7)
12·5 
(12·0–13·0)
87·1 
(85·9–88·3)
2010–14 13·0 
(10·6– 15·4)
27·6 
(25·7– 29·5)
63·2 
(62·0– 64·5)
59·5 
(57·4– 61·5)
17·3 
(15·4– 19·2)
7·7 
(6·3– 9·2)
13·5 
(12·7–14·3)
86·8 
(84·8–88·7)
Sweden*
2000–04 11·4 
(9·6– 13·1)
21·2 
(19·8– 22·6)
60·2 
(59·2– 61·2)
59·9 
(58·7– 61·1)
7·8 
(6·4– 9·1)
4·9 
(4·1– 5·8)
13·9 
(13·2–14·6)
88·9 
(88·1–89·8)
2005–09 13·1 
(11·4– 14·8)
23·6 
(22·1– 25·1)
64·2 
(63·3– 65·2)
63·0 
(61·9– 64·2)
13·0 
(11·4– 14·6)
7·9 
(6·9– 8·9)
16·6 
(15·9–17·3)
90·3 
(89·5–91·0)
2010–14 14·8 
(12·8– 16·7)
24·8 
(23·3– 26·3)
64·9 
(64·0– 65·8)
64·7 
(63·5– 65·8)
16·6 
(14·9– 18·3)
9·7 
(8·7– 10·8)
19·5 
(18·7–20·2)
91·5 
(90·9–92·2)
Switzerland (ten registries)‡
2000–04 16·1 
(13·6– 18·6)
29·2 
(26·9– 31·4)
62·8 
(61·3– 64·3)
59·5 
(57·2– 61·8)
12·2 
(10·3– 14·0)
5·6 
(4·4– 6·9)
14·7 
(13·8–15·6)
90·7 
(88·4–92·9)
2005–09 20·6 
(17·9– 23·2)
31·4 
(29·0– 33·7)
65·1 
(63·7– 66·6)
65·6 
(63·5– 67·7)
13·4 
(11·6– 15·3)
7·0 
(5·8– 8·2)
17·3 
(16·5–18·2)
92·4 
(91·3–93·5)
2010–14 23·9 
(21·0– 26·9)
32·2 
(29·9– 34·5)
67·3 
(65·7– 68·9)
67·3 
(65·0– 69·6)
15·4 
(13·5– 17·4)
9·4 
(7·9– 10·8)
20·4 
(19·4–21·4)
93·6 
(92·4–94·7)
UK (four registries)*
2000–04 11·5 
(11·1– 11·9)
16·2 
(15·7– 16·6)
52·0 
(51·6– 52·3)
54·6 
(54·0– 55·1)
7·1 
(6·6– 7·7)
3·7 
(3·4– 4·0)
8·3 
(8·1–8·5)
86·4 
(85·9–86·8)
2005–09 14·0 
(13·5– 14·4)
19·2 
(18·7– 19·7)
56·5 
(56·2– 56·9)
58·7 
(58·2– 59·2)
9·7 
(9·1– 10·2)
5·2 
(4·9– 5·5)
10·1 
(9·9–10·3)
89·2 
(88·9–89·6)
2010–14 15·7 
(15·3– 16·1)
20·7 
(20·1– 21·2)
60·0 
(59·7– 60·4)
62·5 
(62·0– 63·0)
13·0 
(12·4– 13·6)
6·8 
(6·5– 7·2)
13·3 
(13·1–13·5)
90·9 
(90·6–91·3)
Oceania
Australia (eight registries)*
2000–04 18·0 
(16·9– 19·2)
27·7 
(26·7– 28·8)
63·7 
(63·2– 64·3)
64·4 
(63·5– 65·2)
14·2 
(13·1– 15·3)
7·3 
(6·7– 8·0)
14·8 
(14·4–15·2)
92·0 
(91·7–92·4)
2005–09 19·9 
(18·7– 21·0)
29·8 
(28·8– 30·9)
68·1 
(67·6– 68·6)
68·6 
(67·8– 69·5)
17·7 
(16·6– 18·7)
9·1 
(8·5– 9·8)
17·1 
(16·7–17·5)
92·5 
(92·2–92·8)
2010–14 23·7 
(22·4– 25·0)
31·8 
(30·7– 32·9)
70·7 
(70·1– 71·2)
71·0 
(70·2– 71·9)
19·2 
(18·1– 20·3)
12·0 
(11·2– 12·8)
19·4 
(19·0–19·9)
92·9 
(92·5–93·2)
New Zealand*
2000–04 11·5 
(9·4– 13·6)
24·6 
(22·4– 26·8)
61·4 
(60·2– 62·7)
60·1 
(58·0– 62·1)
12·4 
(9·9– 15·0)
7·0 
(5·5– 8·5)
11·4 
(10·5–12·2)
90·0 
(89·1–90·8)
2005–09 14·5 
(12·1– 16·8)
24·8 
(22·5– 27·0)
62·8 
(61·6– 64·0)
63·3 
(61·4– 65·3)
16·8 
(14·4– 19·1)
7·7 
(6·3– 9·0)
12·4 
(11·6–13·3)
91·1 
(90·3–91·8)
2010–14 15·3 
(13·0– 17·7)
25·7 
(23·5– 27·9)
64·0 
(62·8– 65·1)
66·0 
(64·1– 67·9)
19·0 
(16·7– 21·4)
8·1 
(6·7– 9·6)
15·3 
(14·3–16·2)
91·8 
(91·1–92·5)
Some registries contributed data for selected cancers or calendar periods. Countries that only provided data for childhood cancers (Belarus, Greece, and Mexico) are not 
included in this table (see table 7 for childhood cancers). *Data with 100% coverage of the national population. †Survival estimate is not age-standardised. ‡Data with 100% 
coverage of the national population for childhood malignancies only. §Survival estimate considered less reliable because 15% or more of patients were (1) lost to follow-up or 
censored alive within 5 years of diagnosis or, if diagnosed in 2010 or later, before Dec 31, 2014; or (2) registered only from a death certificate or at autopsy; or (3) patients 
with unknown vital status or registered with incomplete dates—ie, unknown year of birth, unknown month or year of diagnosis, or unknown year of last known vital status. 
Table 6: Age-standardised 5-year net survival (%) with 95% CI: adults (15–99 years) diagnosed with one of eight common malignancies (oesophagus, 
stomach, colon, rectum, liver, pancreas, lung, or melanoma of the skin) by continent, country, and calendar period of diagnosis
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Netherlands, and Switzerland [western Europe]); and 
Australia. The increase was about 20% or more in China, 
Korea, and Slovenia.
Liver
Results are available for 1 178 364 adults from 
291 registries in 61 countries (tables 2, 4).
5-year net survival was in the range 5–30% throughout 
2000–14 (appendix p 252). Estimates are often flagged as 
less reliable than for other solid tumours (table 6; appendix 
pp 139–151) because of the exclusion of higher proportions 
of DCO registrations (table 3; appendix pp 32–36).
For patients diagnosed during 2010–14, age-
standardised 5-year net survival was in the range 20–29% 
only in Korea, Singapore, and Taiwan; and Belgium and 
Italy. Survival was in the range 10–19% in 27 countries: 
Canada and the USA; Martinique; three Asian countries 
(China [east Asia]; and Kuwait and Turkey [west Asia]); 
13 European countries (Iceland, Ireland, Latvia, Norway, 
Sweden, and the UK [northern Europe]; Portugal and 
Spain [southern Europe]; Poland [eastern Europe]; France, 
Germany, the Netherlands, and Switzerland [western 
Europe]); and Australia and New Zealand. 5-year survival 
was less than 10% in Denmark, Slovenia, Thailand, the 
Czech Republic, Russia, and Estonia.
In most countries, survival has changed very little 
during the 20-year period 1995–99 to 2000–14. It 
increased by 5–10% in Canada and the USA; Japan; 
eight European countries (Denmark, Ireland, and the 
UK [northern Europe]; Italy and Spain [southern Europe]; 
and France, the Netherlands, and Switzerland [western 
Europe]); and Australia and New Zealand. Survival 
increased by more than 10% in China, Korea, and Taiwan; 
and Norway, Portugal, and Sweden.
Pancreas
Results are available for 1 229 379 adults from 
290 registries in 59 countries (tables 2, 4).
Age-standardised 5-year net survival estimates were 
generally in the range 5–15% throughout 2000–14 
(appendix p 253). Similarly to liver cancer, some 
estimates are less reliable (table 6; appendix pp 139–151) 
owing to the high proportion of DCO registrations 
(table 3; appendix pp 37–41).
For patients diagnosed during 2010–14, survival was 
high in Kuwait (23·6%) and Malaysia (Penang; 19·0%; 
table 6; appendix p 215). Survival was in the range 10–15% 
in 15 countries: Canada and the USA; Martinique; China, 
Korea, and Turkey; eight European countries (Estonia, 
Ireland, Latvia, Norway, and Sweden [northern Europe]; 
Portugal [southern Europe]; and Belgium and Germany 
[western Europe]); and Australia. 5-year net survival 
ranged between 5% and 9% in 14 countries. Survival was 
very low in Russia (4·4%).
Trends in 5-year survival between 2000–04 and 2010–14 
were generally flat, but increases of 3–5% were seen in 
Canada and the USA; Korea and Singapore; 12 European 
countries (Denmark, Estonia, Ireland, Latvia, Norway, 
Sweden, and the UK [northern Europe]; Portugal 
[southern Europe]; the Czech Republic [eastern Europe]; 
and Belgium, the Netherlands, and Switzerland [western 
Europe]); and Australia (appendix p 234).
Lung
Results are available for 6 051 262 adults from 
290 registries in 61 countries (tables 2, 4).
Age-standardised 5-year net survival was in the range 
10–20% in most countries (table 6; appendix p 254). Most 
estimates in Central and South America were less reliable 
owing to the high proportion of DCO registrations 
excluded from analysis (table 6; appendix pp 152–164), 
although the proportion of DCOs has generally decreased 
worldwide (table 3; appendix pp 42–46).
For patients diagnosed during 2010–14, 5-year survival 
was high in Japan (32·9%). It was in the range 20–30% in 
12 countries: Mauritius; Canada and the USA; four Asian 
countries (China, Korea, and Taiwan [east Asia]; and Israel 
[west Asia]); and five European countries (Latvia, Iceland, 
and Sweden [northern Europe]; and Austria and 
Switzerland [western Europe]; table 6; appendix p 216). In 
most countries, however, survival was in the range 
10–19%: Martinique and Puerto Rico; five Asian countries 
(Malaysia [Penang] and Singapore [south Asia]; and 
Cyprus, Kuwait, and Turkey [west Asia]); 21 European 
countries (Denmark, Estonia, Finland, Ireland, Lithuania, 
Norway, and the UK [northern Europe]; Croatia, Italy, 
Malta, Portugal, Slovenia, and Spain [southern Europe]; 
the Czech Republic, Poland, Russia, and Slovakia [eastern 
Europe]; and Belgium, France, Germany, and the 
Netherlands, [western Europe]); and Australia and New 
Zealand. Survival was less than 10% in Thailand, Brazil, 
Bulgaria, and India (table 6).
Lung cancer survival trends between 1995–99 and 
2000–14 were generally flat, but survival increased by 
5–10% in 21 countries: Canada and the USA; Israel, 
Japan, and Taiwan; 15 European countries (Denmark, 
Estonia, Iceland, Ireland, Latvia, Norway, Sweden, and 
the UK [northern Europe]; Portugal and Slovenia 
[southern Europe]; and Austria, France, Germany, the 
Netherlands, and Switzerland [western Europe]); and 
Australia. Survival increased by more than 10% in China 
and Korea (table 6; appendix p 235).
Melanoma of the skin
Results are available for 1 553 109 adults from 281 registries 
in 59 countries (tables 2, 4).
Age-standardised 5-year net survival was in the 
range 60–90% in most countries (appendix p 255). Most 
estimates were considered reliable (table 6; appendix 
pp 152–164). For patients diagnosed during 2010–14, 
5-year survival estimates exceeded 90% in 11 countries: 
the USA; eight European countries (Denmark, Sweden, 
and the UK [northern Europe]; and Belgium, France, 
Germany, the Netherlands, and Switzerland [western 
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Women's cancers Prostate Brain 
(adults)
Haemopoietic malignancies 
(adults)
Childhood malignancies
Breast Cervix Ovary Myeloid Lymphoid Brain Acute 
lymphoblastic 
leukaemia
Lymphoma
Africa
Algeria (three registries)
2000–04 38·9§ 
(29·1–48·7)
61·1§ 
(55·5–66·7)
50·7†§ 
(35·6–65·8)
89·9†§ 
(77·8–100·0)
·· 21·1†§ 
(6·0–36·2)
23·3§ 
(13·8–32·8)
·· 30·9†§ 
(10·1–51·6)
6·0†§ 
(0·0–15·1)
2005–09 55·6§ 
(47·4–63·8)
70·7§ 
(64·5–77·0)
54·3§ 
(44·7–63·8)
50·3§ 
(41·0–59·6)
51·9§ 
(43·4–60·4)
17·1†§ 
(0·1–34·1)
47·8§ 
(39·9–55·8)
43·3§ 
(29·4–57·2)
100·0†§ 
(100·0–100·0)
78·9†§ 
(62·5–95·3)
2010–14 77·0§ 
(68·5–85·6)
72·4§ 
(66·0–78·7)
66·5§ 
(53·5–79·5)
64·1§ 
(56·6–71·6)
46·5§ 
(37·5–55·5)
17·9§ 
(5·3–30·6)
59·1§ 
(49·9–68·3)
54·1§ 
(39·2–69·0)
·· 77·5§ 
(65·4–89·7)
Mali (Bamako)
2000–04 ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2005–09 ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2010–14 0·0†§ 
(0·0–0·0)
·· ·· ·· ·· ·· ·· ·· ·· ··
Mauritius*
2000–04 ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2005–09 83·6 
(75·9–91·3)
80·8 
(76·0–85·6)
79·7 
(69·6–89·8)
61·8 
(54·1–69·4)
·· ·· ·· ·· ·· ··
2010–14 ·· ·· ·· 63·5 
(54·7–72·4)
43·7† 
(25·5–61·9)
50·1† 
(34·4–65·8)
65·9 
(53·4–78·4)
·· ·· ··
Morocco (Casablanca)
2000–04 ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2005–09 86·7§ 
(71·7–100·0)
·· ·· ·· ·· ·· ·· ·· ·· ··
2010–14 99·7§ 
(95·8–100·0)
·· ·· ·· ·· ·· ·· ·· ·· ··
Nigeria (Ibadan)
2000–04 ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2005–09 98·8§ 
(95·6–100·0)
58·6§ 
(46·5–70·7)
59·4†§ 
(24·9–93·9)
73·9§ 
(50·2–97·6)
88·6†§ 
(60·4–100·0)
57·4†§ 
(29·0–85·8)
86·8§ 
(54·9–100·0)
·· ·· 51·0§ 
(31·5–70·6)
2010–14 97·5§ 
(89·9–100·0)
49·8§ 
(36·5–63·1)
49·1§ 
(33·8–64·4)
58·7§ 
(40·1–77·2)
54·9†§ 
(19·7–90·0)
28·4†§ 
(3·0–53·7)
56·4§ 
(32·2–80·5)
·· ·· 6·0§ 
(0·0–13·6)
South Africa (Eastern Cape)
2000–04 53·0†§ 
(23·4–82·7)
70·7§ 
(56·7–84·7)
82·5†§ 
(42·5–100·0)
77·6†§ 
(55·0–100·0)
·· ·· ·· ·· ·· ··
2005–09 32·0§ 
(23·3–40·7)
40·2§ 
(32·2–48·1)
81·0†§ 
(58·8–100·0)
38·6§ 
(25·1–52·0)
·· ·· 29·5†§ 
(10·8–48·2)
·· ·· ··
2010–14 40·1§ 
(30·7–49·6)
37·1§ 
(31·4–42·9)
67·8†§ 
(47·4–88·2)
37·8§ 
(25·5–50·1)
51·6†§ 
(0·6–100·0)
·· 47·7†§ 
(31·1–64·4)
·· ·· ··
America (Central and South)
Argentina (five registries)‡
2000–04 82·3 
(79·4–85·2)
58·3 
(52·6–64·0)
40·4 
(32·4–48·4)
83·5 
(78·5–88·6)
29·8§ 
(22·6–37·0)
47·9 
(39·4–56·3)
54·5 
(49·1–59·8)
45·1 
(41·8–48·3)
65·0 
(62·7–67·3)
79·9 
(76·7–83·0)
2005–09 82·0 
(80·4–83·6)
55·6 
(52·0–59·1)
43·2 
(38·6–47·9)
83·6 
(81·2–86·0)
27·7§ 
(24·4–31·0)
39·5 
(34·5–44·6)
48·8 
(45·9–51·6)
56·1 
(52·9–59·3)
72·0 
(69·7–74·2)
76·9 
(73·5–80·3)
2010–14 84·4 
(82·6–86·2)
52·7 
(48·7–56·7)
38·6 
(34·3–42·9)
87·6 
(84·9–90·4)
30·7§ 
(26·8–34·6)
37·4 
(32·1–42·6)
48·2 
(45·0–51·5)
62·9§ 
(59·4–66·4)
76·1§ 
(73·7–78·4)
83·4 
(80·1–86·6)
Brazil (six registries)
2000–04 68·7§ 
(67·5–69·8)
69·3 
(66·1–72·6)
42·1 
(36·0–48·1)
90·0 
(87·2–92·8)
31·3§ 
(26·2–36·4)
31·1† 
(7·3–54·9)
48·2 
(43·7–52·6)
55·7 
(44·7–66·6)
67·7 
(57·8–77·6)
69·2 
(57·3–81·1)
2005–09 76·9§ 
(75·7–78·0)
63·2 
(59·9–66·5)
34·1 
(29·4–38·9)
92·5 
(90·2–94·8)
28·2§ 
(24·4–32·1)
41·6 
(31·4–51·8)
49·4 
(45·6–53·2)
34·7 
(21·9–47·5)
69·8 
(60·0–79·6)
86·3 
(77·1–95·5)
2010–14 75·2§ 
(73·9–76·5)
60·3 
(56·3–64·3)
34·9 
(29·5–40·3)
91·6 
(89·1–94·1)
28·1§ 
(23·7–32·6)
39·1 
(28·7–49·5)
46·2 
(42·2–50·2)
28·9 
(15·8–41·9)
66·0 
(53·3–78·8)
88·2 
(78·2–98·3)
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Chile (four registries)
2000–04 74·6 
(68·2–81·1)
58·2 
(52·3–64·0)
25·8 
(18·5–33·1)
82·6 
(77·2–88·0)
12·4† 
(0·0–26·7)
29·1 
(19·1–39·1)
28·9 
(23·4–34·3)
46·7† 
(22·7–70·7)
76·7 
(65·6–87·7)
70·1† 
(43·3–96·9)
2005–09 73·5 
(68·4–78·6)
57·2 
(51·6–62·9)
29·0 
(23·3–34·7)
84·4 
(80·7–88·1)
21·8 
(14·3–29·3)
25·8 
(20·8–30·8)
37·1 
(33·7–40·5)
56·7† 
(37·0–76·4)
67·4 
(57·3–77·4)
69·7† 
(51·4–88·0)
2010–14 75·5§ 
(69·4–81·5)
56·7§ 
(50·0–63·4)
28·0§ 
(21·3–34·7)
82·0§ 
(78·4–85·5)
24·2 
(15·2–33·2)
16·5 
(11·4–21·6)
32·5 
(23·8–41·2)
·· 63·9 
(48·5–79·3)
··
Colombia (four registries)
2000–04 72·3 
(68·9–75·7)
56·6§ 
(53·5–59·8)
33·5 
(28·0–39·0)
83·6 
(80·7–86·5)
23·8 
(20·1–27·5)
16·3 
(11·4–21·2)
37·2 
(33·4–40·9)
44·9§ 
(32·9–57·0)
52·3 
(43·5–61·2)
68·4§ 
(55·3–81·6)
2005–09 79·1 
(76·1–82·0)
55·4 
(52·6–58·1)
35·4 
(30·3–40·6)
87·8 
(85·4–90·3)
27·4 
(23·5–31·4)
30·7 
(25·7–35·7)
42·3 
(39·2–45·4)
33·9§ 
(23·4–44·5)
57·3 
(47·8–66·9)
85·0§ 
(76·1–93·9)
2010–14 72·1§ 
(69·0–75·2)
49·4§ 
(46·5–52·3)
33·3§ 
(28·2–38·4)
80·3§ 
(77·6–83·1)
20·8§ 
(17·1–24·4)
31·8§ 
(26·6–37·1)
40·3§ 
(37·0–43·6)
46·9§ 
(35·9–57·9)
68·9 
(51·6–86·3)
··
Costa Rica*
2000–04 87·0 
(83·6–90·3)
84·9§ 
(81·2–88·6)
54·3 
(43·7–64·9)
94·0 
(92·0–96·1)
30·8§ 
(24·9–36·7)
35·0 
(25·4–44·6)
50·0 
(45·2–54·8)
77·1† 
(55·1–99·0)
97·8† 
(93·2–100·0)
··
2005–09 86·4 
(84·0–88·7)
78·3§ 
(75·3–81·3)
47·1 
(40·5–53·7)
92·6 
(90·9–94·2)
18·9§ 
(15·1–22·8)
21·2 
(15·7–26·7)
50·4 
(46·9–53·9)
71·2 
(61·2–81·3)
87·4 
(82·8–91·9)
93·0 
(86·7–99·3)
2010–14 86·7 
(84·6–88·9)
78·0§ 
(74·8–81·2)
56·9 
(49·1–64·7)
93·2 
(91·5–94·9)
21·5§ 
(17·5–25·6)
29·4 
(23·3–35·4)
52·4 
(49·1–55·7)
69·8 
(57·8–81·8)
80·0 
(69·3–90·7)
93·5 
(86·2–100·0)
Cuba*
2000–04 73·7 
(72·2–75·1)
64·1 
(62·3–65·9)
29·5 
(26·7–32·3)
26·1§ 
(24·6–27·6)
·· ·· 44·0§ 
(41·6–46·5)
·· ·· 72·4§ 
(67·1–77·8)
2005–09 81·8 
(80·5–83·0)
68·8 
(67·0–70·7)
38·4 
(35·6–41·3)
53·8§ 
(52·1–55·6)
·· ·· 49·4§ 
(46·7–52·0)
·· ·· 77·4§ 
(71·5–83·3)
2010–14 75·1 
(73·7–76·5)
72·9 
(70·5–75·2)
49·3§ 
(45·0–53·5)
71·4§ 
(68·9–74·0)
·· ·· 60·1§ 
(56·3–63·8)
·· ·· 78·5§ 
(70·5–86·6)
Ecuador (five registries)
2000–04 72·1 
(67·3–76·9)
47·4 
(44·1–50·7)
34·5 
(26·5–42·5)
85·7 
(82·0–89·5)
24·2 
(19·4–28·9)
20·5 
(12·6–28·4)
33·1 
(29·1–37·0)
48·0§ 
(35·2–60·8)
48·3§ 
(40·3–56·4)
73·4§ 
(62·7–84·1)
2005–09 75·7 
(72·7–78·7)
50·4 
(47·8–52·9)
38·8 
(33·1–44·5)
80·7 
(78·0–83·5)
20·9 
(17·6–24·2)
20·3 
(15·5–25·0)
39·4 
(36·7–42·0)
31·2 
(20·9–41·5)
51·5 
(44·9–58·0)
72·2 
(63·7–80·7)
2010–14 75·5 
(72·4–78·7)
52·0 
(49·3–54·7)
37·9 
(32·1–43·7)
82·2 
(79·4–85·0)
25·8 
(22·0–29·6)
24·4 
(18·9–29·9)
40·1 
(37·4–42·8)
48·2 
(35·9–60·5)
49·8 
(42·7–56·9)
67·3 
(57·4–77·2)
Guadeloupe*
2000–04 ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2005–09 69·8§ 
(60·0–79·7)
20·9†§ 
(3·3–38·5)
24·2†§ 
(8·9–39·5)
82·8§ 
(78·2–87·5)
0·2†§ 
(0·0–0·6)
37·5†§ 
(9·8–65·3)
25·7§ 
(17·3–34·0)
·· ·· ··
2010–14 50·2§ 
(39·6–60·8)
19·4§ 
(9·0–29·9)
29·5†§ 
(13·8–45·2)
71·4§ 
(65·5–77·2)
9·6†§ 
(0·0–19·5)
32·3§ 
(21·4–43·2)
36·0§ 
(27·3–44·6)
·· ·· ··
Martinique*
2000–04 78·9 
(73·5–84·3)
69·7 
(62·5–76·9)
29·5 
(17·8–41·1)
93·2 
(90·5–95·8)
32·6 
(22·4–42·8)
46·2 
(36·8–55·6)
49·8 
(44·1–55·5)
·· 77·5† 
(55·9–99·2)
··
2005–09 87·8 
(83·5–92·1)
57·6 
(48·9–66·3)
34·0 
(24·6–43·4)
97·8 
(95·7–99·9)
28·1 
(19·9–36·2)
49·7 
(41·8–57·6)
48·7 
(43·9–53·6)
·· ·· ··
2010–14 89·8 
(84·5–95·1)
57·5 
(46·2–68·8)
35·7§ 
(23·4–48·0)
97·9 
(95·1–100·0)
35·8 
(26·4–45·3)
47·9 
(39·4–56·5)
49·4 
(43·3–55·4)
·· ·· ··
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Mexico (childhood)‡
2000–04 ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2005–09 ·· ·· ·· ·· ·· ·· ·· 41·2 
(35·1–47·4)
52·5 
(49·8–55·2)
75·1§ 
(70·7–79·5)
2010–14 ·· ·· ·· ·· ·· ·· ·· 36·5 
(30·0–43·0)
52·7 
(49·4–56·1)
72·0§ 
(66·4–77·7)
Peru (Lima)
2000–04 ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2005–09 ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2010–14 84·0 
(81·4–86·7)
57·2 
(54·8–59·6)
·· ·· ·· 36·3§ 
(29·5–43·0)
46·2§ 
(42·9–49·6)
·· 60·4 
(53·4–67·3)
73·4§ 
(64·8–82·1)
Puerto Rico*
2000–04 83·4 
(81·9–84·9)
60·6 
(56·9–64·4)
34·9 
(30·8–39·0)
98·7 
(97·6–99·7)
31·7§ 
(28·0–35·4)
25·6§ 
(21·4–29·8)
49·1 
(46·8–51·4)
71·2 
(62·1–80·3)
79·3 
(70·2–88·4)
94·5 
(90·1–98·8)
2005–09 83·0 
(81·6–84·4)
58·8 
(55·3–62·4)
37·2 
(33·4–41·0)
99·0 
(98·1–99·9)
34·8 
(31·5–38·0)
38·8 
(35·6–42·0)
53·5 
(51·6–55·4)
76·1 
(67·6–84·6)
86·2 
(78·1–94·4)
90·9 
(83·1–98·7)
2010–14 84·1 
(82·0–86·3)
63·5 
(57·9–69·1)
37·3 
(32·0–42·6)
98·4 
(97·0–99·8)
36·3 
(31·2–41·4)
44·9 
(39·6–50·1)
60·3 
(57·2–63·4)
70·5 
(56·3–84·7)
93·1 
(83·6–100·0)
96·3 
(89·9–100·0)
Uruguay*
2000–04 ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2005–09 ·· 55·7 
(51·6–59·8)
37·4 
(31·9–42·8)
84·7 
(82·1–87·3)
·· ·· ·· ·· ·· ··
2010–14 ·· 56·5 
(51·8–61·1)
37·4§ 
(31·4–43·4)
86·5 
(83·7–89·3)
·· ·· ·· ·· ·· ··
America (North)
Canada (nine registries)
2000–04 85·9 
(85·5–86·4)
67·9 
(66·4–69·5)
37·6 
(36·6–38·6)
93·0 
(92·6–93·3)
24·7 
(23·4–26·0)
47·5 
(46·1–48·8)
60·1 
(59·5–60·7)
73·3 
(68·2–78·4)
91·0 
(88·8–93·3)
89·4 
(85·9–92·9)
2005–09 87·6 
(87·2–88·0)
66·9 
(65·3–68·5)
41·0 
(40·0–42·0)
94·2 
(93·9–94·5)
29·8 
(28·5–31·1)
49·2 
(47·9–50·5)
66·0 
(65·4–66·5)
72·5 
(67·7–77·2)
92·1 
(90·0–94·3)
88·5 
(84·4–92·5)
2010–14 88·2 
(87·8–88·6)
66·6 
(65·1–68·1)
40·9 
(39·9–41·8)
93·6 
(93·3–94·0)
29·9 
(28·6–31·1)
50·4 
(49·2–51·6)
68·6 
(68·1–69·1)
72·7 
(68·0–77·4)
92·6 
(90·7–94·6)
92·3 
(89·1–95·6)
USA (48 registries)
2000–04 88·9 
(88·7–89·0)
64·3 
(63·7–64·8)
40·4 
(40·0–40·7)
97·5 
(97·3–97·6)
26·8 
(26·5–27·1)
41·0 
(40·7–41·3)
61·2 
(61·0–61·4)
72·1 
(71·1–73·2)
86·7 
(85·8–87·5)
88·5 
(87·4–89·6)
2005–09 89·8 
(89·6–89·9)
63·0 
(62·5–63·5)
42·0 
(41·7–42·4)
98·1 
(98·0–98·2)
35·1 
(34·8–35·4)
45·9 
(45·6–46·2)
66·1 
(66·0–66·3)
76·8 
(75·9–77·7)
88·1 
(87·3–88·9)
90·2 
(89·2–91·3)
2010–14 90·2 
(90·1–90·4)
62·6 
(62·0–63·1)
43·4 
(43·1–43·8)
97·4 
(97·3–97·5)
36·5 
(36·1–36·8)
46·7 
(46·4–47·0)
68·1 
(67·9–68·3)
78·2 
(77·3–79·2)
89·5 
(88·8–90·3)
94·3 
(93·6–95·1)
Asia
China (21 registries)
2000–04 75·9 
(70·9–80·9)
53·3 
(48·1–58·5)
42·4 
(38·2–46·6)
57·7 
(52·3–63·0)
22·7 
(20·5–25·0)
18·6 
(15·8–21·5)
33·9 
(31·6–36·2)
32·7 
(21·0–44·4)
61·8 
(46·5–77·2)
44·2† 
(29·7–58·8)
2005–09 80·4 
(79·3–81·5)
63·0 
(61·2–64·9)
40·6 
(38·8–42·5)
62·5 
(59·9–65·1)
26·4 
(25·2–27·7)
20·1 
(18·7–21·4)
35·4 
(34·2–36·6)
39·1 
(31·2–47·0)
53·5 
(44·6–62·4)
52·3 
(39·5–65·0)
2010–14 83·2 
(82·1–84·3)
67·6 
(65·8–69·5)
41·8 
(39·8–43·7)
69·2 
(66·4–72·0)
32·0 
(30·6–33·5)
24·8 
(23·2–26·4)
38·3 
(37·0–39·5)
41·1 
(32·0–50·1)
57·7 
(46·6–68·7)
61·1 
(47·5–74·8)
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Cyprus*
2000–04 89·3§ 
(80·8–97·8)
60·4†§ 
(41·0–79·8)
42·6†§ 
(24·6–60·6)
91·0§ 
(84·0–97·9)
32·1†§ 
(13·4–50·8)
60·0†§ 
(39·1–80·9)
61·4§ 
(52·2–70·6)
·· ·· ··
2005–09 92·0§ 
(88·7–95·4)
66·9§ 
(60·0–73·8)
46·2§ 
(39·9–52·4)
98·3§ 
(95·4–100·0)
24·6§ 
(18·6–30·7)
39·8§ 
(33·3–46·2)
69·4§ 
(65·1–73·7)
·· 85·2†§ 
(72·1–98·3)
100·0†§ 
(86·3–100·0)
2010–14 92·8§ 
(89·7–95·9)
73·3§ 
(65·1–81·6)
46·4§ 
(40·0–52·7)
99·2§ 
(96·4–100·0)
25·2§ 
(19·5–31·0)
36·0§ 
(30·2–41·9)
65·7§ 
(61·8–69·6)
·· 86·6§ 
(78·2–95·0)
··
Hong Kong*
2000–04 ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2005–09 82·2 
(80·9–83·5)
66·7 
(64·5–69·0)
·· ·· ·· ·· ·· ·· ·· ··
2010–14 83·3 
(82·1–84·6)
65·8 
(63·6–68·1)
·· ·· ·· ·· ·· ·· ·· ··
India (two registries)
2000–04 57·6 
(48·1–67·1)
45·2 
(34·8–55·6)
25·6† 
(12·2–39·1)
24·8† 
(6·3–43·3)
22·4†§ 
(8·3–36·5)
19·7† 
(6·3–33·1)
40·6† 
(28·1–53·1)
·· 54·0† 
(28·3–79·8)
··
2005–09 59·1 
(46·6–71·6)
51·6 
(40·5–62·6)
13·2 
(7·7–18·7)
33·2† 
(16·3–50·0)
16·7 
(10·4–23·0)
6·1 
(2·5–9·6)
45·4 
(34·2–56·6)
·· 75·5† 
(52·1–99·0)
··
2010–14 66·1 
(51·5–80·8)
59·0 
(47·5–70·5)
15·6 
(10·2–21·1)
44·3 
(32·1–56·6)
30·0† 
(17·5–42·6)
29·0† 
(16·8–41·3)
45·6 
(33·0–58·1)
·· ·· ··
Iran (Golestan)
2000–04 ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2005–09 ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2010–14 ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
Israel*
2000–04 85·1 
(84·2–86·1)
65·0 
(61·6–68·5)
40·1 
(37·8–42·4)
92·5 
(91·4–93·6)
29·7 
(27·8–31·7)
51·3 
(49·1–53·5)
63·7 
(62·5–64·9)
74·5 
(69·3–79·6)
86·4 
(81·6–91·2)
89·1 
(84·6–93·5)
2005–09 87·8 
(86·8–88·7)
65·9 
(62·7–69·1)
43·5 
(41·1–45·9)
95·7 
(94·7–96·6)
32·3 
(30·4–34·3)
43·9 
(41·9–46·0)
65·2 
(64·1–66·3)
72·0 
(67·2–76·9)
86·7 
(82·2–91·2)
90·8 
(87·3–94·3)
2010–14 88·0 
(87·0–89·0)
66·6 
(63·2–70·1)
45·0 
(42·3–47·7)
95·6 
(94·5–96·7)
32·8 
(30·6–34·9)
39·7 
(37·6–41·9)
65·5 
(64·2–66·7)
77·6 
(72·6–82·6)
87·9 
(83·1–92·6)
92·3 
(89·0–95·6)
Japan (16 registries)
2000–04 85·9 
(85·2–86·6)
67·5 
(66·3–68·7)
35·5 
(33·8–37·2)
85·9 
(84·9–87·0)
27·9§ 
(26·3–29·5)
24·8 
(23·4–26·1)
47·5 
(46·3–48·7)
65·3 
(59·2–71·5)
79·7 
(74·9–84·4)
86·0 
(80·2–91·7)
2005–09 88·9 
(88·4–89·3)
69·2 
(68·3–70·1)
43·9 
(42·8–45·1)
91·4 
(90·8–92·0)
38·5§ 
(37·2–39·7)
27·5 
(26·7–28·3)
52·0 
(51·4–52·6)
62·5 
(58·1–66·8)
83·7 
(80·6–86·9)
84·7 
(79·5–89·9)
2010–14 89·4 
(88·9–89·9)
71·4 
(70·4–72·3)
46·3 
(44·9–47·7)
93·0 
(92·4–93·6)
46·3§ 
(44·9–47·7)
33·3 
(32·4–34·3)
57·3 
(56·5–58·0)
69·6 
(64·4–74·7)
87·6 
(84·2–91·0)
89·6 
(84·2–95·0)
Jordan*
2000–04 87·6§ 
(83·5–91·7)
75·6§ 
(66·8–84·3)
·· 88·5§ 
(83·7–93·3)
55·8§ 
(49·0–62·6)
57·1§ 
(48·1–66·1)
76·0§ 
(69·4–82·6)
73·5§ 
(65·7–81·3)
75·4§ 
(69·7–81·2)
92·4§ 
(88·1–96·6)
2005–09 86·6§ 
(83·2–90·0)
70·6§ 
(63·9–77·4)
·· 88·6§ 
(83·3–93·9)
46·7§ 
(41·1–52·4)
56·5§ 
(46·9–66·1)
74·6§ 
(68·3–80·9)
66·0§ 
(58·6–73·3)
89·2§ 
(84·8–93·6)
91·1§ 
(86·4–95·8)
2010–14 84·4§ 
(80·9–88·0)
56·4§ 
(48·2–64·6)
·· 86·1§ 
(81·1–91·0)
32·9§ 
(26·8–39·0)
42·5§ 
(35·3–49·6)
65·1§ 
(60·3–69·9)
57·3§ 
(49·9–64·8)
88·0§ 
(83·1–92·8)
87·0§ 
(81·4–92·6)
Korea*
2000–04 79·5 
(78·0–81·0)
76·0 
(75·3–76·7)
43·0 
(41·2–44·7)
76·0 
(74·6–77·5)
27·6 
(26·4–28·9)
31·7 
(30·4–33·0)
39·8 
(38·8–40·8)
54·2 
(50·8–57·6)
73·1 
(70·4–75·8)
82·4 
(79·3–85·4)
2005–09 84·0 
(83·0–85·0)
77·0 
(76·4–77·7)
44·1 
(42·7–45·5)
87·3 
(86·5–88·1)
31·9 
(30·8–33·0)
41·5 
(40·5–42·5)
47·5 
(46·7–48·4)
61·4 
(58·1–64·7)
78·6 
(76·1–81·0)
83·0 
(80·0–85·9)
2010–14 86·6 
(85·8–87·5)
77·3 
(76·6–78·0)
47·5 
(46·2–48·9)
89·9 
(89·2–90·5)
33·7 
(32·6–34·7)
45·9 
(44·9–46·8)
52·5 
(51·8–53·3)
60·3 
(56·9–63·8)
84·4 
(82·1–86·7)
91·0 
(88·9–93·1)
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Kuwait*
2000–04 68·3 
(58·0–78·7)
54·8 
(45·2–64·3)
38·9† 
(26·3–51·5)
78·8† 
(66·7–90·9)
30·3†§ 
(19·1–41·5)
38·6 
(27·1–50·0)
52·1 
(42·9–61·2)
47·1† 
(24·4–69·8)
76·1§ 
(65·7–86·5)
93·0 
(86·2–99·8)
2005–09 71·0 
(63·8–78·2)
73·8† 
(61·7–86·0)
35·4 
(25·2–45·6)
71·9 
(63·7–80·0)
24·9 
(17·3–32·6)
24·0 
(15·9–32·0)
63·2 
(55·8–70·7)
59·2† 
(39·2–79·1)
74·9 
(65·6–84·1)
90·7 
(83·2–98·2)
2010–14 75·2 
(66·4–83·9)
56·6 
(44·2–69·0)
35·1 
(25·6–44·7)
84·0 
(74·1–94·0)
31·8 
(23·2–40·4)
25·6 
(17·7–33·6)
68·2 
(59·5–76·9)
·· 88·4 
(80·6–96·2)
96·3 
(91·4–100·0)
Malaysia (Penang)
2000–04 ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2005–09 74·4§ 
(66·3–82·4)
56·3§ 
(49·5–63·0)
36·4§ 
(27·3–45·6)
74·9 
(67·5–82·3)
20·5† 
(10·7–30·4)
20·3 
(11·5–29·1)
31·4 
(24·7–38·1)
41·3†§ 
(19·0–63·6)
72·8§ 
(62·4–83·3)
95·3§ 
(89·2–100·0)
2010–14 65·0§ 
(52·1–78·0)
57·1§ 
(48·3–65·9)
46·8§ 
(34·5–59·0)
87·7 
(80·8–94·5)
28·3† 
(14·7–42·0)
29·6 
(21·2–38·0)
51·3 
(39·6–63·1)
63·4†§ 
(45·7–81·2)
82·3§ 
(72·0–92·5)
85·0†§ 
(66·2–100·0)
Mongolia*
2000–04 ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2005–09 76·7 
(60·0–93·4)
·· ·· ·· ·· ·· ·· ·· ·· ··
2010–14 76·1 
(63·8–88·4)
·· ·· ·· ·· ·· ·· ·· ·· ··
Qatar*
2000–04 59·2§ 
(48·7–69·7)
83·9†§ 
(68·5–99·2)
47·1†§ 
(25·1–69·0)
81·5†§ 
(60·7–100·0)
52·9†§ 
(34·0–71·9)
63·8†§ 
(49·8–77·7)
46·5§ 
(34·5–58·4)
11·1†§ 
(0·0–27·1)
67·3†§ 
(44·3–90·3)
69·0§ 
(52·6–85·4)
2005–09 73·3§ 
(63·0–83·7)
55·6†§ 
(35·3–76·0)
62·6†§ 
(47·5–77·6)
98·2†§ 
(87·1–100·0)
32·4†§ 
(19·0–45·8)
52·1†§ 
(39·7–64·6)
60·3§ 
(45·9–74·7)
·· 82·6†§ 
(61·2–100·0)
88·5†§ 
(73·8–100·0)
2010–14 71·9§ 
(58·4–85·5)
63·5†§ 
(44·2–82·8)
39·2§ 
(26·3–52·1)
89·6§ 
(79·0–100·0)
36·1†§ 
(20·5–51·7)
56·9§ 
(42·0–71·9)
75·0§ 
(58·8–91·2)
65·5†§ 
(34·5–96·5)
100·0§ 
(100·0–100·0)
95·3§ 
(87·3–100·0)
Singapore*
2000–04 76·3 
(73·9–78·7)
68·3 
(65·2–71·5)
42·5 
(37·9–47·0)
83·4 
(80·3–86·5)
26·2 
(21·5–30·9)
39·2 
(35·1–43·3)
46·0 
(43·0–48·9)
60·9 
(48·0–73·8)
79·8 
(72·3–87·2)
86·9 
(77·5–96·3)
2005–09 80·3 
(78·3–82·3)
63·3 
(60·1–66·6)
46·8 
(42·8–50·7)
86·7 
(84·5–88·9)
30·3 
(26·2–34·4)
43·7 
(40·1–47·4)
55·3 
(52·7–57·9)
57·5 
(45·9–69·0)
90·4 
(84·2–96·6)
73·8 
(61·6–86·0)
2010–14 80·3 
(78·4–82·2)
63·4 
(60·2–66·6)
43·9 
(40·7–47·0)
87·8 
(85·8–89·8)
34·4 
(30·6–38·2)
44·1 
(41·1–47·1)
58·7 
(56·4–61·1)
62·0 
(51·4–72·5)
88·6 
(81·8–95·4)
92·1 
(85·2–99·1)
Taiwan*
2000–04 80·2 
(78·9–81·6)
74·3 
(73·4–75·2)
44·1 
(41·8–46·4)
75·5 
(73·8–77·2)
26·5 
(24·8–28·1)
23·1 
(21·6–24·6)
40·3 
(39·2–41·4)
57·1 
(52·4–61·8)
72·1 
(68·2–75·9)
80·1 
(75·6–84·7)
2005–09 82·2 
(81·2–83·2)
73·2 
(72·2–74·2)
47·5 
(45·5–49·5)
79·8 
(78·7–81·0)
27·6 
(26·0–29·2)
30·4 
(29·1–31·7)
46·8 
(45·8–47·8)
58·8 
(54·1–63·5)
78·8 
(75·3–82·3)
84·0 
(79·6–88·4)
2010–14 84·2 
(83·3–85·1)
70·0 
(68·9–71·1)
48·8 
(46·9–50·8)
83·0 
(81·9–84·0)
28·4 
(26·9–29·9)
33·4 
(32·2–34·6)
50·5 
(49·6–51·5)
54·8 
(49·9–59·6)
76·5 
(72·8–80·1)
86·7 
(82·5–90·8)
Thailand (six registries)
2000–04 56·6§ 
(52·0–61·3)
53·5§ 
(51·3–55·7)
41·8§ 
(34·8–48·7)
52·1§ 
(46·6–57·6)
11·7§ 
(9·2–14·3)
9·4§ 
(7·2–11·6)
30·3§ 
(26·7–34·0)
23·4§ 
(15·2–31·5)
54·5§ 
(46·7–62·4)
43·9†§ 
(27·1–60·8)
2005–09 64·8§ 
(62·5–67·0)
55·8§ 
(54·0–57·7)
35·8 
(32·3–39·3)
71·8 
(69·0–74·7)
17·6 
(15·2–20·0)
18·2 
(16·0–20·4)
36·1 
(33·7–38·4)
38·4 
(30·6–46·3)
60·6 
(54·2–67·1)
63·7§ 
(52·3–75·0)
2010–14 68·7§ 
(66·6–70·8)
53·9§ 
(52·1–55·8)
37·2 
(34·0–40·5)
68·0 
(65·2–70·8)
14·7 
(12·6–16·9)
25·4 
(22·8–28·0)
35·0 
(32·8–37·1)
44·5§ 
(35·9–53·1)
65·9§ 
(59·2–72·6)
73·9§ 
(65·0–82·7)
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Turkey (nine registries)
2000–04 84·8 
(81·5–88·0)
64·8 
(59·7–69·9)
46·1§ 
(38·3–53·8)
83·4§ 
(79·3–87·5)
32·1§ 
(27·9–36·2)
35·9§ 
(30·6–41·2)
54·3§ 
(49·6–58·9)
56·8 
(46·3–67·2)
72·4 
(64·3–80·6)
79·9 
(70·9–88·9)
2005–09 80·6 
(79·2–82·1)
59·2 
(56·5–61·9)
40·0 
(37·4–42·6)
81·2 
(79·9–82·6)
34·0 
(32·4–35·6)
49·0 
(46·8–51·2)
50·3 
(48·7–51·8)
61·1 
(56·2–66·0)
78·7 
(74·9–82·6)
85·0 
(81·4–88·7)
2010–14 82·1 
(80·7–83·5)
60·7 
(58·1–63·3)
39·7 
(37·3–42·0)
83·8 
(82·5–85·1)
35·6 
(34·1–37·0)
54·0 
(51·8–56·1)
54·5 
(53·0–56·1)
62·5 
(58·4–66·7)
80·9 
(77·2–84·6)
82·9 
(79·1–86·7)
Europe
Austria*
2000–04 81·7 
(80·9–82·4)
65·4 
(63·4–67·4)
40·9 
(39·4–42·5)
90·1 
(89·3–90·8)
24·2 
(22·6–25·9)
25·0 
(23·1–26·8)
57·6 
(56·5–58·7)
·· ·· ··
2005–09 83·9 
(83·2–84·6)
66·0 
(63·7–68·2)
41·2 
(39·6–42·8)
90·8 
(90·1–91·5)
28·5 
(26·9–30·1)
29·6 
(27·7–31·5)
62·2 
(61·1–63·3)
·· ·· ··
2010–14 84·8 
(84·1–85·5)
63·9 
(61·6–66·2)
41·0 
(39·4–42·7)
90·2 
(89·5–90·9)
26·3 
(24·7–27·9)
32·0 
(30·1–34·0)
63·3 
(62·3–64·4)
·· ·· ··
Belarus (childhood)‡
2000–04 ·· ·· ·· ·· ·· ·· ·· 66·1 
(59·8–72·3)
78·5 
(73·0–83·9)
86·5 
(80·7–92·3)
2005–09 ·· ·· ·· ·· ·· ·· ·· 70·4 
(64·0–76·8)
87·0 
(81·9–92·2)
84·6 
(77·0–92·2)
2010–14 ·· ·· ·· ·· ·· ·· ·· 68·5 
(61·6–75·5)
86·6 
(81·7–91·5)
85·2 
(78·0–92·4)
Belgium*
2000–04 84·8 
(83·5–86·0)
65·1 
(61·1–69·0)
42·7 
(39·4–45·9)
92·1 
(90·8–93·4)
31·5 
(28·5–34·5)
49·7 
(46·7–52·7)
65·5 
(63·6–67·4)
84·1 
(75·6–92·6)
80·4 
(69·8–91·0)
94·2 
(87·9–100·0)
2005–09 85·3 
(84·7–85·8)
65·7 
(63·8–67·6)
42·8 
(41·3–44·3)
93·2 
(92·6–93·7)
31·9 
(30·6–33·2)
53·2 
(51·9–54·5)
68·0 
(67·2–68·8)
75·2 
(70·3–80·1)
90·5 
(87·0–94·1)
95·6 
(92·9–98·2)
2010–14 86·4 
(85·9–86·9)
65·4 
(63·5–67·2)
43·1 
(41·6–44·6)
93·8 
(93·2–94·3)
31·2 
(29·9–32·5)
55·4 
(54·2–56·5)
70·6 
(69·8–71·4)
74·5 
(70·2–78·9)
90·8 
(87·3–94·3)
95·4 
(92·7–98·1)
Bulgaria*
2000–04 70·9 
(69·7–72·1)
49·2 
(47·6–50·7)
32·9 
(30·9–34·9)
49·4 
(47·1–51·7)
·· 29·9§ 
(27·2–32·6)
38·1 
(36·1–40·0)
·· 63·5 
(55·5–71·5)
70·7 
(62·2–79·2)
2005–09 75·9 
(74·8–77·0)
53·2 
(51·7–54·7)
33·9 
(32·2–35·5)
54·8 
(52·7–56·9)
·· 40·1 
(37·6–42·6)
39·9 
(38·1–41·6)
·· 74·8 
(68·4–81·1)
74·3 
(64·9–83·7)
2010–14 78·3 
(77·2–79·4)
54·8 
(53·3–56·3)
37·3 
(35·4–39·1)
68·3 
(66·2–70·5)
·· 41·6§ 
(39·2–44·1)
43·5 
(41·8–45·2)
·· 78·3 
(71·7–84·9)
87·7 
(80·6–94·9)
Croatia*
2000–04 73·6 
(72·2–75·0)
63·2 
(60·6–65·8)
36·9 
(34·6–39·2)
65·7 
(63·6–67·9)
37·0 
(35·1–38·8)
31·1 
(28·6–33·6)
42·7 
(41·0–44·4)
65·7 
(58·3–73·1)
81·7 
(74·3–89·1)
76·6 
(66·8–86·3)
2005–09 78·2 
(77·0–79·4)
64·3 
(61·9–66·7)
33·4 
(31·3–35·5)
78·3 
(76·7–79·9)
39·6 
(37·8–41·5)
29·2 
(26·8–31·6)
51·0 
(49·3–52·6)
75·2 
(67·9–82·5)
86·7 
(81·1–92·3)
84·6 
(76·2–93·0)
2010–14 78·6 
(77·4–79·7)
63·2 
(60·8–65·6)
36·0 
(33·9–38·2)
80·9 
(79·3–82·4)
42·2 
(40·4–44·0)
32·2 
(29·7–34·7)
52·7 
(51·1–54·3)
73·4 
(65·6–81·3)
85·2 
(79·1–91·3)
94·5 
(89·1–99·9)
Czech Republic*
2000–04 75·7 
(74·8–76·5)
60·4 
(58·9–61·9)
34·3 
(33·0–35·5)
71·0 
(69·9–72·2)
19·5 
(18·2–20·8)
19·9 
(18·2–21·7)
49·9 
(48·8–51·0)
55·6 
 (47·9–63·3)
88·0 
(82·9–93·1)
89·0 
(82·7–95·3)
2005–09 79·1 
(78·4–79·9)
62·7 
(61·2–64·1)
35·3 
(34·0–36·5)
81·5 
(80·7–82·3)
22·1 
(20·8–23·4)
33·5 
(31·8–35·1)
53·2 
(52·2–54·3)
64·3 
 (57·4–71·3)
90·3 
(85·6–95·0)
82·9 
(73·2–92·5)
2010–14 81·4 
(80·7–82·1)
61·0 
(59·5–62·4)
36·5 
(35·2–37·8)
85·3 
(84·6–86·0)
21·4 
(20·1–22·7)
36·8 
(35·2–38·5)
57·2 
(56·1–58·2)
69·7 
 (63·2–76·2)
88·2 
(82·1–94·3)
89·6 
(82·5–96·6)
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Denmark*
2000–04 80·3 
(79·4–81·2)
63·0 
(60·6–65·4)
33·1 
(31·4–34·8)
63·6 
(62·1–65·1)
30·5 
(28·8–32·2)
35·7 
(33·6–37·8)
57·7 
(56·4–59·0)
68·8 
(62·1–75·5)
84·3 
(78·6–90·0)
90·2 
(82·2–98·2)
2005–09 84·0 
(83·2–84·8)
66·7 
(64·3–69·1)
37·4 
(35·7–39·2)
82·5 
(81·6–83·4)
35·1 
(33·4–36·7)
45·0 
(43·0–47·0)
66·9 
(65·7–68·0)
79·4 
(72·9–85·8)
93·1 
(88·4–97·7)
90·0 
(83·1–97·0)
2010–14 86·1 
(85·4–86·9)
69·5 
(67·0–72·0)
39·7 
(37·8–41·6)
85·6 
(84·7–86·4)
38·9 
(37·3–40·6)
47·6 
(45·7–49·6)
70·9 
(69·8–72·1)
79·5 
(73·3–85·6)
94·0 
(90·1–97·9)
93·8 
(89·0–98·7)
Estonia*
2000–04 70·9 
(68·2–73·6)
62·3 
(58·5–66·1)
31·2 
(27·7–34·6)
67·9 
(64·5–71·3)
25·2 
(21·4–29·0)
36·6 
(31·6–41·6)
48·8 
(45·6–52·0)
81·2 
(69·9–92·5)
63·7 
(51·0–76·4)
88·3† 
(73·4–100·0)
2005–09 75·4 
(73·1–77·6)
66·9 
(63·4–70·4)
37·2 
(33·8–40·7)
83·2 
(80·9–85·6)
26·1 
(22·6–29·6)
42·4 
(38·1–46·8)
53·5 
(50·6–56·4)
72·3† 
(57·9–86·7)
85·4† 
(73·6–97·1)
85·8† 
(68·1–100·0)
2010–14 76·6 
(73·8–79·3)
66·5 
(62·2–70·7)
42·3 
(37·4–47·1)
86·3 
(83·5–89·0)
31·0 
(26·1–36·0)
37·8 
(32·1–43·5)
53·8 
(50·2–57·4)
64·5 
(47·3–81·8)
87·7 
(76·4–98·9)
88·0 
(73·1–100·0)
Finland*
2000–04 86·5 
(85·5–87·5)
67·8 
(64·3–71·3)
41·2 
(39·2–43·1)
90·0 
(89·1–90·9)
35·4 
(33·5–37·4)
40·1§ 
(37·4–42·8)
56·8 
(55·5–58·1)
78·5 
(72·5–84·6)
84·7 
(78·0–91·4)
90·5 
(84·3–96·7)
2005–09 87·7 
(86·9–88·5)
65·2 
(61·4–69·0)
44·2 
(42·2–46·2)
93·4 
(92·6–94·1)
35·8 
(34·0–37·6)
41·6§ 
(39·2–44·0)
62·5 
(61·2–63·7)
78·0 
(71·5–84·5)
88·1 
(83·2–92·9)
92·0 
(84·5–99·6)
2010–14 88·5 
(87·7–89·3)
67·4 
(63·8–71·1)
41·1 
(39·2–43·0)
93·2 
(92·4–93·9)
37·6 
(35·7–39·4)
47·2§ 
(44·7–49·6)
64·4 
(63·2–65·5)
75·6 
(69·0–82·2)
95·2 
(91·5–98·9)
91·2 
(84·3–98·1)
France (23 registries)‡
2000–04 86·8 
(86·1–87·4)
61·7 
(59·4–64·0)
41·6 
(39·8–43·3)
90·1 
(89·4–90·8)
21·8 
(20·3–23·3)
53·3 
(51·9–54·7)
64·4 
(63·6–65·3)
67·2 
(65·0–69·5)
88·1 
(86·4–89·8)
92·7 
(90·8–94·6)
2005–09 87·2 
(86·6–87·8)
62·1 
(60·0–64·2)
42·1 
(40·4–43·7)
93·6 
(93·1–94·1)
27·2 
(25·8–28·7)
54·6 
(53·3–55·8)
69·9 
(69·1–70·7)
70·8 
(68·6–73·0)
90·0 
(88·4–91·6)
92·6 
(90·6–94·6)
2010–14 86·7 
(85·5–88·0)
65·0 
(60·3–69·7)
43·5 
(40·0–46·9)
93·1 
(91·9–94·2)
27·2 
(24·2–30·3)
57·5 
(54·9–60·1)
69·6 
(67·9–71·3)
70·8 
(68·1–73·5)
88·6 
(86·5–90·8)
94·2 
(92·0–96·4)
Germany (ten registries)
2000–04 83·9 
(83·4–84·4)
64·9 
(63·8–66·1)
40·8 
(39·3–42·2)
90·4 
(89·9–90·9)
29·1 
(24·8–33·3)
46·0 
(43·9–48·1)
61·2 
(60·4–62·0)
63·1 
(56·0–70·2)
94·0 
(90·7–97·3)
90·4 
(84·2–96·5)
2005–09 85·6 
(85·2–85·9)
65·7 
(64·6–66·8)
40·6 
(39·6–41·6)
91·8 
(91·3–92·2)
27·3 
(26·2–28·5)
51·9 
(50·7–53·1)
65·7 
(65·1–66·3)
67·8 
(61·1–74·6)
92·1 
(89·2–95·0)
93·8 
(88·9–98·8)
2010–14 86·0 
(85·7–86·4)
65·2 
(64·0–66·4)
41·2 
(40·2–42·2)
91·6 
(91·2–92·0)
29·6 
(28·3–30·9)
54·9 
(53·5–56·3)
67·9 
(67·3–68·6)
69·5 
(61·8–77·2)
91·1 
(87·4–94·8)
96·9 
(94·2–99·6)
Gibraltar*
2000–04 79·3†§ 
(66·5–92·1)
·· ·· 62·5†§ 
(31·5–93·5)
·· ·· ·· ·· ·· ··
2005–09 72·1§ 
(56·8–87·4)
·· ·· 42·3†§ 
(9·1–75·6)
·· ·· ·· ·· ·· ··
2010–14 ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
Greece (childhood)‡
2000–04 ·· ·· ·· ·· ·· ·· ·· ·· 80·3 
(75·3–85·4)
89·2 
(82·6–95·8)
2005–09 ·· ·· ·· ·· ·· ·· ·· ·· 84·8 
(80·4–89·3)
84·9 
(78·3–91·6)
2010–14 ·· ·· ·· ·· ·· ·· ·· 68·9 
(60·3–77·4)
84·2 
(80·0–88·3)
87·5 
(81·5–93·5)
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Iceland*
2000–04 87·4 
(82·9–91·8)
81·8† 
(72·8–90·8)
39·6 
(30·9–48·3)
80·1 
(75·5–84·7)
24·1 
(19·5–28·6)
48·2 
(38·3–58·1)
66·6 
(60·4–72·8)
80·0† 
(56·6–100·0)
·· ··
2005–09 85·8 
(81·4–90·2)
87·6† 
(79·5–95·7)
40·9 
(31·3–50·5)
89·7 
(86·5–92·9)
21·0 
(14·3–27·6)
47·9 
(39·7–56·1)
67·9 
(62·6–73·1)
73·4† 
(51·8–94·9)
·· ··
2010–14 89·1 
(85·1–93·1)
80·1† 
(71·2–89·1)
40·3 
(31·2–49·4)
90·8 
(87·7–93·9)
29·2 
(20·8–37·7)
43·4 
(35·8–50·9)
71·5 
(66·3–76·6)
90·1† 
(72·4–100·0)
92·4† 
(78·4–100·0)
··
Ireland*
2000–04 77·2 
(75·8–78·5)
57·8 
(54·1–61·6)
29·4 
(27·2–31·7)
83·7 
(82·5–84·9)
26·9 
(24·9–29·0)
47·6 
(44·9–50·2)
55·4 
(53·8–57·0)
67·8 
(60·0–75·6)
82·9 
(76·6–89·2)
97·4 
(94·6–100·0)
2005–09 81·4 
(80·2–82·6)
58·7 
(55·5–61·9)
31·2 
(28·9–33·4)
89·7 
(88·7–90·7)
30·8 
(28·7–33·0)
52·5 
(50·1–55·0)
64·2 
(62·7–65·7)
68·6 
(61·1–76·1)
87·1 
(80·9–93·4)
96·2 
(92·0–100·0)
2010–14 82·0 
(80·7–83·3)
63·6 
(60·1–67·2)
32·8 
(30·3–35·3)
91·1 
(90·1–92·2)
34·5 
(32·0–36·9)
53·1 
(50·5–55·8)
66·9 
(65·3–68·5)
74·0 
(66·4–81·5)
88·3 
(82·4–94·3)
95·3 
(89·6–100·0)
Italy (45 registries)
2000–04 84·2 
(83·8–84·5)
67·3 
(66·0–68·7)
37·7 
(36·8–38·6)
87·2 
(86·7–87·7)
24·1 
(23·2–25·1)
46·4 
(45·5–47·3)
58·5 
(57·9–59·0)
68·5 
(64·5–72·5)
82·6 
(79·2–86·0)
88·3 
(84·9–91·8)
2005–09 85·9 
(85·5–86·2)
67·7 
(66·5–68·9)
39·3 
(38·5–40·1)
89·6 
(89·2–90·0)
27·0 
(26·2–27·8)
49·2 
(48·5–49·9)
61·9 
(61·5–62·4)
75·5 
(72·3–78·8)
89·2 
(86·8–91·6)
89·4 
(86·5–92·4)
2010–14 86·0 
(85·5–86·4)
66·8 
(65·1–68·5)
39·4 
(38·3–40·5)
89·5 
(89·0–89·9)
28·8 
(27·8–29·9)
49·2 
(48·2–50·2)
62·6 
(61·9–63·2)
74·8 
(70·4–79·2)
87·8 
(84·4–91·2)
91·6 
(87·4–95·7)
Latvia*
2000–04 79·7 
(77·1–82·2)
52·8 
(49·0–56·6)
40·3 
(36·6–44·0)
69·9 
(66·5–73·3)
22·2 
(18·8–25·7)
22·2 
(18·7–25·7)
59·8 
(54·9–64·8)
79·7† 
(67·1–92·2)
80·5 
(70·0–91·0)
··
2005–09 79·9 
(77·8–82·1)
57·7 
(54·2–61·2)
39·8 
(36·5–43·1)
88·8 
(86·0–91·6)
23·9 
(20·8–27·0)
17·9 
(14·4–21·4)
64·7 
(60·5–68·9)
72·3† 
(52·2–92·3)
77·0 
(66·4–87·7)
··
2010–14 82·2 
(80·3–84·2)
56·0 
(52·6–59·5)
45·5 
(41·9–49·0)
90·4 
(87·6–93·2)
26·1 
(22·7–29·5)
21·4 
(17·9–25·0)
71·6 
(67·8–75·4)
67·1 
(51·2–83·1)
84·1 
(73·2–94·9)
··
Lithuania*
2000–04 64·6 
(62·9–66·4)
53·8 
(51·6–56·0)
30·2 
(28·1–32·3)
75·8 
(73·7–77·9)
19·4 
(17·2–21·6)
25·4 
(22·5–28·3)
43·5 
(41·5–45·5)
47·5 
(36·2–58·8)
74·3 
(65·2–83·3)
86·1 
(77·2–95·0)
2005–09 71·3 
(69·6–73·1)
59·1 
(56·9–61·3)
31·6 
(29·5–33·8)
93·8 
(92·6–95·1)
22·0 
(19·7–24·3)
47·5 
(45·1–49·9)
50·8 
(48·9–52·7)
66·6 
(53·4–79·8)
67·7 
(56·5–78·8)
79·6† 
(67·1–92·1)
2010–14 73·5 
(71·3–75·7)
59·2 
(56·4–62·0)
35·0 
(32·0–37·9)
94·3 
(92·7–95·8)
23·4§ 
(20·4–26·4)
52·8 
(49·7–56·0)
56·7 
(54·0–59·3)
61·8 
(44·7–78·9)
74·7 
(62·8–86·5)
93·7 
(85·9–100·0)
Malta*
2000–04 79·7 
(75·6–83·8)
46·4† 
(30·8–62·0)
39·6 
(31·6–47·5)
81·9 
(76·6–87·2)
22·3 
(15·2–29·3)
32·7 
(24·6–40·8)
43·4 
(37·8–49·0)
60·1† 
(31·7–88·6)
87·5† 
(71·8–100·0)
··
2005–09 84·8 
(81·3–88·2)
65·1† 
(51·4–78·9)
27·5 
(22·0–33·0)
86·4 
(81·9–91·0)
20·1 
(14·0–26·1)
25·4§ 
(18·0–32·8)
52·4 
(47·3–57·6)
·· 93·8† 
(82·3–100·0)
··
2010–14 86·9 
(83·1–90·6)
57·4 
(46·8–68·1)
28·0 
(21·4–34·6)
88·2 
(83·9–92·5)
28·0 
(19·7–36·2)
46·3§ 
(38·3–54·3)
61·9 
(55·8–68·0)
·· ·· ··
Netherlands*
2000–04 83·9 
(83·4–84·4)
66·1 
(64·1–68·0)
36·3 
(35·1–37·6)
83·4 
(82·7–84·1)
21·4 
(20·4–22·5)
39·4 
(38·2–40·6)
54·7 
(53·9–55·4)
62·7 
(58·4–67·0)
84·1 
(80·7–87·4)
86·5 
(81·9–91·2)
2005–09 85·8 
(85·3–86·3)
65·5 
(63·6–67·3)
37·2 
(36·0–38·5)
87·5 
(86·9–88·1)
26·3 
(25·2–27·3)
49·9 
(48·8–51·0)
63·7 
(63·0–64·4)
66·0 
(61·9–70·1)
89·8 
(86·9–92·6)
86·5 
(82·3–90·8)
2010–14 86·6 
(86·1–87·1)
67·5 
(65·6–69·3)
37·5 
(36·2–38·7)
88·5 
(87·9–89·0)
28·2 
(27·2–29·3)
52·2 
(51·2–53·2)
66·4 
(65·8–67·1)
69·1 
(65·1–73·1)
90·4 
(87·5–93·3)
87·9 
(83·5–92·2)
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Norway*
2000–04 84·7 
(83·7–85·8)
70·9 
(68·0–73·7)
41·4 
(39·3–43·6)
83·8 
(82·8–84·9)
32·4 
(30·5–34·3)
41·5 
(39·2–43·8)
57·5 
(56·1–58·8)
79·7 
(73·8–85·5)
87·7 
(82·4–93·1)
93·3 
(87·2–99·4)
2005–09 87·2 
(86·1–88·3)
70·7 
(67·8–73·6)
42·8 
(40·7–45·0)
90·3 
(89·5–91·1)
36·7 
(34·9–38·5)
50·9 
(48·8–53·0)
64·9 
(63·7–66·2)
75·9 
(69·7–82·1)
84·9 
(78·2–91·6)
90·9 
(84·3–97·5)
2010–14 87·7 
(86·6–88·8)
73·3 
(70·3–76·3)
45·5 
(43·3–47·7)
92·9 
(92·2–93·7)
36·8 
(34·9–38·7)
52·7 
(50·7–54·7)
68·4 
(67·2–69·6)
74·3 
(67·6–81·0)
83·0 
(76·5–89·5)
95·2 
(90·9–99·4)
Poland (16 registries)*
2000–04 71·3 
(70·7–71·9)
51·6 
(50·8–52·5)
32·7 
(31·9–33·6)
68·8 
(67·9–69·7)
26·6 
(25·6–27·7)
18·9 
(17·9–19·9)
40·3 
(39·6–41·0)
62·6 
(59·2–66·0)
79·6 
(76·3–82·9)
81·7 
(77·8–85·6)
2005–09 74·7 
(74·2–75·2)
54·4 
(53·6–55·3)
35·4 
(34·6–36·2)
75·0 
(74·4–75·7)
29·0 
(28·2–29·8)
26·3 
(25·2–27·5)
47·8 
(47·2–48·5)
61·7 
(58·1–65·3)
84·4 
(81·7–87·0)
89·4 
(86·4–92·4)
2010–14 76·5 
(76·1–77·0)
55·1 
(54·2–55·9)
37·5 
(36·7–38·3)
78·1 
(77·5–78·7)
28·2 
(27·4–28·9)
27·3 
(26·2–28·4)
52·1 
(51·4–52·8)
62·5 
(58·7–66·4)
86·9 
(84·1–89·7)
92·6 
(89·7–95·5)
Portugal (four registries)*
2000–04 81·6 
(80·7–82·5)
60·4 
(58·6–62·2)
39·9 
(37·7–42·1)
87·2 
(86·2–88·1)
22·9 
(21·3–24·6)
43·7 
(41·6–45·8)
51·3 
(50·1–52·6)
62·0 
(55·0–69·1)
80·8 
(75·3–86·4)
86·2 
(81·0–91·4)
2005–09 86·1 
(85·3–86·9)
65·3 
(63·6–67·0)
41·8 
(39·7–44·0)
90·0 
(89·3–90·8)
23·8 
(22·4–25·3)
49·0 
(47·1–50·9)
58·2 
(57·1–59·2)
63·1 
(56·5–69·7)
84·1 
(78·8–89·5)
94·0 
(90·1–97·9)
2010–14 87·6 
(85·9–89·3)
66·2 
(62·6–69·8)
43·6 
(38·7–48·4)
90·9 
(89·1–92·6)
22·7 
(19·7–25·8)
49·8 
(45·4–54·2)
59·7 
(57·3–62·1)
70·5 
(57·0–84·1)
89·8 
(80·7–98·9)
94·7 
(88·9–100·0)
Romania (Cluj)
2000–04 ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2005–09 74·8 
(70·4–79·3)
61·7 
(57·0–66·5)
28·9§ 
(22·3–35·6)
78·2 
(72·5–83·8)
20·4§ 
(14·0–26·7)
44·9 
(37·2–52·5)
47·3 
(42·0–52·5)
·· ·· ··
2010–14 74·8 
(68·5–81·1)
65·3 
(59·7–70·9)
37·2§ 
(29·7–44·6)
77·1 
(70·0–84·2)
34·0§ 
(23·8–44·1)
51·5 
(42·7–60·3)
40·4 
(33·3–47·5)
60·1† 
(31·6–88·5)
53·9† 
(28·2–79·6)
··
Russia (five registries)
2000–04 71·6 
(69·8–73·4)
59·8 
(57·3–62·2)
38·1 
(35·2–41·1)
58·8 
(55·4–62·1)
25·2 
(21·3–29·0)
33·1 
(28·7–37·5)
40·5 
(37·4–43·5)
61·2 
(50·4–72·0)
71·3 
(62·6–80·0)
67·0 
(54·9–79·1)
2005–09 67·7 
(66·4–69·0)
58·0 
(56·0–59·9)
33·2 
(31·3–35·0)
68·6 
(66·2–71·0)
21·2 
(19·2–23·2)
35·3 
(31·7–39·0)
42·4 
(39·8–45·0)
61·2 
(50·3–72·0)
74·2 
(65·3–83·0)
73·5 
(62·6–84·4)
2010–14 70·8 
(69·5–72·1)
57·7 
(55·7–59·7)
34·8 
(32·8–36·8)
79·3 
(77·1–81·5)
22·8 
(20·8–24·9)
33·2 
(29·8–36·7)
45·5 
(42·9–48·2)
61·7 
(51·5–71·8)
76·9 
(68·4–85·4)
92·1 
(84·6–99·6)
Slovakia*
2000–04 75·3 
(73·5–77·2)
61·8 
(59·4–64·3)
35·0 
(32·4–37·6)
63·6 
(61·1–66·0)
22·0§ 
(20·0–24·0)
35·1§ 
(32·2–38·1)
46·6 
(44·6–48·6)
67·9 
(60·5–75·4)
79·2 
(71·8–86·5)
83·8 
(75·1–92·5)
2005–09 76·6 
(75·1–78·2)
58·9 
(56·5–61·3)
34·5 
(31·7–37·3)
74·4 
(72·7–76·2)
27·2 
(25·3–29·0)
37·1 
(34·8–39·4)
49·6 
(48·0–51·2)
70·0 
(62·5–77·5)
80·7 
(73·8–87·7)
94·6 
(90·1–99·1)
2010–14 75·5 
(72·4–78·5)
60·5 
(56·2–64·9)
33·4 
(28·6–38·2)
74·7 
(70·9–78·6)
28·5 
(24·3–32·8)
37·5 
(32·2–42·8)
51·6 
(48·0–55·2)
80·6 
(69·4–91·7)
87·0 
(77·3–96·7)
88·6 
(75·4–100·0)
Slovenia*
2000–04 78·7 
(76·9–80·5)
67·2 
(63·8–70·7)
37·8 
(34·4–41·2)
74·4 
(71·9–76·9)
23·0 
(19·9–26·1)
42·4 
(38·5–46·2)
52·7 
(50·2–55·2)
76·5 
(66·8–86·3)
89·7 
(82·1–97·3)
80·1 
(68·7–91·5)
2005–09 82·5 
(81·0–84·1)
67·1 
(63·3–70·9)
35·4 
(32·3–38·4)
83·2 
(81·6–84·8)
24·1 
(21·2–27·0)
39·8 
(36·6–42·9)
56·7 
(54·6–58·9)
61·2 
(49·2–73·1)
79·1† 
(67·1–91·1)
100·0† 
(86·3–100·0)
2010–14 83·5 
(81·8–85·2)
65·5 
(61·3–69·8)
37·0 
(33·4–40·5)
85·0 
(83·3–86·7)
24·8 
(21·4–28·3)
37·5 
(34·2–40·7)
59·0 
(56·6–61·3)
60·1 
(44·2–76·1)
70·1 
(54·4–85·8)
100·0 
(100·0–100·0)
(Table 7 continues on next page)
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Women's cancers Prostate Brain 
(adults)
Haemopoietic malignancies 
(adults)
Childhood malignancies
Breast Cervix Ovary Myeloid Lymphoid Brain Acute 
lymphoblastic 
leukaemia
Lymphoma
(Continued from previous page)
Spain (ten registries)
2000–04 82·9 
(82·0–83·8)
63·6 
(61·3–65·9)
36·0 
(34·1–37·9)
85·0 
(84·1–85·9)
21·6 
(20·2–23·0)
45·4 
(43·6–47·2)
58·2 
(57·1–59·3)
63·6 
(57·7–69·4)
80·9 
(76·3–85·5)
85·8 
(80·2–91·4)
2005–09 84·6 
(83·8–85·4)
64·5 
(62·2–66·8)
37·9 
(36·1–39·6)
90·4 
(89·7–91·1)
27·2 
(25·8–28·7)
52·3 
(50·8–53·8)
62·2 
(61·3–63·2)
63·4 
(58·2–68·6)
80·0 
(75·4–84·5)
89·9 
(85·9–94·0)
2010–14 85·2 
(84·0–86·5)
64·5 
(60·8–68·1)
39·8 
(36·9–42·7)
89·7 
(88·6–90·7)
27·4 
(25·2–29·7)
50·0 
(47·7–52·3)
62·0 
(60·5–63·6)
66·2 
(58·0–74·4)
84·7 
(77·6–91·7)
92·9 
(87·5–98·3)
Sweden*
2000–04 85·6 
(84·9–86·3)
66·9 
(64·7–69·1)
43·2 
(41·6–44·8)
85·9 
(85·3–86·5)
26·5 
(25·1–28·0)
30·7 
(28·9–32·6)
58·5 
(57·6–59·5)
75·9 
(70·5–81·3)
86·8 
(82·6–90·9)
84·7 
(75·8–93·6)
2005–09 87·9 
(87·2–88·5)
67·7 
(65·6–69·9)
42·9 
(41·2–44·6)
90·1 
(89·6–90·6)
29·0 
(27·5–30·4)
54·6 
(53·1–56·1)
64·2 
(63·3–65·1)
78·4 
(73·2–83·6)
87·1 
(82·6–91·5)
88·6 
(81·5–95·8)
2010–14 88·8 
(88·2–89·4)
68·3 
(66·1–70·4)
46·5 
(44·8–48·2)
90·7 
(90·2–91·2)
31·6 
(30·1–33·0)
57·5 
(56·0–58·9)
66·7 
(65·9–67·6)
79·8 
(74·9–84·7)
89·0 
(84·6–93·3)
88·0 
(80·4–95·7)
Switzerland (ten registries)‡
2000–04 84·4 
(83·3–85·5)
63·4 
(58·4–68·4)
36·9 
(34·4–39·5)
86·9 
(85·8–87·9)
26·4 
(23·9–28·8)
46·5 
(43·9–49·1)
61·6 
(60·1–63·2)
73·7 
(67·7–79·8)
87·3 
(82·4–92·2)
94·0 
(89·5–98·6)
2005–09 86·4 
(85·3–87·4)
69·4 
(65·1–73·6)
42·0 
(39·5–44·4)
88·6 
(87·6–89·5)
29·0 
(26·7–31·2)
51·6 
(49·3–53·9)
70·9 
(69·5–72·3)
68·0 
(61·2–74·8)
89·2 
(84·9–93·4)
94·2 
(89·5–98·9)
2010–14 86·2 
(85·1–87·3)
71·4 
(66·6–76·2)
44·1 
(41·3–46·8)
89·2 
(88·2–90·3)
29·7 
(27·5–31·9)
49·7 
(47·2–52·2)
72·0 
(70·4–73·5)
71·6 
(65·1–78·0)
90·3 
(86·1–94·5)
93·6 
(88·1–99·1)
UK (four registries)*
2000–04 79·8 
(79·5–80·1)
58·9 
(58·0–59·9)
30·2 
(29·7–30·7)
81·9 
(81·6–82·3)
20·6 
(20·1–21·2)
42·3 
(41·7–42·9)
54·3 
(53·9–54·6)
68·4 
(66·2–70·7)
85·9 
(84·1–87·7)
86·8 
(84·1–89·5)
2005–09 83·8 
(83·6–84·1)
61·9 
(61·0–62·9)
33·2 
(32·6–33·7)
86·7 
(86·4–86·9)
23·8 
(23·3–24·4)
47·7 
(47·1–48·2)
60·7 
(60·4–61·1)
69·1 
(66·9–71·3)
91·4 
(89·9–92·8)
90·6 
(88·3–93·0)
2010–14 85·6 
(85·4–85·9)
63·8 
(62·8–64·7)
36·2 
(35·7–36·8)
88·7 
(88·5–89·0)
26·3 
(25·7–26·8)
48·7 
(48·1–49·2)
64·9 
(64·6–65·3)
71·9 
(69·8–74·0)
92·2 
(90·9–93·6)
91·7 
(89·7–93·8)
Oceania
Australia (eight registries)*
2000–04 87·0 
(86·5–87·4)
67·9 
(66·1–69·6)
37·3 
(36·1–38·6)
87·8 
(87·4–88·2)
24·5 
(23·5–25·4)
43·3 
(42·3–44·3)
61·5 
(60·9–62·1)
62·0 
(57·7–66·3)
86·5 
(83·8–89·1)
91·4 
(88·0–94·8)
2005–09 88·5 
(88·1–89·0)
67·5 
(65·7–69·3)
41·0 
(39·8–42·2)
93·2 
(92·9–93·5)
28·9 
(27·9–29·8)
50·3 
(49·4–51·1)
68·1 
(67·6–68·7)
60·6 
(56·4–64·9)
90·3 
(87·9–92·6)
94·2 
(91·4–96·9)
2010–14 89·5 
(89·1–90·0)
66·4 
(64·5–68·2)
42·0 
(40·8–43·2)
94·5 
(94·1–94·8)
30·2 
(29·2–31·2)
51·8 
(50·9–52·7)
71·2 
(70·6–71·8)
67·1 
(62·9–71·4)
90·7 
(88·3–93·1)
92·3 
(89·2–95·4)
New Zealand*
2000–04 82·8 
(81·6–84·1)
67·4 
(63·8–71·1)
38·7 
(36·0–41·4)
89·1 
(88·1–90·0)
19·0 
(16·8–21·2)
40·3 
(37·8–42·9)
61·0 
(59·6–62·5)
60·2 
(50·6–69·8)
85·8 
(79·9–91·6)
93·6 
(88·7–98·4)
2005–09 86·1 
(84·9–87·3)
64·4 
(60·4–68·4)
33·4 
(31·0–35·9)
89·3 
(88·4–90·2)
22·7 
(20·4–25·0)
49·7 
(47·7–51·8)
63·5 
(62·1–64·9)
54·4 
(42·9–66·0)
91·2 
(86·8–95·6)
93·5 
(88·0–99·0)
2010–14 87·6 
(86·4–88·7)
67·4 
(63·4–71·5)
36·7 
(34·1–39·3)
90·3 
(89·4–91·1)
23·3 
(21·0–25·7)
44·1 
(42·1–46·2)
65·6 
(64·3–66·9)
58·2 
(46·1–70·4)
91·4 
(86·7–96·1)
96·6 
(92·7–100·0)
Some registries contributed data for selected cancers or calendar periods. *Data with 100% coverage of the national population. †Survival estimate is not age-standardised. ‡Data with 100% coverage of the 
national population for childhood malignancies only. §Survival estimate considered less reliable because 15% or more of patients were (1) lost to follow-up or censored alive within 5 years of diagnosis or, if 
diagnosed in 2010 or later, before Dec 31, 2014; or (2) registered only from a death certificate or at autopsy; or (3) patients with unknown vital status or registered with incomplete dates—ie, unknown year 
of birth, unknown month or year of diagnosis, or unknown year of last known vital status. 
Table 7: Age-standardised 5-year net survival (%) with 95% CI: adults (15–99 years) diagnosed with one of seven common malignancies (breast, cervix, ovary, prostate, brain, myeloid, 
and lymphoid) and children (0–14 years) diagnosed with one of three common malignancies (brain, acute lymphoblastic leukaemia, and lymphoma) by continent, country, and calendar 
period of diagnosis
Articles
1062 www.thelancet.com   Vol 391   March 17, 2018
0 10 20 30 40 50 60 70 80 90 100
Age-standardised 5-year net survival (%)
Colon cancer
2000–04 0
2005–09 1
2010–14 1
2000–04 9
2005–09 14
2010–14 10
2000–04 49
2005–09 49
2010–14 47
2000–04 24
2005–09 49
2010–14 47
2000–04 107
2005–09 129
2010–14 116
2000–04 9
2005–09 9
2010–14 9
America (Central and South)
America (North)
Europe
Asia
Oceania
Africa
Period Registries
Breast cancer (women)
2000–04 0
2005–09 1
2010–14 0
2000–04 17
2005–09 20
2010–14 16
2000–04 50
2005–09 50
2010–14 48
2000–04 29
2005–09 53
2010–14 50
2000–04 114
2005–09 128
2010–14 115
2000–04 9
2005–09 9
2010–14 9
America (Central and South)
America (North)
Europe
Asia
Oceania
Africa
Acute lymphoblastic leukaemia (children)
2000–04 0
2005–09 0
2010–14 0
2000–04 4
2005–09 8
2010–14 8
2000–04 36
2005–09 35
2010–14 40
2000–04 10
2005–09 23
2010–14 21
2000–04 47
2005–09 50
2010–14 59
2000–04 6
2005–09 6
2010–14 7
America (Central and South)
America (North)
Europe
Asia
Oceania
Africa
Figure 4: Global range of 
age-standardised 5-year net 
survival estimates for colon 
cancer, breast cancer 
(women), and acute 
lymphoblastic leukaemia 
(children) among 296 cancer 
registry populations in 
64 countries, by continent 
and calendar period of 
diagnosis
Each box plot shows the range 
of survival estimates among 
all cancer registries for which 
suitable estimates could be 
obtained for patients 
diagnosed in each calendar 
period, in each continent. 
Survival estimates considered 
less reliable are not included. 
The vertical line inside each 
box represents the median 
survival estimate among all 
contributing registries (the 
central value in the range, or 
50th centile). The box covers 
the IQR between the lower 
and upper quartiles (25th and 
75th centiles). Where there are 
only a few widely scattered 
estimates, the median might 
be close to the lower or upper 
quartile. The extreme limits of 
the box plot are 1·5 × IQR 
below the lower quartile and 
1·5 × IQR above the upper 
quartile. Open circles indicate 
outlier values, outside this 
range. See appendix 
(pp 247–265) for other 
cancers.
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Europe]); and Australia and New Zealand (table 6; 
appendix p 217).
Survival was in the range 80–89% in 14 countries: 
Canada; Israel; and 12 European countries (Estonia, 
Finland, Iceland, Ireland, and Norway [northern Europe]; 
Italy, Malta, Portugal, Slovenia, and Spain [southern 
Europe]; the Czech Republic [eastern Europe]; and 
Austria [western Europe]).
Survival was in the range 70–79% in ten countries: four 
countries in Central and South America (Argentina, 
Brazil, Costa Rica, and Puerto Rico); and six European 
countries (Latvia and Lithuania [northern Europe]; 
Croatia [southern Europe]; and Poland, Romania [Cluj], 
and Slovakia [eastern Europe]).
Survival was in the range 60–69% in six countries: four 
Asian countries (Singapore [south Asia]; Korea and Japan 
[east Asia]; and Turkey [western Asia]); and Bulgaria and 
Russia. Survival was less than 60% in Ecuador, China, 
and Taiwan.
Trends between 2000–04 and 2010–14 were generally 
stable in North America, Oceania, and Japan, and in 
several European countries, where 5-year survival was 
already around 85–90% among patients diagnosed 
during 2000–04. Survival increased by 5–10% in Korea 
and in 12 European countries (Denmark, Estonia, Latvia, 
Lithuania, and the UK [northern Europe]; Croatia, 
Portugal, and Slovenia [southern Europe]; Bulgaria, the 
Czech Republic, and Poland [eastern Europe]; and 
Belgium [western Europe]).
Breast (women)
Results are available for 6 422 553 women from 298 cancer 
registries in 66 countries (tables 2, 5).
The range of survival estimates is still wide in each 
continent, apart from North America and Oceania 
(figure 4; appendix p 256). Most estimates were 
considered reliable (table 7; appendix pp 152–164).
For women diagnosed during 2010–14, age-standardised 
5-year net survival was 85% or higher in 25 countries: Costa 
Rica and Martinique; Canada and the USA; Israel, Japan, 
and Korea; 16 European countries (Denmark, Finland, 
Iceland, Norway, Sweden, and the UK [northern Europe]; 
Austria, Belgium, France, Germany, the Netherlands, and 
Switzerland [western Europe]; and Italy, Malta, Portugal, 
and Spain [southern Europe]); and Australia and New 
Zealand (table 7; figure 2; appendix p 218).
5-year survival was in the range 80–84% in 12 countries: 
three countries in Central and South America (Argentina, 
Peru [Lima], and Puerto Rico); five Asian countries 
(Singapore [south Asia]; China, Hong Kong, and Taiwan 
[east Asia]; and Turkey [west Asia]); and four European 
countries (Ireland [northern Europe]; the Czech Republic 
and Latvia [eastern Europe]; and Slovenia [southern 
Europe]). Survival was in the range 70–79% in 12 countries: 
Cuba and Ecuador; Kuwait and Mongolia; and eight 
countries in Europe (Estonia and Lithuania [northern 
Europe]; Croatia [southern Europe]; and Bulgaria, Poland, 
Romania [Cluj], Russia, and Slovakia [eastern Europe]). 
Survival was still low in India (Karunagappally; table 7).
5-year net survival continued to increase up to 2010–14 
in most countries in Central and South America, east 
and west Asia, and in all of Europe. Even so, survival 
remains lower in eastern Europe than in other parts of 
the continent. In North America and Oceania, 5-year net 
survival approached 90% (figure 3; appendix p 237).
Cervix
Results are available for 660 744 women from 295 cancer 
registries in 64 countries (tables 2, 5). The global range 
in cervical cancer survival is still wide (50–70%), 
especially in Central and South America, Asia, and 
Europe (table 7; appendix p 257). Most survival estimates 
are reliable (appendix pp 152–164).
For women diagnosed during 2010–14, age-
standardised 5-year net survival was 70% or higher in 
seven countries (Japan, Korea, and Taiwan; Denmark, 
Norway, and Switzerland; and Cuba), of which five had 
national coverage (table 7; appendix p 219).
Survival was in the range 60–69% in 29 countries: 
Canada and the USA; Brazil and Puerto Rico; 
five countries in Asia (China and Hong Kong [east Asia]; 
Singapore [south Asia]; and Israel and Turkey [west Asia]); 
18 countries in Europe; and Australia and New Zealand.
Survival was in the range 50–59% in five countries 
in Central and South America (Argentina, Ecuador, 
Martinique, Peru [Lima], and Uruguay); India and 
Kuwait; and six European countries (Latvia and Lithuania 
[northern Europe]; Bulgaria, Poland, and Russia [eastern 
Europe]; and Malta [southern Europe]).
Over the 20 years from 1995 to 2014, 5-year survival has 
increased by 4–7% in Cuba; Israel, Japan, and Korea; and 
six European countries (Denmark, Ireland, Lithuania, 
Norway, and the UK [northern Europe]; and Poland 
[eastern Europe]; appendix p 238). Survival increased by 
8–10% in India; and in Bulgaria, Estonia, and Switzerland. 
In China, 5-year survival increased by 14·3% from 
2000–04 to 2010–14 (table 7).
Ovary
Results are available for 865 501 women from 
289 registries in 61 countries (tables 2, 5).
Age-standardised 5-year net survival was mostly in the 
range 30–50%, with even wider variation in Europe and 
Asia (appendix p 258). Most survival estimates were 
reliable (table 7; appendix pp 152–164).
For women diagnosed during 2010–14, 5-year survival 
was still less than 50% in most countries, except Costa 
Rica (table 7; appendix pp 220, 239, 258). Survival was in 
the range 40–49% in 24 countries: in Canada and the 
USA; seven countries in Asia (Singapore [south Asia]; 
China, Korea, Japan, and Taiwan [east Asia]; and Israel 
and Turkey [west Asia]); 14 European countries 
(Denmark, Estonia, Finland, Iceland, Latvia, Norway, and 
Sweden [northern Europe]; Portugal and Spain [southern 
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Europe]; and Austria, Belgium, France, Germany, and 
Switzerland [western Europe]); and Australia.
Survival was in the range 30–39% in 19 countries: four 
in Central and South America (Argentina, Brazil, Ecuador, 
and Puerto Rico); Kuwait and Thailand; 12 European 
countries (Ireland, Lithuania, and the UK [northern 
Europe]; Croatia, Italy, and Slovenia [southern Europe]; 
Bulgaria, the Czech Republic, Poland, Russia, and Slovakia 
[eastern Europe]; and the Netherlands [western Europe]); 
and New Zealand. Survival was less than 30% in Malta 
and less than 20% in India (Karunagappally; table 7).
Survival trends between 1995–99 and 2010–14 were 
fairly flat in most countries. However, 5-year survival 
rose by 5–10% in the USA; Israel, Korea, and Taiwan; 
11 European countries (Denmark, Iceland, Ireland, 
Norway, and Sweden [northern Europe]; Portugal and 
Spain [southern Europe]; Bulgaria and Poland [eastern 
Europe]; and France and Switzerland [western Europe]); 
and Australia. Survival increased by more than 10% in 
Estonia and Latvia, and by 20% in Japan.
Prostate
Results are available for 5 864 878 men from 290 registries 
in 62 countries (tables 2, 5).
Age-standardised 5-year net survival was in the range 
70–100% in most countries (appendix p 259). Most 
estimates were reliable (table 7; appendix pp 152–164).
For men diagnosed during 2010–14, 5-year survival was 
approaching 100% in Puerto Rico, Martinique, and the 
USA. Survival was at least 90% in a further 22 countries: 
Brazil and Costa Rica; Canada; Israel, Japan, and Korea; 
14 European countries (Iceland, Ireland, Finland, Latvia, 
Lithuania, Norway, and Sweden [northern Europe]; Italy, 
Portugal, and Spain [southern Europe]; Austria, Belgium, 
France, and Germany [western Europe]); and Australia 
and New Zealand.
Survival was in the range 80–89% in 17 countries: 
Argentina, Ecuador, and Uruguay; five Asian countries 
(Malaysia [Penang] and Singapore [south Asia]; Taiwan 
[east Asia]; Kuwait and Turkey [west Asia]); and 
nine European countries (Denmark, Estonia, and the 
UK [northern Europe]; Croatia, Malta, and Slovenia 
[southern Europe]; the Czech Republic [eastern Europe]; 
and the Netherlands and Switzerland [western Europe]).
Survival approached 80% in Russia, Poland, and 
Romania (Cluj). It was less than 80% in Slovakia; less 
than 70% in China, Mauritius, Bulgaria, and Thailand; 
and less than 50% in India (Karunagappally; table 7).
Over the 20-year period between 1995–99 and 2010–14, 
age-standardised 5-year net survival rose in most 
countries. Survival increased by 5–10% in Brazil and 
Ecuador; Canada; China and Turkey; Austria and Portugal; 
and New Zealand. During the same period, 5-year survival 
rose by more than 10% in Israel, Taiwan, and Thailand, 
and in 12 European countries (Finland, Iceland, Norway, 
and Sweden [northern Europe]; Croatia, Italy, Malta, and 
Spain [southern Europe]; and France, Germany, the 
Netherlands, and Switzerland [western Europe]); and 
Australia. Survival increased by more than 20% in 
13 countries: Japan, Korea, and Malaysia (Penang); and 
ten European countries (Denmark, Estonia, Ireland, 
Latvia, Lithuania, and the UK [northern Europe]; Slovenia 
[southern Europe]; and Bulgaria, the Czech Republic, and 
Poland [eastern Europe]).
Brain (adults)
Results are available for 656 659 adults from 286 registries 
in 59 countries (tables 2, 5). Age-standardised 5-year net 
survival was in the range 20–40% in most countries 
(appendix p 260). Most estimates were considered 
reliable (table 7; appendix pp 165–177).
For patients diagnosed during 2010–14, 5-year survival 
was higher than 40% only in Croatia (table 7). Survival 
was in the range 30–40% in 20 countries: Canada and the 
USA; Puerto Rico and Martinique; six Asian countries 
(Singapore [south Asia]; China and Korea [east Asia]; and 
Israel, Kuwait, and Turkey [west Asia]); nine European 
countries (Denmark, Estonia, Finland, Ireland, Norway, 
and Sweden [northern Europe]; and Belgium, Germany, 
and Switzerland [western Europe]); and Australia.
Survival was in the range 20–29% in 19 countries: Chile 
and Ecuador; Taiwan; 15 European countries (Iceland, 
Latvia, and the UK [northern Europe]; Italy, Malta, 
Portugal, Slovenia, and Spain [southern Europe]; the 
Czech Republic, Poland, Russia, and Slovakia [eastern 
Europe]; and Austria, France, and the Netherlands 
[western Europe]); and New Zealand (table 7). 5-year 
survival was 14·7% in Thailand.
Trends in 5-year survival between 2000–04 and 2010–14 
were generally rather flat, but survival increased by 3–5% 
in 12 countries: Martinique; Canada; Israel; eight European 
countries (Iceland, Latvia, Norway, and Sweden [northern 
Europe]; Croatia and Italy [southern Europe]; and France 
and Switzerland [western Europe]); and New Zealand.
Survival increased by 6–10% in a further 12 countries: 
the USA; China, Korea, and Singapore; and seven 
European countries (Denmark, Estonia, Ireland, and the 
UK [northern Europe]; Malta and Spain [southern Europe]; 
and the Netherlands [western Europe]); and Australia.
Myeloid malignancies
Results are available for 1 151 226 adults from 
286 registries in 61 countries (tables 2, 5).
Age-standardised 5-year net survival was in the range 
30–50% in most countries, although lower in Asia 
(appendix p 261). Most estimates were considered reliable 
(table 7; appendix pp 165–177).
For patients diagnosed during 2010–14, survival was 
55–60% in Belgium, France, Germany, and Sweden; and 
in the range 50–54% in Canada; Turkey; eight European 
countries (Ireland, Lithuania, and Norway [northern 
Europe]; Portugal and Spain [southern Europe]; Romania 
[Cluj; eastern Europe]; and the Netherlands and 
Switzerland [western Europe]); and Australia.
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5-year survival was in the range 40–49% in 11 countries: 
the USA; Martinique and Puerto Rico; Israel, Korea, and 
Singapore; four European countries (Denmark, Iceland, 
and the UK [northern Europe]; and Italy [southern 
Europe]); and New Zealand.
Survival was in the range 30–39% in 12 countries: 
Argentina and Brazil; Japan, Malaysia (Penang), and 
Taiwan; and seven European countries (Estonia [northern 
Europe]; Croatia and Slovenia [southern Europe]; the 
Czech Republic, Russia, and Slovakia [eastern Europe]; 
and Austria [western Europe]). Survival was less than 
30% in Chile and Ecuador; China, Kuwait, and Thailand; 
and Latvia and Poland.
Over the 15 years between 2000–04 and 2010–14, age-
standardised 5-year net survival increased by 5–10% in 
14 countries: the USA; China, Japan, Singapore, and 
Taiwan; eight European countries (Ireland and the UK 
[northern Europe]; Portugal and Spain [southern Europe]; 
Poland [eastern Europe]; and Austria, Belgium, and 
Germany [western Europe]); and Australia. Survival rose 
by more than 10% in Korea, Denmark, the Netherlands, 
and Norway.
Survival increased dramatically in Lithuania (27·4%), 
Sweden (26·8%), and the Czech Republic (16·9%).
Lymphoid malignancies
Results are available for 3 011 054 adults from 289 regis-
tries in 62 countries (tables 2, 5).
5-year age-standardised net survival was usually in the 
range 40–70% in most countries, but lower in Asia and in 
Central and South America (appendix p 262). Most 
estimates were considered reliable (table 7; appendix 
pp 165–177).
For patients diagnosed during 2010–14, 5-year survival 
was 70% or higher in six European countries (Denmark, 
Iceland, and Latvia [northern Europe]; and Belgium, 
France, and Switzerland [western Europe]); and Australia. 
Survival was in the range 60–69% in Mauritius; 
Puerto Rico; Canada and the USA; Israel and Kuwait; 
12 European countries (Finland, Ireland, Norway, 
Sweden, and the UK [northern Europe]; Italy, Malta, 
Portugal, and Spain [southern Europe]; and Austria, 
Germany, and the Netherlands [western Europe]); and 
New Zealand.
Survival was 50–59% in 14 countries: Costa Rica; 
six Asian countries (Malaysia [Penang] and Singapore 
[south Asia]; Japan, Korea, and Taiwan [east Asia]; and 
Turkey [west Asia]); and seven European countries 
(Estonia and Lithuania [northern Europe]; Croatia and 
Slovenia [southern Europe]; and the Czech Republic, 
Poland, and Slovakia [eastern Europe]).
Survival was lower than 50% in five countries in 
Central and South America (Argentina, Brazil, Chile, 
Ecuador, and Martinique); China, India (Karunagappally), 
and Thailand; and Bulgaria, Romania (Cluj), and Russia.
5-year survival trends between 2000–04 and 2010–14 
were increasing in most countries. Survival increased by 
5–10% in 23 countries: Ecuador; Canada and the USA; 
Japan and Taiwan; 15 European countries (Finland, 
Estonia, Iceland, and Sweden [northern Europe]; Croatia, 
Portugal, and Slovenia [southern Europe]; Bulgaria, the 
Czech Republic, Russia, and Slovakia [eastern Europe]; 
and Austria, Belgium, France, and Germany [western 
Europe]); and Australia and New Zealand.
Survival increased by more than 10% in 14 countries: 
Puerto Rico; Korea, Kuwait, and Singapore; and ten 
European countries (Denmark, Ireland, Latvia, Lithuania, 
Norway, and the UK [northern Europe]; Malta [southern 
Europe]; Poland [eastern Europe]; and the Netherlands 
and Switzerland [western Europe]).
Brain (children)
Results are available for 66 814 children from 260 registries 
in 60 countries (tables 2, 5). Age-standardised 5-year net 
survival was in the range 40–80% in most countries 
(appendix p 263). Most estimates were reliable (table 7; 
appendix pp 165–177).
For children diagnosed during 2010–14, age-standardised 
5-year net survival was close to 80% in Denmark, Slovakia, 
and Sweden. Survival was in the range 70–79% in 
18 countries: Canada and the USA; Costa Rica and Puerto 
Rico; Israel and Japan; and 12 European countries 
(Finland, Ireland, Norway, and the UK [northern Europe]; 
Croatia, Italy, and Portugal [southern Europe]; the Czech 
Republic [eastern Europe]; and Belgium, France, Germany, 
and Switzerland [western Europe]).
Survival was in the range 60–69% in 14 countries: Korea, 
Singapore, and Turkey; ten European countries (Estonia, 
Latvia, and Lithuania [northern Europe]; Greece, Slovenia, 
and Spain [southern Europe]; Belarus, Poland, and Russia 
[eastern Europe]; and the Netherlands [western Europe]); 
and Australia. 5-year survival was less than 40% in Brazil 
and Mexico.
Survival trends between 2000–04 and 2010–14 were 
generally stable or increasing. 5-year age-standardised 
survival increased by 5–10% in the USA; China, Korea, 
and Turkey; six European countries (Ireland [northern 
Europe]; Croatia, Italy, and Portugal [southern Europe]; 
and Germany and the Netherlands [western Europe]); 
and Australia.
Survival increased by 10% or more in four European 
countries (Denmark and Lithuania [northern Europe]; 
and the Czech Republic and Slovakia [eastern Europe]).
Acute lymphoblastic leukaemia (children)
Results are available for 87 351 children from 254 regis-
tries in 61 countries (tables 2, 5).
The global range in survival was very wide, from 50% 
to more than 90% (figure 2; appendix pp 226, 264). Most 
estimates were considered reliable. For children 
diagnosed during 2010–14, age-standardised 5-year net 
survival was 90% or more in Puerto Rico; Canada and the 
USA; eight European countries (Denmark, Finland, and 
the UK [northern Europe]; Portugal [southern Europe]; 
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Belgium, Germany, the Netherlands, and Switzerland 
[western Europe]); and Australia and New Zealand.
Survival was in the range 80–89% in Costa Rica; 
six Asian countries (Singapore [south Asia]; Japan and 
Korea [east Asia]; and Israel, Kuwait, and Turkey [west 
Asia]); and 14 European countries (Estonia, Ireland, Latvia, 
Norway, and Sweden [northern Europe]; Croatia, Greece, 
Italy, and Spain [southern Europe]; Belarus, the Czech 
Republic, Poland, and Slovakia [eastern Europe]; and 
France [western Europe]; table 7; figure 2; appendix p 226).
5-year net survival was still less than 70%, even after 
adjustment for the very high background mortality in 
childhood, in Brazil, Chile, Colombia, and Peru (Lima). 
Survival was less than 60% in China, Ecuador, and Mexico.
In the 20-year period between 1995–99 and 2010–2014, 
5-year survival increased by 10% or more in 14 countries: 
Colombia; five Asian countries (China, Japan, Korea, and 
Taiwan [east Asia]; and Turkey [west Asia]); eight 
European countries (Finland, Lithuania, and the UK 
[northern Europe]; Portugal and Spain [southern Europe]; 
Belarus and Bulgaria [eastern Europe]; and Belgium 
[western Europe]; appendix p 245).
Lymphoma (children)
Results are available for 41 196 children from 257 registries 
in 62 countries (tables 2, 5).
5-year age-standardised net survival was generally 
in the range 80–95% (table 7; appendix p 265). Most 
estimates were reliable. For children diagnosed during 
2010–14, 5-year survival was at least 90% in 29 countries: 
Canada and the USA; Costa Rica and Puerto Rico; 
five Asian countries (Singapore [south Asia]; Japan and 
Korea [east Asia]; and Israel and Kuwait [west Asia]); 
18 European countries (Denmark, Finland, Ireland, 
Lithuania, Norway, and the UK [northern Europe]; Croatia, 
Italy, Portugal, Slovenia, and Spain [southern Europe]; the 
Czech Republic, Poland, and Russia [eastern Europe]; and 
Belgium, France, Germany, and Switzerland [western 
Europe]); and Australia and New Zealand. 5-year survival 
was less than 70% only in Ecuador and China (table 7).
5-year survival trends were generally rather flat over the 
15 years between 2000–04 and 2010–14 (appendix p 246), 
but survival increased by 5–10% in the USA; Korea, 
Singapore, and Taiwan; and six European countries (the 
UK and Lithuania [northern Europe]; Portugal and Spain 
[southern Europe]; Slovakia [eastern Europe]; and 
Germany [western Europe]).
5-year survival increased by more than 10% in Brazil, 
Bulgaria, Croatia, and Poland, and by at least 20% in 
Slovenia and Russia (table 7).
Discussion
CONCORD-3 updates the worldwide surveillance of 
cancer survival to 2014. It is the largest and most up-to-
date study of international cancer survival trends. 
It includes individual data for more than 37·5 million 
patients diagnosed with cancer during the 15-year period 
2000–14. Data were provided by more than 320 population-
based cancer registries in 71 countries and territories, in 
47 of which the data covered 100% of the population. The 
participating countries were home to 67% of the world’s 
population in 2014 (7·3 billion people).28 The registries 
record all cancers diagnosed in a combined population of 
almost 1 billion people, or 14% of the world population. 
Internationally comparable survival trends are now 
available for 18 cancers that collectively represent 75% of 
all cancers diagnosed worldwide every year.
We used a similar design and statistical approach to 
those used in CONCORD-26 to enable evaluation of 
survival trends for ten cancers over the 20-year period 
1995–2014. Worldwide survival trends are also available 
for the first time for melanoma of the skin and cancers of 
the oesophagus and pancreas in adults, and for brain 
tumours and lymphomas in both adults and children.
5-year survival has been recognised by clinicians as an 
index of the effectiveness of the treatment of cancer for 
more than 60 years. When applied to hospital case series, 
it has often been labelled as the 5-year cure rate, because 
“with so mortal a disease as cancer, those who survive for 
this length of time can be considered cured”.44 5-year 
survival has increased for many cancers since the 1950s, 
but it remains a widely used benchmark, even though it 
cannot be directly interpreted as the proportion of 
patients who are cured.45
Population-based cancer survival is increasingly 
recognised as a key indicator of the overall effectiveness 
of health systems in managing care and treatment for all 
patients with cancer.46,47 Other outcome measures with 
applications in cancer control include the number of 
avoidable premature deaths,48–53 person-years of life 
lost,54,55 disability-adjusted life-years lost,56 and estimates 
of the proportion of patients with cancer who can be 
considered to have been cured.57–61 Cancer survival has 
applications to cancer control and health policy at the 
state, national, and global levels, in both high-income 
and low-income countries.62
In some countries, population-based cancer survival 
estimates might be considered as too high, potentially 
discouraging ministerial action to improve survival. 
Estimates showing ethnic or regional variation in cancer 
survival can be politically sensitive. Survival estimates 
can also be considered too low if they are seen as a 
reflection of clinical competence.63 Low levels of survival 
in a country or region should not be interpreted as an 
indicator of the competence of the health professionals 
who work there. Population-based survival reflects the 
overall effectiveness of the health service, which depends 
on much wider issues than the competence of any 
individual doctor or team.64–66
The Organisation for Economic Co-operation and 
Development (OECD) recently concluded from the wide 
international variation in cancer survival that many 
countries could do better in cancer control.64 It 
recommended a national cancer plan, adequate funding, 
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and initiatives for early detection and rapid access to 
high-quality treatment.64 The OECD also recommended 
improving the quality of cancer data to support 
monitoring improvements in survival.
From 2017, the OECD has included age-standardised 
5-year net survival estimates from the CONCORD 
programme for colorectal and breast cancers in adults 
and acute lymphoblastic leukaemia in children among 
the indicators of health-care quality in its biennial and 
online publications Health at a Glance.67 This is formal 
recognition of the global coverage, methodological 
rigour, and international comparability of the CONCORD 
survival estimates, which will now contribute to the 
comparative evaluation of health systems performance 
in 48 countries, including all OECD member countries. 
The findings will also help to monitor progress toward 
the overarching goal of the 2013 World Cancer 
Declaration: to achieve major improvements in cancer 
survival by 2020.68
We carried out extensive checks on data quality and 
liaised with the cancer registries to resolve problems. 
Many registries told us that the CONCORD data quality 
reports helped them to improve their data. Some centres 
in Nigeria and India have modified hospital admission 
forms or pathology request forms to capture telephone 
numbers of patients and their next of kin, to facilitate 
follow-up of their patients. We extended our programs 
and reports on data quality control. Rectifying errors or 
inconsistencies in the data often led to extensive 
discussion with registry staff and resubmission of data 
with higher quality.
The quality and completeness of cancer registration 
data and follow-up vary between countries, and this can 
affect the comparability of survival estimates. We have 
provided extensive documentation of data quality with 
standard indicators69 for each cancer and each cancer 
registry (appendix pp 6–101). Survival figures and trends 
should be interpreted alongside those indicators. The 
overall proportion of tumour records excluded because of 
incomplete dates (0·5%) or for other reasons such as 
missing vital status (1·2%) has remained very low. The 
overall proportion of cancers registered solely from a 
DCO or detected at autopsy dropped to 2·9%, but remains 
high in some countries where cancer registration 
processes are slow, especially for the more rapidly lethal 
cancers of the oesophagus, pancreas, and liver. These are 
well known issues in population-based cancer 
registration. DCOs can be included in cancer incidence 
statistics under certain assumptions, but they reflect 
some underestimation of incidence.69 By contrast, DCO 
cases must be excluded from survival analyses, because 
the patient’s survival time is unknown: this tends to 
inflate survival estimates.70
In some countries, survival estimates have fluctuated 
or declined in successive calendar periods; this is likely to 
reflect improvements in the completeness of cancer 
registration data and in the completeness of follow-up for 
vital status. In Jordan, for example, linkage with the 
national death index has been insufficient because only 
about 70% of deaths are certified. Survival estimates were 
very high for stomach and colorectal cancers and are 
flagged as less reliable. A recent hospital-based survival 
study71 from Jordan suggests that colon cancer survival in 
Jordan is much lower than the estimates we have 
obtained. Other countries with incomplete death 
registration, such as India, follow up their patients 
actively to determine their vital status.
Despite these problems, we believe our findings 
represent the best that can be achieved with the available 
coverage and quality of cancer registration systems and 
vital statistics systems worldwide. The quality of 
diagnostic evidence is generally high. Data quality has 
improved in many countries, with increasing proportions 
of cases for which the diagnosis was confirmed by 
pathology, imaging, or biomarkers, and a reduction in the 
proportion of patients lost to follow-up. Pathological 
confirmation of a primary, invasive malignancy was 
available for more than 94% of all patients. The proportion 
varies widely between countries and for different cancers, 
but the evidence supporting a cancer diagnosis in routine 
cancer registry data is far more precise and definitive 
than for the cause or causes of death recorded on death 
certificates, from which mortality statistics are derived.72–75
In some cases, especially in South America, the 
improvement in data quality is reflected in survival 
estimates that are actually lower than those previously 
published,6 with fewer DCO registrations and more 
complete follow-up. In Brazil, for example, improvement 
in the quality and completeness of the national death 
registry76 during 2000–15 has enabled more complete 
linkage of death records with the cancer registries. In 
several countries, survival estimates that were flagged as 
less reliable in CONCORD-2 are now more reliable, even 
if the survival estimates are lower.
To estimate the global burden of cancer incidence, 
assumptions are required where no cancer registries 
exist, usually by modelling incidence and mortality data 
from other countries in the same world region.2,77 By 
contrast, we have made no attempt to model cancer 
survival in countries or regions where population-based 
cancer registration data were not available. Cancer 
survival cannot be estimated or modelled by assuming 
that the health system is as effective as in some other 
country for which population-based survival estimates 
are available. On the contrary, cancer survival estimates 
are required to assess the overall effectiveness of a 
country’s health system in the first place. For that, cancer 
registries are essential.
The survival estimates reported here are derived 
directly from the records of individual patients diagnosed 
with cancer, and from long-term follow-up to ascertain 
their vital status, followed by standardised quality control 
and central analysis. This is not a compilation of 
published reports or a meta-analysis.
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Survival for most cancers remains among the highest 
in the world in the USA, Canada, Australia, and New 
Zealand, and in Finland, Iceland, Norway, and Sweden. 
Publications that showed surprisingly low survival in 
Denmark78,79 prompted national cancer plans in 2000, 
2005, and 2011 that were all focused on early diagnosis 
and treatment to improve survival.80 From 2007, cancer 
was regarded as an acute life-threatening disease, leading 
to accelerated cancer-specific pathways for diagnosis, 
with public monitoring of hospitals’ compliance with 
waiting times. For most cancers, survival has increased 
more rapidly in Denmark, nearly catching up with the 
other Nordic countries.81,82 Norway and Sweden have now 
established similar pathways for cancer patients.
Cancer survival trends are generally increasing, even 
for some of the more lethal cancers. In some countries, 
survival increased by up to 5% for cancers of the liver, 
pancreas, or lung. For example, survival trends for liver 
cancer were generally stable during 1995–2014, but 
survival increased by more than 10% in Korea, Singapore, 
and Norway.
However, for cancers for which 5-year survival remains 
extremely low in all countries (eg, pancreatic cancer, in 
the range 5–15%), international efforts will be required to 
understand risk factors, improve prevention, and promote 
earlier diagnosis and better treatment to improve 
outcomes. International comparisons of survival for 
pancreatic cancer include both ductal adenocarcinomas 
and the less common neuroendocrine tumours, for 
which survival is generally higher. The effect of variation 
in these proportions will require detailed analysis.
Age-standardised 5-year net survival for stomach cancer 
was less than 30% in most countries, but high in Korea 
(68·9%) and Japan (60·3%), where it increased by 10% or 
more between 2000–04 and 2010–14. This pattern is likely 
to be associated with long-standing population-based 
endoscopic screening programmes for early detection of 
gastric and oesophageal cancers, which are very common. 
Population awareness is high. Gastric cancer screening in 
Korea started in 1999 as part of the National Cancer 
Screening Programme, with biennial contrast radiology or 
endoscopy for adults aged 40 years or older.83 This doubles 
the chances of early diagnosis compared with unscreened 
patients.84 Endoscopic resection with clear margins can be 
curative in stage I oesophageal and gastric cancers (up to 
2 cm diameter) if invasion is limited to the superficial 
submucosa and there is no lymphovascular invasion.85 By 
contrast, in countries where gastric cancer is a less serious 
public health issue, and in the absence of screening, this 
cancer is often diagnosed at an advanced stage. In Russia 
in 2015, for example, stomach cancer was most often 
diagnosed in stage IV (40%), and open laparotomy, 
chemotherapy, and radiation were required for 22% and 
25% of cases in stages II and III, respectively. Screening 
for oesophageal and gastric cancers should be considered 
as part of national cancer control plans in countries where 
these tumours are common, or in high-risk populations.86
Survival trends for colorectal cancer were generally flat, 
or increasing, over the 20 years 1995–2014. Survival for 
rectal cancer was very similar among the Nordic countries 
(64–69%) and among most southern European countries 
(61%).
Survival from melanoma of the skin is generally lower 
in Asian populations than in the rest of the world. One 
explanation might be lower public awareness because 
melanoma is less common in Asian populations, but it 
could also be that Asian patients typically present with 
more advanced disease and with acral lentiginous 
melanoma. This is one of the more lethal subtypes, and it 
is more common in Asian populations than in western 
populations.87 In the CONCORD data (not shown), acral 
lentiginous melanoma represents 1·2% of all skin 
melanomas, and 1% in Europe and North America, but 
6% in Asia.
The increasing trend in 5-year net survival from breast 
cancer during the 15 years 1995–20096 has continued in 
most countries up to 2014, but remains lower in India, 
Thailand, and several of the eastern European countries.
5-year survival from cervical cancer has increased in 
several European and Asian countries. However, survival 
can even decline following an increase in diagnostic 
activity. In North America and Oceania, survival is lower 
than in other countries due to more intensive screening 
programmes that detect precancerous cells and in-situ 
tumours. These can be cured with a range of simple 
techniques, reducing the incidence of invasive malignancy 
by removal of the more indolent pre-invasive lesions, 
whereas the more aggressive tumours are less likely to be 
detected by screening.
Some of the global range in survival might be attributable 
to differences in the intensity of diagnostic activity, and to 
overdiagnosis from the detection of very small or less 
aggressive tumours that would not have been expected to 
lead to symptomatic diagnosis or death in the patient’s 
expected lifetime.88,89 As in CONCORD-2,6 we were unable 
to use the proportion of in-situ cancers to compare the 
intensity of diagnostic activity for solid tumours. Some 
registries still do not record in-situ tumours and other 
registries did not submit data for in-situ tumours.
Because screening programmes are only available in 
wealthier countries, mainly in selected age ranges for 
cancers of the breast, cervix, and colon, the extent of 
overdiagnosis seems unlikely to have a large effect on 
the global range of cancer survival. Measures of 
overdiagnosis are only available at the population level, 
so their application in the interpretation of cancer 
survival patterns would be limited to ecological 
comparisons, as for gross domestic product (GDP) or 
total national expenditure on health. By contrast, data 
on stage at diagnosis are available for individuals. 
Analyses of the distribution of stage at diagnosis and 
stage-specific survival will be expected to provide 
further insight into international variation in cancer 
survival.90,91
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Survival from the adult leukaemias up to 2009 in Asian 
populations was much lower than in Europe, North 
America, and Oceania.6 One possible explanation was the 
relative rarity in Asian populations of chronic lymphocytic 
leukaemia, which has a relatively good prognosis in 
western populations. However, survival from chronic 
lymphocytic leukaemia is also much lower in Taiwan 
than in the USA,92 and the findings reported here also 
show that survival in adults is generally lower in southeast 
Asia than in other countries, for both myeloid and 
lymphoid malignancies. The difference between the 
median of the survival estimates for Asian populations 
and for other populations narrowed between 2000–04 and 
2010–14, for both myeloid and lymphoid malignancies. In 
most southeast Asian countries, survival for myeloid 
malignancies has risen by 5–14%, and by 10% or more for 
lymphoid malignancies.
Survival from brain tumours in children is generally 
higher than for adults, but the global range is much 
more pronounced. Some of the international variation in 
survival from brain tumours might be due to variation in 
the proportion that are benign. Where benign tumours 
are registered, the proportion typically ranges up 
to 10–15% in both adults and children (data not shown). 
However, some registries do not record benign brain 
tumours, and this varies both between and within 
countries. For example, in Australia, benign brain 
tumours are not registrable in New South Wales or 
Western Australia (45% of the national population), 
whereas they comprise up to 5% of brain tumours in 
Queensland and Victoria, with a similar combined 
population. The impact of morphology, behaviour, and 
grade on international patterns of brain tumour survival 
needs further research.
International variation in survival for childhood 
lymphoma was less marked than for childhood acute 
lymphoblastic leukaemia. The marked increase in 5-year 
survival among children diagnosed with lymphoma in 
Brazil (from 69·2% in 2000–04 to 88·2% in 2010–14) is 
likely to reflect a real improvement in diagnosis and 
treatment.
Cancer kills more than 100 000 children every year, 
mainly in low-income and middle-income countries,93 
where access to health services is often poor and 
abandonment of treatment is a major problem.94,95 
Reliable data on the cost and the effectiveness of health 
services in managing childhood cancer are scarce, yet 
such data would offer important evidence for countries 
to compare the impact of their strategies for managing 
children with cancer.96 Survival estimates published here 
for children diagnosed with a brain tumour, lymphoma, 
or leukaemia will be used in a Lancet Oncology 
Commission on childhood cancer, designed to establish 
the evidence for investing in effective interventions to 
reduce the burden of childhood cancer.
Survival trends could not be systematically assessed in 
Africa. In some registries, the proportion of records with 
incomplete dates reached up to 40%. Survival estimates 
for acute lymphoblastic leukaemia in Algeria were 
considered less reliable because follow-up was less than 
5 years for more than 50% of children. For Nigeria 
(Ibadan) and South Africa (Eastern Cape), data were only 
available for 12 and seven children, respectively, and 
survival was not estimated. Where survival could be 
estimated with some confidence, it was often very low, 
although survival in Mauritius was generally higher. In 
Nigeria, for example, there are no trained medical 
oncologists. Some haematologists and paediatric 
oncologists administer chemotherapy, but the availability 
of chemotherapy is limited in both the public and private 
sectors. Most patients pay out of their own pocket, and 
the cost is prohibitive. These factors frequently disrupt 
treatment and are likely to lead to poor outcomes.
To control for background mortality by age and sex, we 
updated the library of life tables for 1995–2010 by country, 
registry, race (selected countries), and calendar year to 
2014, with a statistical summary for each set of life tables. 
The updated library is available from the Cancer Survival 
Group website. In some countries, it has become more 
difficult to obtain the death and population counts 
required to construct life tables.
Survival estimates from CONCORD-2 for cancers of 
the breast and cervix were used in a recent Lancet Series 
on women’s cancers,97,98 to help to describe trends in the 
global burden of these cancers. Survival for the 2 million 
women diagnosed with one of these cancers every year 
remains highly dependent on the country in which they 
live. The Series highlighted the urgent need for more 
cost-effective cancer control strategies in low-income and 
middle-income countries.
The global economic cost of treating the 12·9 million 
new patients diagnosed with cancer worldwide in 2009 
was estimated at US$285·8 billion.99 The costs of cancer 
treatment and care in the USA alone were projected to 
rise by 23% between 2010 and 2020, from $124·6 to 
$157·7 billion, solely on the basis of demographic 
change, and with fixed incidence rates, survival 
probabilities, and treatment costs.100 If treatment costs 
rise by 2% a year in the first and last phases of treatment, 
the overall cost of treatment and care in the USA could 
reach $172·8 billion, a 39% increase. If incidence rates 
continue to rise, the prevalence of cancer survivors will 
increase further, triggering still further increase in the 
costs of care.
On the basis of these figures, it seems plausible that the 
global cost of cancer treatment and care in 2017 must 
already be substantially higher than $300 billion a year. 
Spiralling costs101 threaten the viability of health systems 
and national economies. Where universal health coverage 
has not been achieved, the out-of-pocket costs of cancer 
treatment can lead to financial catastrophe for individuals 
and families.3
The indirect economic costs associated with premature 
death and lost productivity from the growing cancer 
For the life tables from the 
CONCORD programme see 
http://csg.lshtm.ac.uk/tools-
analysis#tools
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burden have been estimated at $1·16 trillion a year,3 or 
approaching 2% of global GDP.102 The increasing cost 
and complexity of cancer treatment might require a 
radical shift in cancer policy, in which inequitable access 
to affordable cancer treatment ceases to be politically 
acceptable.103 Population-based data on cancer survival 
trends that are comparable within and between countries 
are part of the evidence base needed to drive such a 
policy shift.
With this background, cancer registries can be seen 
as efficient public health instruments, producing a 
continuous stream of valuable information for cancer 
control at low cost.104 In Europe in 2013, the average cost 
per patient registered, including the registry’s costs for 
personnel, information technology, and infrastructure, 
was €51 (range €6–213; equivalent to $59 [7–252]). This is 
less than the typical cost of a chest x-ray. For the 
population as a whole, the cost was less than €1 ($1·18) 
per person per year.
In 2015, the UN introduced 17 Sustainable Development 
Goals (SDGs), aiming to end poverty, protect the planet, 
and ensure prosperity for all.105 Goal 3 is “to ensure healthy 
lives and promote well-being for all at all ages”. For this 
goal, target 3.4 is to reduce “premature” mortality (among 
people aged 30–70 years) from non-communicable 
diseases, including cancer, by a third by 2030, through 
prevention and treatment.106 The challenge will be to 
secure overall improvements in health outcomes that do 
not lead to wider inequalities.107
Achieving the SDG target of a one-third reduction in 
premature mortality by 2030 clearly requires more 
effective prevention to reduce cancer incidence. However, 
the 15-year timeframe is short, and achieving the target 
will also require investment in more effective health 
systems, to improve survival.46
WHO recently called for the development of population-
based cancer registries, so that effective policies for cancer 
control can be founded on accurate data.3 It also called for 
stronger civil registration and vital statistics systems. 
These systems support the basic functions of government 
and enable measurement of progress towards development 
goals,108 yet population coverage is poor in low-income and 
middle-income countries, and closely related to gross 
national income.109
Most cancer registries establish the vital status of all 
patients registered with cancer by linkage with vital 
statistics data (regional or national death indexes). This is 
known as passive follow-up, although many registries 
also contact patients’ doctors or families directly (active 
follow-up). For passive follow-up to work, efficient civil 
registration systems that capture information on all 
deaths are required. This process underpins the 
estimation of population-based cancer survival, even 
though active follow-up can be effective in some 
populations. Yet cancer registries report increasing 
difficulty in linking their databases to regional or national 
death indexes. Legal and administrative obstacles and 
technical difficulties have all been reported. Some 
national authorities holding death indexes clearly give 
very low priority to such linkages.
These problems undermine the public health purpose of 
cancer registration. Of the 400 operational registries we 
contacted, more than 20 were unable to follow up all 
registered patients to ascertain their vital status. This 
problem arose in 16 countries, including some high-
income countries. Some registries were unable to provide 
survival data at all. In Canada, for example, national 
coverage of cancer survival statistics was achieved for the 
first time in CONCORD-2,6 with data from all 13 provinces 
and territories for 1995–2009, but several jurisdictions 
were unable to participate in CONCORD-3 because of 
legal or administrative difficulties in linking their cancer 
registry with death records. For eight countries that 
expressed interest or even submitted data, these difficulties 
meant that no survival estimates could be produced at all: 
Benin, Bosnia and Herzegovina, Indonesia, Panama, the 
Philippines, Saudi Arabia, Serbia, and Tunisia.
It is crucial for national and regional governments to 
recognise that population-based cancer registries are key 
policy tools, both to monitor the impact of cancer 
prevention strategies and to evaluate the effectiveness of 
the health system for all patients diagnosed with cancer. 
All registries, especially those in low-income and middle-
income countries, need to be given adequate resources to 
register all patients with cancer in a timely fashion, the 
right to access up-to-date national and regional death 
records to establish their vital status, and the legislative 
stability to operate efficiently over the long term.110
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CONCORD Working Group
Africa: Algeria: S Bouzbid (Registre du Cancer d’Annaba); 
M Hamdi-Chérif*, Z Zaidi (Registre du Cancer de Sétif); K Meguenni, 
D Regagba (Registre du Cancer Tlemcen); Mali: S Bayo, T Cheick 
Bougadari (Kankou Moussa University); Mauritius: S S Manraj 
(Mauritius National Cancer Registry); Morocco: K Bendahhou (Registre 
du Cancer du Grand Casablanca); Nigeria: A Fabowale, O J Ogunbiyi* 
(Ibadan Cancer Registry); South Africa: D Bradshaw, N I M Somdyala 
(Eastern Cape Province Cancer Registry). America (Central and South): 
Argentina: I Kumcher, F Moreno (National Childhood Cancer Registry); 
G H Calabrano, S B Espinola (Chubut Cancer Registry); B Carballo 
Quintero, R Fita (Registro Provincial de Tumores de Córdoba); 
M C Diumenjo, W D Laspada (Registro Provincial de Tumores de 
Mendoza); S G Ibañez (Population Registry of Cancer of the Province 
Tierra del Fuego); Brazil: C A Lima (Registro de Câncer de Base 
Populacional de Aracaju); P C F De Souza (Registro de Câncer de Base 
Populacional de Cuiabá); K Del Pino, C Laporte (Registro de Curitiba); 
M P Curado, J C de Oliveira (Registro de Goiânia); C L A Veneziano, 
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D B Veneziano (Registro de Câncer de Base Populacional de Jaú); 
M R D O Latorre, L F Tanaka (Registro de Câncer de São Paulo); 
M S Rebelo, M O Santos (Instituto Nacional de Câncer, Rio de Janeiro); 
G Azevedo e Silva* (University of Rio de Janeiro); Chile: J C Galaz 
(Registro Poblacional de Cáncer Region de Antofagasta); M Aparicio 
Aravena, J Sanhueza Monsalve (Registro Poblacional de Cáncer de la 
Provincia de Biobio; Registro Poblacional de Cáncer Provincia de 
Concepción); D A Herrmann, S Vargas (Registro Poblacional Region de 
Los Rios); Colombia: V M Herrera, C J Uribe (Registro Poblacional de 
Cáncer Area Metropolitana de Bucaramanga); L E Bravo, L S Garcia (Cali 
Cancer Registry); N E Arias-Ortiz, D Morantes (Registro Poblacional de 
Cáncer de Manizales); D M Jurado, M C Yépez Chamorro (Registro 
Poblacional de Cáncer del Municipio de Pasto); Costa Rica: S Delgado, 
M Ramirez (Registro Nacional de Tumores de Costa Rica); Cuba: 
Y H Galán Alvarez, P Torres (Registro Nacional de Cáncer de Cuba); 
Ecuador: F Martínez-Reyes (Cuenca Tumor Registry); L Jaramillo, 
R Quinto (Guayaquil Cancer Registry); J Castillo (Loja Cancer Registry); 
M Mendoza (Manabí Cancer Registry); P Cueva, J G Yépez (Quito 
Cancer Registry); France: B Bhakkan, J Deloumeaux (Registre des 
cancers de la Guadeloupe); C Joachim, J Macni (General Cancer Registry 
of Martinique); Mexico: R Carrillo, J Shalkow Klincovstein (Centro 
Nacional para la Salud de la Infancia y la Adolescencia); R Rivera Gomez 
(Registro Poblacional de Cancer Region Fronteriza Norte de Mexico 
Zona Tijuana); Peru: E Poquioma (Lima Metropolitan Cancer Registry); 
Puerto Rico: G Tortolero-Luna, D Zavala (Puerto Rico Central Cancer 
Registry); Uruguay: R Alonso, E Barrios (Registro Nacional de Cáncer).
America (North): Canada: A Eckstrand, C Nikiforuk (Alberta Cancer 
Registry); R R Woods (British Columbia Cancer Registry); G Noonan, 
D Turner* (Manitoba Cancer Registry); E Kumar, B Zhang 
(New Brunswick Provincial Cancer Registry); F R McCrate, S Ryan 
(Newfoundland & Labrador Cancer Registry); M MacIntyre, 
N Saint-Jacques (Nova Scotia Cancer Registry); D E Nishri* (Ontario 
Cancer Registry); C A McClure, K A Vriends (Prince Edward Island 
Cancer Registry); S Kozie, H Stuart-Panko (Saskatchewan Cancer 
Agency); USA: T Freeman, J T George (Alabama Statewide Cancer 
Registry); J T Brockhouse, D K O’Brien (Alaska Cancer Registry); A Holt 
(Arkansas Central Cancer Registry); L Almon (Metropolitan Atlanta 
Registry); S Kwong, C Morris (California State Cancer Registry); 
R Rycroft (Colorado Central Cancer Registry); L Mueller, C E Phillips 
(Connecticut Tumor Registry); H Brown, B Cromartie (Delaware Cancer 
Registry); A G Schwartz, F Vigneau (Metropolitan Detroit Cancer 
Surveillance System); G M Levin, B Wohler (Florida Cancer Data 
System); R Bayakly (Georgia Cancer Registry); K C Ward (Georgia 
Cancer Registry; Metropolitan Atlanta Registry); S L Gomez, M McKinley 
(Greater Bay Area Cancer Registry); R Cress (Cancer Registry of Greater 
California); M D Green, K Miyagi (Hawaii Tumor Registry); C J Johnson 
(Cancer Data Registry of Idaho); L P Ruppert (Indiana State Cancer 
Registry); C F Lynch (State Health Registry of Iowa); B Huang, 
T C Tucker* (Kentucky Cancer Registry); D Deapen, L Liu (Los Angeles 
Cancer Surveillance Program); M C Hsieh, X C Wu (Louisiana Tumor 
Registry); M Schwenn (Maine Cancer Registry); S T Gershman, 
R C Knowlton (Massachusetts Cancer Registry); G Alverson, 
G E Copeland (Michigan State Cancer Surveillance Program); 
S Bushhouse (Minnesota Cancer Surveillance System); D B Rogers 
(Mississippi Cancer Registry); J Jackson-Thompson (Missouri Cancer 
Registry and Research Center); D Lemons, H J Zimmerman (Montana 
Central Tumor Registry); M Hood, J Roberts-Johnson (Nebraska Cancer 
Registry); J R Rees, B Riddle (New Hampshire State Cancer Registry); 
K S Pawlish, A Stroup (New Jersey State Cancer Registry); C Key, 
C Wiggins (New Mexico Tumor Registry); A R Kahn, M J Schymura 
(New York State Cancer Registry); S Radhakrishnan, C Rao (North 
Carolina Central Cancer Registry); L K Giljahn, R M Slocumb (Ohio 
Cancer Incidence Surveillance System); R E Espinoza, F Khan 
(Oklahoma Central Cancer Registry); K G Aird, T Beran (Oregon State 
Cancer Registry); J J Rubertone, S J Slack (Pennsylvania Cancer 
Registry); L Garcia, D L Rousseau (Rhode Island Cancer Registry); 
T A Janes, S M Schwartz (Seattle Cancer Surveillance System); 
S W Bolick, D M Hurley (South Carolina Central Cancer Registry); 
M A Whiteside (Tennessee Cancer Registry); P Miller-Gianturco, 
M A Williams (Texas Cancer Registry); K Herget, C Sweeney (Utah 
Cancer Registry); A T Johnson (Vermont Cancer Registry); M B Keitheri 
Cheteri, P Migliore Santiago (Washington State Cancer Registry); 
S E Blankenship, S Farley (West Virginia Cancer Registry); R Borchers, 
R Malicki (Wisconsin Department of Health Services); J R Espinoza, 
J Grandpre (Wyoming Cancer Surveillance Program); H K Weir*, 
R Wilson (Centers for Disease Control and Prevention); B K Edwards*, 
A Mariotto (National Cancer Institute). Asia: China: Y Lei, N Wang 
(Beijing Cancer Registry); J S Chen, Y Zhou (Changle City Cancer 
Registry); Y T He, G H Song (Cixian Cancer Registry); X P Gu (Dafeng 
County Center for Disease Control and Prevention); D Mei, H J Mu 
(Dalian Centers for Disease Prevention and Control); H M Ge, T H Wu 
(Donghai County Center for Disease Prevention and Control); Y Y Li, 
D L Zhao (Feicheng County Cancer Registry); F Jin, J H Zhang (Ganyu 
Center for Disease Prevention and Control); F D Zhu (Guanyun Cancer 
Registry); Q Junhua, Y L Yang (Haimen Cancer Registry); C X Jiang 
(Haining City Cancer Registry); W Biao, J Wang (Jianhu Cancer 
Registry); Q L Li (Jiashan County Cancer Registry); H Yi, X Zhou (Jintan 
Cancer Registry); J Dong, W Li (Lianyungang Center for Disease 
Prevention and Control); F X Fu, S Z Liu (Linzhou Cancer Registry); 
J G Chen, J Zhu (Qidong County Cancer Registry); Y H Li, Y Q Lu (Sihui 
Cancer Registry); M Fan, S Q Huang (Taixing Cancer Registry); G P Guo, 
H Zhaolai (Cancer Institute of Yangzhong City); K Wei (Zhongshan City 
Cancer Registry); W Q Chen*, H Zeng (The National Cancer Center); 
Cyprus: A V Demetriou (Cyprus Cancer Registry); Hong Kong: 
W K Mang, K C Ngan (Hong Kong Cancer Registry); India: A C Kataki, 
M Krishnatreya (Guwahati Cancer Registry); P A Jayalekshmi, 
P Sebastian (Karunagappally Cancer Registry); A Nandakumar* 
(National Centre for Disease Informatics and Research); Iran: 
R Malekzadeh, G Roshandel (Golestan Population-based Cancer 
Registry); Israel: L Keinan-Boker, B G Silverman (Israel National Cancer 
Registry); Japan: H Ito, H Nakagawa (Aichi Cancer Registry); M Sato, 
F Tobori (Akita Prefectural Cancer Registry); I Nakata, N Teramoto 
(Ehime Prefectural Cancer Registry); M Hattori, Y Kaizaki (Fukui Cancer 
Registry); F Moki (Gunma Prefectural Cancer Registry); H Sugiyama, 
M Utada (Hiroshima Prefecture Cancer Registry); M Nishimura, 
K Yoshida (Hyogo Prefectural Cancer Registry); K Kurosawa, Y Nemoto 
(Ibaraki Prefectural Cancer Registry); H Narimatsu, M Sakaguchi 
(Kanagawa Cancer Registry); S Kanemura (Miyagi Prefectural Cancer 
Registry); M Naito, R Narisawa (Niigata Prefecture Cancer Registry); 
I Miyashiro, K Nakata (Osaka Cancer Registry); S Sato, M Yoshii (Saga 
Prefectural Cancer Registry); I Oki (Tochigi Prefectural Cancer Registry); 
N Fukushima, A Shibata (Yamagata Prefectural Cancer Registry); 
K Iwasa, C Ono (Yamanashi Cancer Registry); T Matsuda* (National 
Cancer Center); Jordan: O Nimri (Jordan National Cancer Registry); 
Korea: K W Jung, Y J Won (Korea Central Cancer Registry); Kuwait: 
E Alawadhi, A Elbasmi (Kuwait Cancer Registry); Malaysia: A Ab Manan 
(Malaysia National Cancer Registry); F Adam (Penang Cancer Registry); 
Mongolia: E Sanjaajmats, U Tudev (Cancer Registry of Mongolia); 
C Ochir (Mongolian National University of Medical Sciences); Qatar: 
A M Al Khater, M M El Mistiri (Qatar Cancer Registry); Singapore: 
G H Lim, Y Y Teo (Singapore Cancer Registry); Taiwan: C J Chiang, 
W C Lee (Taiwan Cancer Registry); Thailand: R Buasom, S Sangrajrang 
(Bangkok Cancer Registry); S Kamsa-ard, S Wiangnon (Khon Kaen 
Provincial Cancer Registry); K Daoprasert, D Pongnikorn (Lampang 
Cancer Registry; Lamphun Cancer Registry); A Leklob, 
S Sangkitipaiboon (Lopburi Cancer Registry); S L Geater, H Sriplung 
(Songkhla Cancer Registry); Turkey: O Ceylan, I Kög (Ankara Cancer 
Registry); O Dirican (Antalya Cancer Registry); T Köse (Bursa Cancer 
Registry); T Gurbuz (Edirne Cancer Registry); F E Karaşahin, D Turhan 
(Erzurum Cancer Registry Center); U Aktaş, Y Halat (Eskişehir Cancer 
Registry); S Eser, C I Yakut (Izmir Cancer Registry); M Altinisik, 
Y Cavusoglu (Samsun Cancer Registry); A Türkköylü, N Üçüncü 
(Trabzon Cancer Registry). Europe: Austria: M Hackl (Austrian National 
Cancer Registry); Belarus: A A Zborovskaya (Belarus Childhood Cancer 
Subregistry); O V Aleinikova (Belarusian Research Center for Pediatric 
Oncology, Hematology and Immunology); Belgium: K Henau, 
L Van Eycken (Belgian Cancer Registry); Bulgaria: Z Valerianova, 
M R Yordanova (Bulgarian National Cancer Registry); Croatia: M Šekerija 
(Croatian National Cancer Registry); Czech Republic: L Dušek, M Zvolský 
(Czech National Cancer Registry); Denmark: G Engholm, H Storm* 
(Danish Cancer Society); Estonia: K Innos, M Mägi (Estonian Cancer 
Registry); Finland: N Malila, K Seppä (Cancer Society of Finland); 
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France: J Jégu, M Velten (Bas-Rhin General Cancer Registry); E Cornet, 
X Troussard (Registre Régional des Hémopathies Malignes de Basse 
Normandie); A M Bouvier (Registre Bourguignon des Cancers 
Digestifs); A V Guizard (Registre Général des Tumeurs du Calvados); 
V Bouvier, G Launoy (Registre des Tumeurs Digestives du Calvados); 
P Arveux (Breast cancers registry of Côte-d’Or France); M Maynadié, 
M Mounier (Hémopathies Malignes de Côte d’Or); A S Woronoff (Doubs 
and Belfort Territory General Cancer Registry); M Daoulas, 
M Robaszkiewicz (Finistère Cancer Registry); J Clavel, S Goujon (French 
National Registry of Childhood Hematopoietic Malignancies); B Lacour 
(National Registry of Childhood Solid Tumors); I Baldi, C Pouchieu 
(Gironde Registry of Primary Central Nervous System Tumors); 
B Amadeo, G Coureau (General Cancer Registry of Gironde 
Department); A Monnereau (Registre des Hémopathies Malignes de la 
Gironde; French Network of Cancer Registries (FRANCIM)); S Orazio 
(Registre des Hémopathies Malignes de la Gironde); P M Preux, 
F Rharbaoui (Registre Général des Cancers de Haute-Vienne); E Marrer 
(Haut-Rhin Cancer Registry); B Trétarre (Registre des Tumeurs de 
l’Hérault); M Colonna, P Delafosse (Registre du Cancer du Département 
de l’Isère); K Ligier, S Plouvier (Registre Général des Cancers de Lille et 
de sa Region); A Cowppli-Bony, F Molinié (Loire-Atlantique-Vendée 
Cancer Registry); S Bara (Manche Cancer Registry); O Ganry, B Lapôtre-
Ledoux (Registre du Cancer de la Somme); P Grosclaude (Tarn Cancer 
Registry); N Bossard, Z Uhry (Hospices Civils de Lyon); F Bray*, 
M Piñeros* (International Agency for Research on Cancer); J Estève 
(Université Claude Bernard, Lyon); Germany: R Stabenow, 
H Wilsdorf-Köhler (Common Cancer Registry of the Federal States); 
A Eberle, S Luttmann (Bremen Cancer Registry); I Löhden, 
A L Nennecke (Hamburg Cancer Registry); J Kieschke, E Sirri 
(Epidemiological Cancer Registry of Lower Saxony); K Emrich, 
S R Zeissig (Rhineland Palatinate Cancer Registry); B Holleczek 
(Saarland Cancer Registry); N Eisemann, A Katalinic (Schleswig-
Holstein Cancer Registry); Gibraltar: R A Asquez, V Kumar (Gibraltar 
Cancer Registry); Greece: E Petridou (Nationwide Registry for Childhood 
Haematological Malignancies and Solid Tumors); Iceland: E J Ólafsdóttir, 
L Tryggvadóttir (Icelandic Cancer Registry, Icelandic Cancer Society); 
Ireland: K Clough-Gorr, P M Walsh (National Cancer Registry Ireland); 
H Sundseth* (European Institute of Women’s Health); Italy: 
G Mazzoleni, F Vittadello (Registro Tumori Alto Adige); E Coviello, 
F Cuccaro (Registro Tumori Puglia—Sezione ASL BT); R Galasso 
(Registro Tumori di Basilicata); G Sampietro (Registro Tumori di 
Bergamo); A Giacomin† (Piedmont Cancer Registry Provinces of Biella 
and Vercelli); M Magoni (Registro Tumori Dell’ASL Di Brescia); 
A Ardizzone (Registro Tumori Brindisi); A D’Argenzio (Caserta Cancer 
Registry); M Castaing, G Grosso (Integrated Cancer Registry of 
Catania-Messina-Siracusa-Enna); A M Lavecchia, A Sutera Sardo 
(Registro Tumori Catanzaro); G Gola (Registro Tumori della Provincia di 
Como); L Gatti, P Ricci (Registro Tumori Cremona; Registro Tumori 
Mantova); S Ferretti (Registro Tumori della Provincia di Ferrara); 
D Serraino, A Zucchetto (Registro Tumori del Friuli Venezia Giulia); 
M V Celesia, R A Filiberti (Registro Tumori Regione Liguria); 
F Pannozzo (Registro Tumori della Provincia di Latina); A Melcarne, 
F Quarta (Registro Tumori Della Provincia Di Lecce Sezione RTP); 
A G Russo (Registro Tumori Milano); G Carrozzi, C Cirilli (Registro 
Tumori della Provincia di Modena); L Cavalieri d’Oro, M Rognoni 
(Registro Tumori di Monza e Brianza); M Fusco, M F Vitale (Registro 
Tumori della ASL Napoli 3 Sud); M Usala (Nuoro Cancer Registry); 
R Cusimano, W Mazzucco (Registro Tumori di Palermo e Provincia); 
M Michiara, P Sgargi (Registro Tumori della Provincia di Parma); 
L Boschetti (Cancer Registry of the province of Pavia); E Borciani, 
P Seghini (Registro Tumori Piacenza); M M Maule, F Merletti (Piedmont 
Childhood Cancer Registry); R Tumino (Registro Tumori della Provincia 
di Ragusa); P Mancuso, M Vicentini (Registro Tumori Reggio Emilia); 
T Cassetti, R Sassatelli (Pancreas Tumour Registry of Reggio Emilia 
Province); F Falcini, S Giorgetti (Registro Tumori della Romagna); 
A L Caiazzo, R Cavallo (Registro Tumori Salerno); R Cesaraccio, 
D R Pirino (Registro Tumori della Provincia di Sassari); M L Contrino, 
F Tisano (Registro Tumori Siracusa); A C Fanetti, S Maspero (Registro 
Tumori della Provincia di Sondrio); S Carone, A Mincuzzi (Registro 
Tumori Taranto); G Candela, T Scuderi (Registro Tumori Trapani); 
M A Gentilini, S Piffer (Registro Tumori Trento); S Rosso (Piedmont 
Cancer Registry); A Barchielli, A Caldarella (Registro Tumori della 
Regione Toscana); F Bianconi, F Stracci (Registro Tumori Umbro di 
Popolazione); P Contiero, G Tagliabue (Registro Tumori Lombardia, 
Provincia di Varese); M Rugge, M Zorzi (Registro Tumori Veneto); 
S Beggiato, A Brustolin (Registro Tumori Della Provincia Di Viterbo); 
F Berrino*, G Gatta, M Sant* (Fondazione IRCCS Istituto Nazionale dei 
Tumori); C Buzzoni, L Mangone (Italian Association of Cancer 
Registries [AIRTUM]); R Capocaccia*, R De Angelis (National Centre for 
Epidemiology); R Zanetti* (International Association of Cancer 
Registries; Piedmont Cancer Registry); Latvia: A Maurina, S Pildava 
(Latvian Cancer Registry); Lithuania: N Lipunova, I Vincerževskienė 
(Lithuanian Cancer Registry); Malta: D Agius, N Calleja (Malta National 
Cancer Registry); Netherlands: S Siesling, O Visser (Netherlands Cancer 
Registry, IKNL); Norway: S Larønningen, B Møller (The Cancer Registry 
of Norway); Poland: A Dyzmann-Sroka, M Trojanowski (Greater Poland 
Cancer Registry); S Góźdź, R Mężyk (Holy Cross Cancer Registry); 
T Mierzwa (Kuiavian-Pomeranian Cancer Registry); L Molong, J Rachtan 
(Lesser Poland Cancer Registry); S Szewczyk (Łódź Cancer Registry); 
J Błaszczyk, K Kępska (Lower Silesian Cancer Registry); B Kościańska 
(Lublin Cancer Registry); K Tarocińska (Lubush Cancer Registry); 
M Zwierko (Mazovian Cancer Registry); K Drosik (Opole Cancer 
Registry); K M Maksimowicz, E Purwin-Porowska (Podlahian Cancer 
Registry); E Reca, J Wójcik-Tomaszewska (Pomeranian Cancer Registry); 
A Tukiendorf (Silesian Cancer Registry); M Grądalska-Lampart, 
A U Radziszewska (Subcarpathian Cancer Registry); A Gos 
(Varmian-Mazurian Cancer Registry); M Talerczyk, M Wyborska 
(West-Pomeranian Cancer Registry); J A Didkowska, U Wojciechowska 
(National Cancer Registry); M Bielska-Lasota (National Institute of Public 
Health, NIH); Portugal: G Forjaz de Lacerda, R A Rego (Registo 
Oncológico Regional dos Açores); J Bastos, M A Silva (Registo Oncológico 
Regional do Centro); L Antunes, J Laranja Pontes (Registo Oncológico 
Regional do Norte); A Mayer-da-Silva, A Miranda (Registo 
Oncólogico Regional do Sul); Romania: L M Blaga, D Coza (Cancer 
Institute I. Chiricuta); Russia: M Y Valkov (Arkhangelsk Regional Cancer 
Registry); L Gusenkova, O Lazarevich (Population Cancer Registry of the 
Republic of Karelia); O Prudnikova, D M Vjushkov (Omsk Regional 
Cancer Registry); A G Egorova, A E Orlov (Samara Cancer Regional 
Registry); L A Kudyakov, L V Pikalova (Tomsk Regional Cancer Registry); 
Slovakia: J Adamcik, C Safaei Diba (National Cancer Registry of 
Slovakia); Slovenia: M Primic-Žakelj, V Zadnik (Cancer Registry of 
Republic of Slovenia); Spain: N Larrañaga, A Lopez de Munain (Basque 
Country Cancer Registry); A A Herrera, R Redondas (Registro 
Poblacional de Cáncer de la Comunidad Autónoma de Canarias); 
R Marcos-Gragera, M L Vilardell Gil (Epidemiology Unit and Girona 
Cancer Registry); E Molina, M J Sánchez Perez (Granada Cancer 
Registry); P Franch Sureda, M Ramos Montserrat (Mallorca Cancer 
Registry); M D Chirlaque, C Navarro (Murcia Cancer Registry); 
E E Ardanaz, M M Guevara (Registro de Cáncer de Navarra); 
R Fernández-Delgado, R Peris-Bonet (Registro Español de Tumores 
Infantiles); M Carulla, J Galceran (Tarragona Cancer Registry); 
C Alberich, M Vicente-Raneda (Comunitat Valenciana Childhood Cancer 
Registry); Sweden: S Khan, D Pettersson (Swedish Cancer Registry); 
P Dickman* (Karolinska Institutet, Stockholm); Switzerland: I Avelina, 
K Staehelin (Basel Cancer Registry); B Camey (Registre Fribourgeois des 
Tumeurs); C Bouchardy, R Schaffar (Geneva Cancer Registry); H Frick, 
C Herrmann (Cancer Registry Grisons and Glarus; Cancer Registry of 
St Gallen-Appenzell); J L Bulliard, M Maspoli-Conconi (Registre 
Neuchâtelois et Jurassien des Tumeurs); C E Kuehni, S M Redmond 
(Swiss Childhood Cancer Registry); A Bordoni, L Ortelli (Registro 
Tumori Canton Ticino); A Chiolero, I Konzelmann (Registre Valaisan 
des Tumeurs); K L Matthes, S Rohrmann (Cancer Registry Zürich and 
Zug); UK: J Broggio, J Rashbass (National Cancer Registration and 
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